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Ifosfamide is a well established oxazaphosphorine alkylating agent used in the
treatment of many malignancies. It is a pro-drug, requiring activation, mainly via the
hepatic cytochrome mixed function oxidase P-450 system, and 4-hydroxylation leads
to the active compound isophosphoramide mustard. Encephalopathy of varying
degrees, usually somnolence, occurs in approximately 10% of patients treated with
intravenous ifosfamide. The development of an oral formulation has been hindered
by a higher incidence of 50%. Pharmacokinetic processes are probably central to the
encephalopathy; the chemical entity responsible has not yet been firmly identified,
but it is likely to be a metabolite of ifosfamide, with chloroacetaldehyde as the main
suspect. Pharmacokinetic investigations have been aided recently by the pairing of
analytical techniques, allowing the study of separate metabolites. It is also becoming
clear that the erythrocyte is a significant carrier of substances in the circulation and
should be considered in such studies. This thesis investigates the plasma and
erythrocyte pharmacokinetics of ifosfamide, and neurotoxicity after oral
administration.
The plasma pharmacokinetics and neurotoxicity of oral ifosfamide were studied in
seven females with carcinoma of the cervix and four males with non-small cell lung
cancer. The median age was 58 years (range 33 - 70). Oral ifosfamide was
administered at a dose of 500 mg twice daily for 14 days; 300 mg of mesna was
given twice daily concurrently for uroprotection. Gas chromatography - mass
spectrometry was used to analyse ifosfamide and seven of its metabolites;
isophosphoramide mustard, 2- and 3- dechloroethylifosfamide, carboxyifosfamide,
ketoifosfamide, chloroethylamine, and 1, 3-oxazolidine-2-one. The basic metabolites
chloroethylamine and 1, 3-oxazolidine-2-one, predicted from the metabolism of
cyclophosphamide, have not been described previously in biological fluids.
Ifosfamide neurotoxicity was assessed using the electroencephalogram, psychometric
testing, the national adult reading test, the mini-mental state examination, and
clinical evaluation of symptoms. The mean Cmax, and AUC to eight hours, of
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ifosfamide were less on day 14, but not significantly so. Ifosfamide Cmax was 53.1
pM (SD ± 18.5) on day 1, and 50.7 pM (SD ± 25.8) on day 14. Corresponding
values for the AUC to eight hours were 293 pM . hr (SD ± 67), and 256 pM . hr (SD
± 118). It was not possible to estimate the AUC to eight hours accurately, on account
of the twice daily dosage regimen. The mean absorption rate constant of ifosfamide
on day 1 was 1.23 hr"1 (SD ± 1.01). The Cmax of most ifosfamide metabolites
increased on day 14, particularly ketoifosfamide, 2- and 3- dechloroethylifosfamide,
carboxyifosfamide and 1, 3-oxazolidine-2-one, whereas that of isophosphoramide
mustard was unchanged. Decreased alpha frequency was seen in the
electroencephalogram, with the development of pathological slow wave activity.
Psychometric performance was also impaired. All patients developed a feeling of
detachment, or an inability to concentrate, and two suffered hallucinations.
The plasma and erythrocyte pharmacokinetics of ifosfamide and its metabolites were
studied in five patients receiving intravenous ifosfamide. Using the newly developed
MESED instrument, a direct determination of red cell associated compounds was
performed on unwashed erythrocytes, maintained in their natural environment,
without disruption of the normal equilibrium existing between red cells and plasma
in whole blood. The mean ratio of erythrocyte AUC to plasma AUC was greater than
unity for ifosfamide and all metabolites. The difference between the AUCs was most
evident for carboxyifosfamide, isophosphoramide mustard, and ifosfamide.
In conclusion, oral ifosfamide 500 mg twice daily for 14 days is too neurotoxic for
routine use, with impairment of psychometric performance and
electroencephalographic appearances. The pharmacokinetic data support the
hypothesis that dechloroethylation is important in the generation of neurotoxicity.
Ifosfamide and its metabolites enter the erythrocyte compartment freely, and
carboxyifosfamide and isophosphoramide mustard are concentrated most
significantly within this fraction.
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1.1 The development of the alkylating agents and oxazaphosphorines
The alkylating agents are the oldest class of anticancer drugs. The first alkylator,
sulphur mustard (dichloroethyl sulphide), was synthesised in 1822 by Despretz (figure








Figure 1.1. The structures of sulphur and nitrogen mustards.
Sulphur mustard was used as an agent of chemical warfare for the first time at
Passchendale in July 1917. The predicted effects on the lungs, eyes and skin were
observed, but in addition unexpected bone marrow aplasia, destruction of lymphoid
tissue, and gastrointestinal ulceration were noted (Krumbaar and Krumbaar 1919).
During the second world war the biological and chemical properties of nitrogen mustard
[methyl bis - (2-chloroethyl)-amine] were investigated. The studies of Gilman and
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colleagues, using transplanted lymphosarcomas in mice, confirmed the cytotoxic action
of nitrogen mustard on lymphoid tissue, and the first clinical trials in 1942 marked the
dawn of modem cancer chemotherapy. In 1945 nitrogen mustard was declassified, and
details of its successful use in Hodgkins disease were published (Gilman and Philips
1946; Goodman et al 1946).
Nitrogen mustard has a narrow therapeutic index. Alkylating agents are not tumour
selective and are cytotoxic by virtue of their ability to alkylate nucleophilic centres in
the DNA molecule; the potential to damage both tumour and normal host tissues was
appreciated early in their development. In 1952 Druckrey and Raabe suggested that the
administration of a highly reactive drug as a chemically masked inactive "transport
form", rather than an active compound, was a possibility; it was envisaged that
transformation into the active form would occur in the body, ideally in tumour cells
(Druckrey and Raabe 1952). This concept was termed "drug latentiation" in 1959
(Harper 1959), and has been influential in the development of more selective
antineoplastic agents.
Inactivation of the highly reactive nitrogen mustard by chemical coupling is necessary
for the formation of a well tolerated transport form. The biological action of the
nitrogen mustards is dependent on the reactivity of the two functional chloroethylamino
groups, which in turn is related to the basicity of the nitrogen atoms. Substituting
electrophilic groups at the amino nitrogen reduces basicity, and therefore the reactivity
of the functional groups. Conversely, introducing a nucleophilic group increases the
reactivity. Arnold and Bourseaux (1958) coupled the mustard group to the electrophilic
phosphoryl group, assuming that the resulting stable oxazaphosphorine would be the
inactive transport form, which would fragment in vivo, releasing the active amine.
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Figure 1.2. The structures of cyclophosphamide, ifosfamide, trofosfamide, sufosfamide
and mafosfamide.
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Since 1958, more than one thousand compounds have been synthesised, and in
addition to cyclophosphamide four possess particularly favourable properties:
trofosfamide, first seen in clinical practice in 1972; ifosfamide, in routine use since
1977; sufosfamide, a mixed function oxazaphosphorine with immunological
properties; and mafosfamide, a stabilised primary oxazaphosphorine metabolite
developed in the 1980s, but excluded from clinical practice by the development of
local tissue irritation after intravenous administration. Ifosfamide is a structural












Figure 1.3. The synthesis of ifosfamide.
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1.2 Synthesis and physical chemistry of ifosfamide
The synthesis of ifosfamide (3-(2-chloroethyl)-2-(2-chloroethylamino) tetrahydro-2H-l,
3, 2-oxazaphosphorine-2-oxide) is shown in figure 1.3. N-(P-chloroethyl)-N-(3-
hydroxypropyl)amine (I) reacts with phosphorus oxychloride, yielding the
oxazaphosphorine derivative II, which is then alkylated with N-P-chloroethylamine
hydrochloride in the presence of triethylamine. Ifosfamide is a white crystalline powder,
weakly hygroscopic, with a molecular weight of 261.08, and a melting point of 48°C to
51°C. It is 10% soluble in water (w/v). The pH of an unbuffered 5% solution of
ifosfamide is 5.5. Ifosfamide is quite soluble in ethanol, chloroform and ethyl acetate,
but only slightly soluble in ether.
1.3 The clinical use of ifosfamide
Ifosfamide was introduced into early clinical trials in 1972, as a less
myelosuppressive alternative to cyclophosphamide. It has since become established in
the treatment of sarcoma, lung cancer, cervical cancer, breast cancer, and also has
activity in ovarian cancer, teratoma and lymphoma. Ifosfamide is used more frequently
than cyclophosphamide in non-small cell lung cancer (NSCLC), where it is often
combined with mitomycin C and cisplatin (Cullen et al 1988), in sarcomas, and in
cervical cancer.
Ifosfamide generates response rates of greater than 20% in soft tissue sarcoma (Keohan
and Taub 1997). A dose of 5 g m"2 has been shown to be more effective than
cyclophosphamide given at myelosuppressive doses (1.5 g m" ). In patients previously
treated with doxorubicin containing regimens, ifosfamide given as a single agent has
resulted in response rates of 8% to 38%, and it is presently the most active single
salvage agent.
Haemorrhagic cystitis was the initial dose limiting toxicity of ifosfamide (Cox 1979), a
problem which was overcome with the introduction of mesna (sodium-2-mercapto-
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ethane sulphonate) in 1983. Myelosuppression is currently the main adverse effect. The
white blood cell count nadir usually occurs between days 8 and 13 of the treatment
cycle. Thrombocytopenia is seen less frequently, and is usually of mild to moderate
severity. The bone marrow recovers completely by day 17 or 18.
Following the concomitant use of mesna, macrohaematuria is reported now in fewer
than 5% of patients. However nephrotoxicity, in the form of glomerular or tubular
dysfunction, remains a potential problem, particularly in paediatric patients. Nausea and
vomiting are quite common, dose-related, and usually of moderate intensity. Alopecia
occurs in almost all patients. Neurotoxicity, varying in severity from somnolence to
severe encephalopathy and coma, can occur in 10% to 20% of patients receiving
intravenous ifosfamide, and in up to 50% ofpatients treated orally.
1.4 The aims of the thesis
Ifosfamide is now well established in the treatment of malignant disease. However, side
effects continue to restrict its use. Ifosfamide is a pro-drug, requiring activation to an
active compound, a process which also generates toxic metabolites. The cystitis, and
probably the neurotoxicity, are a result of this metabolic transformation, a complex and
necessary process. Although the cystitis has been eliminated by the use of mesna,
neurotoxicity has hindered the development of an oral formulation. The neurotoxic
agent has not yet been positively identified, and it is possible that a different profile of
metabolites is produced by the oral compared to the intravenous route. A more
complete understanding of ifosfamide metabolism and pharmacokinetics is required.
Furthermore, work to date has investigated the plasma compartment, but neglected the
red cell compartment. The erythrocyte fraction can be important in the transfer of many
compounds in the circulation (Driessen et al 1989a; 1989b; 1989c), and data is required
on the red cell pharmacokinetics of ifosfamide and its metabolites.
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The aims of the thesis are to:-
a Investigate the pharmacokinetics oforal ifosfamide
b Assess the neurotoxicity oforal ifosfamide
c Explore relationships between pharmacokinetic indices, and the development of
neurotoxicity, following oral ifosfamide; in particular, the hypothesis that
neurotoxicity is caused by the products ofdechloroethylation
d Investigate the uptake of ifosfamide and its metabolites by erythrocytes
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Chapter 2
The Pharmacokinetics of Ifosfamide
2.1 Introduction
Pharmacokinetic processes are those by which the body influences a drug, and
comprise absorption, distribution, metabolism and excretion. Absorption occurs most
commonly from the gastrointestinal tract after oral administration, although other
modes of entry, such as the intramuscular and subcutaneous routes, are also used.
Transfer of a drug from the site of absorption to the blood is followed by rapid
distribution between the plasma, plasma proteins (usually albumin, but sometimes
alpha-1-acid glycoprotein and occasionally globulin), plasma water and erythrocytes.
As most drugs are relatively small molecules, they cross capillaries easily and reach the
extracellular fluid of almost every organ in the body. The majority of drugs are also
lipid soluble enough to cross cell membranes and distribute in the intracellular fluid.
This transfer of drugs from blood to extravascular fluids (ie extracellular and
intracellular water) and tissues is called distribution, which is usually a rapid and
reversible process. The volume of distribution (Vd) is the volume into which a drug
appears to distribute. Soon after intravenous injection, there is a distribution equilibrium
between drug in the plasma and that in erythrocytes, other body fluids, and tissues. As a
consequence of this dynamic equilibrium, changes in the concentration of drug in the
plasma are taken to indicate concentration changes in other tissues. The initial rapid fall
in drug levels after intravenous bolus injection, the distribution-elimination phase, is
characterised by the a half-life, whereas the half-life after distribution, the terminal
half-life, is denoted the p half-life.
Metabolism is the biochemical transformation of a drug in the tissues or plasma to
metabolic products, and the transfer of a drug from the blood to urine, or other
excretory compartments (eg bile, saliva or milk) is the process of excretion. Metabolism
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and excretion are usually irreversible and together comprise drug elimination.
Elimination processes are responsible for the physical or biochemical removal of a drug
from the body. Pharmacokinetic equations are described in chapter 6.
Ifosfamide is a pro-drug, and therefore the metabolic process is central to its action,
an extensive and diverse series of transformations occurring which are not fully
understood. The study of pharmacokinetics is influenced by available analytical
methodology. The plasma nitrobenzylpyridine (NBP) alkylating activity was the
earliest method of measuring ifosfamide metabolites, based on the NBP reaction
(chapter 5), and advances in the analysis of ifosfamide and its metabolites have
preceded the gathering of more complete pharmacokinetic data.
2.2 Absorption
Oral ifosfamide is absorbed relatively quickly with peak levels occurring within one
hour (Wagner and Drings 1986). Bioavailability studies have confirmed the
extensive absorption of oral ifosfamide, with values of 90.5% and 107% for doses of
1 g and 2 g respectively (Cemy et al 1986). In a cross over study of oral and
intravenous ifosfamide, twelve patients received 1 g m"2 and six patients 2 g nfi2,
both groups crossing over on day 3 (Wagner and Drings 1986). The average
bioavailability was 100%; induction of metabolism caused variations in the area
under the plasma concentration-time curve (AUC), which were dependent on the
sequence of administration. A mean bioavailability of 92% was reported by
Kurowski et al (1991), and overall, these results indicate that ifosfamide is probably
totally absorbed from the gastrointestinal tract. The high bioavailability of ifosfamide
implies an insignificant first pass effect, even though ifosfamide is metabolized
mainly by the hepatic cytochrome mixed function oxidase P-450 system (Allen et al
1976). From the intravenous dose, AUC and assumed liver blood flow, a theoretical
maximum first pass effect of 5% to 6% has been calculated (Wagner and Drings
1986). Ifosfamide is also well absorbed when given subcutaneously, with a
bioavailability of 90% to 100% (Cerny et al 1990b).
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The small first pass effect is not consistent with the increased incidence of
neurotoxicity seen after oral administration. Neurotoxicity is thought to be caused by
a metabolite of the dechloroethylation pathway, probably chloroacetaldehyde. A low
first pass effect suggests the generation of a small amount of a very toxic metabolite.
It is possible that different profiles of oxazaphosphorine metabolites are produced
after oral administration compared to the intravenous route, even though the extent of
metabolism is similar, with a negligible first pass effect. In the same patient, Juma et
al (1979) found higher levels of alkylating activity in serum after oral
cyclophosphamide compared to intravenous dosing; the oral biovailability was nearly
100%. Similarly, in the study of Kurowski et al (1991), comparing oral and
intravenous ifosfamide in the same patient (one dose on day 1, the other on day 3),
the concentrations of activated ifosfamide were always higher after oral compared to
intravenous administration. However, although the average oral bioavailability was
92%, when ifosfamide was given intravenously on day 3, a biovailability of more
than 100% was calculated, whereas oral administration on day 3 led to a lower
bioavailability.
2.3 Distribution
Ifosfamide is distributed mainly in body water, and numerous studies have reported a
volume of distribution of about 38 L (Cerny et al 1986; Lind et al 1989a, 1989b;
McNeil and Morgan 1981). Lewis et al (1990) reported median values of the same
order for days 1 and 5 of a fractionated regimen (635 - 721 ml kg"1). The volume of
distribution of ifosfamide is approximately the sum of the vascular and extracellular
spaces, suggesting a lack of binding to plasma and tissue proteins. Similar results
have been obtained following oral ifosfamide administration, with values of 0.76 L
kg"1 and 0.72 L kg"1 after 1 g m"2 and 2 g m"2 respectively (Wagner and Drings 1986).
The metabolites of ifosfamide, unlike the parent compound, bind to plasma proteins
both in vitro and in vivo. The volume of distribution of radiolabelled ifosfamide
metabolites is equal to that of the plasma space volume (5.1 L) indicating that only
limited diffusion occurs out of the plasma, consistent with a high degree of protein
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binding (Allen and Creaven 1975). Ifosfamide microsomal metabolites are known to
bind covalently to microsomal proteins and bovine serum albumin (Allen and
Creaven 1973).
2.4 Metabolism
Ifosfamide is a structural isomer of cyclophosphamide, and follows the same
metabolic pathways, although these are quantitatively different (Norpoth 1976a;
Wagner et al 1981). The oxazaphosphorines require activation, predominantly via the
hepatic cytochrome mixed function oxidase P-450 system (Allen et al 1976). There
are large interindividual differences in the activities of various members of the P-450
superfamilies on account of environmental and genetic factors, and this is reflected in
wide interindividual variability in the extent of activation and inactivation (Boddy et
al 1992a). The lungs are a minor site of oxazaphosphorine metabolism (Brock and
Hohorst 1967; Hill et al 1973). The metabolism of ifosfamide is depicted in figure
2.1.
2.4.1 Activation ofifosfamide
Ifosfamide is activated to 4-hydroxyifosfamide, which exists in equilibrium with its
tautermeric form aldoifosfamide. Aldoifosfamide spontaneously decomposes to form
isophosphoramide mustard (IPM), the ultimate alkylating agent. Information on the
identification and quantitative analysis of 4-hydroxyifosfamide in humans and
animals is sparse (Arndt et al 1988; Ikeuchi and Amano 1985; Kurowski et al 1991;
Kurowski and Wagner 1993; Wagner et al 1981; Wiedemann et al 1993), as it is
extremely unstable in the blood, and relatively low peak plasma concentrations (1
pM - 5 pM) are generated following therapeutic doses of ifosfamide. The plasma
profile parallels - but only reaches 1% - that of ifosfamide. Similarly, few
pharmacokinetic data are available for IPM (Bryant et al 1980). IPM can be converted
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Figure 2.1. The metabolism of ifosfamide.
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Figure 2.2. The conversion of IPM into CEA and OXA.
2.4.2 Acrolein
Acrolein is responsible for ifosfamide induced cystitis, which is routinely prevented
by the concomitant administration of mesna. It is highly reactive with a short half-
life, and is further metabolised to 3-hydroxypropyl mercapturic acid. Consequently
the analysis of acrolein in plasma is difficult (Wagner et al 1981).
2.4.3 Carboxyifosfamide, ketoifosfamide and other by-products ofactivation
4-hydroxyifosfamide undergoes oxidation by an ALDH3 enzyme to
carboxyifosfamide (CIPA), which has slight alkylating properties (Dockham et al
1992). There is a wide variation in the excretion of CIPA, possibly as a result of
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phenotypic variation in ALDH activity (Goedde et al 1967). Boddy and co-workers
found that the variability in plasma metabolite AUCs was greatest for CIPA, and it
was postulated that this compound was formed from aldoifosfamide in the kidney
and excreted without returning to the systemic circulation, or that plasma
concentrations were below the limit of detection (Boddy et al 1993). Patients may be
deficient in the ALDH enzyme systemically, but possess ALDH activity in the
kidney. Phenotypic differences possibly influence efficacy and toxicity, with those
patients possessing high aldehyde dehydrogenase activity less likely to respond to
ifosfamide, whilst an increased susceptability to toxic effects occurs in those with
low activity. Impaired excretion of carboxycyclophosphamide has been described,
but not of CIPA (Boddy et al 1992a; Lind et al 1990b).
Ketoifosfamide (KIPA) is an inactive metabolite. Urinary excretion of KIPA
increases over five days when ifosfamide is given in a fractionated manner, either
intravenously or orally, but the urinary excretion of KIPA and CIPA is negligible,
and it appears that the majority of activated ifosfamide is converted to IPM (Boddy
et al 1993; Gilard et al 1993; Lind et al 1989a; Martino et al 1992). A further
reversible detoxification occurs when 4-hydroxyifosfamide reacts with sulphydryl
groups present in proteins or amino acids, forming 4-thioifosfamide. The inactive
metabolite alcoifosfamide has been detected only in animals (Struck et al 1983).
2.4.4 Dechloroethylation of ifosfamide
Dechloroethylation leads to the formation of 2- and 3-dechloroethylifosfamide (2-
DCEI and 3-DCEI) and chloroacetaldehyde. Ifosfamide and cyclophosphamide
metabolism differ quantitatively in this respect (Norpoth 1976a). The mean Cmax
and AUC of activated cyclophosphamide are three times higher than those reported
for activated ifosfamide, implying that dechloroethylation is the predominant
pathway of ifosfamide metabolism, and possibly explaining the need for higher doses
of ifosfamide compared to cyclophosphamide. (Brade et al 1985; Goldin 1982;
Wagner et al 1981). The dechloroethyl metabolites of ifosfamide were first isolated
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in urine in 1976 (Norpoth 1976a; Norpoth et al 1976b). There is a large
interindividual variation in the ratio of the side chain/ring dechloroethylation to ring
hydroxylation, and it seems that cleavage of the chloroethyl group from the ring
nitrogen is preferred to dechloroethylation of the extracyclic nitrogen atom.
Dechloroethylation of up to 50% of a dose of ifosfamide to either 2-DCEI or 3-DCEI
can occur (Norpoth et al 1975). In physiological conditions 2-DCEI and 3-DCEI are
relatively stable. The urinary excretion of 3-DCEI is approximately three times
higher than that of 2-DCEI, and 3-DCEI levels in plasma have been found to be
higher than those of 2-DCEI, suggesting that dechloroethylation of the nitrogen ring
position of ifosfamide is more common than that of the exocyclic nitrogen
(Kurowski and Wagner 1993).
Boddy et al (1993) gave paediatric patients ifosfamide infusions of 72 hours duration
every three weeks. The concentration of dechloroethylated metabolites in some
individuals continued to rise long after the Tmax of ifosfamide. The urinary recovery
of dechloroethylated metabolites increased with the course of administration, but
corresponding correlations between plasma AUC and treatment course were not
observed. A correlation between the AUCs of ifosfamide and its metabolites with the
recovery of these compounds in urine was lacking. There was no increase in the
excretion of dechloroethyl metabolites during the infusion.
Gilard and co-workers analysed 2-DCEI and 3-DCEI in human urine using
•5 1
[ P]NMR, identifying degradation products of these compounds (Gilard et al 1993).
The proportion of dechloroethylated derivatives was higher than that of the
metabolites of the activation pathway.
There is a wide variation in the plasma concentrations of chloroacetaldehyde
reported in the literature (Cerny and Kiipfer 1989; Goren et al 1986; Kaijser et al
1993; Kurowski and Wagner 1993; Kurowski et al 1991). Goren and colleagues
detected levels of up to 100 pM in children, following an ifosfamide infusion of 1.6 g
m"2 day"1, whilst Cerny and Ktipfer reported levels of 210 pM. Following a dose of
2 11.5 g m" day" of ifosfamide for five days in adults, Kurowski and Wagner
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determined mean chloroacetaldehyde Cmax concentrations of 2.69 pM and 4.85 pM
on days 1 and 5 respectively, with corresponding values for 2-DCEI of 8.6 pM and
16.7 pM, and for 3-DCEI of 12.9 pM and 26.5 pM, almost reaching the
concentrations of ifosfamide itself.
In vivo, chloroacetaldehyde is rapidly converted to chloroacetate. Between 6% and
22% of chloroacetate administered to mice is eliminated unchanged in the urine
(Yllner 1971). The main urinary metabolites of chloroacetate are S-carboxymethyl-
L-cysteine and thiodiacetic acid, with glycolic and oxalic acids generated to a lesser
extent. As well as transformation to chloroacetic acid, chloroacetaldehyde may also
be converted to cysteinyl derivatives and thioacetals. S-carboxymethylcysteine and
thiodiacetic acid are excreted in large amounts after an infusion of ifosfamide
(Norpoth 1976a).
2.4.5 Factors influencing ifosfamide metabolism
a Enzyme induction
There is evidence that ifosfamide induces its own metabolism (Kurowski and
Wagner 1993; Kurowski et al 1991; Lind et al 1989a; Lewis et al 1990; Nelson et al
1976; Piazza et al 1984; Wagner and Drings 1986). Fractionation over a number of
days produces a time dependent decrease in the half-life of ifosfamide without an
increase in renal clearance. Nelson et al (1976) used a fractionated ifosfamide
regimen of 1.6 - 2.4 g m" daily for 3 days in three patients, with a second course
three weeks later, and compared it to a single intravenous bolus dose of 5 g m"2 in
five patients (Allen and Creaven 1975; Creaven et al 1974). The fraction of
ifosfamide metabolised at the lower dose was nearly twice that for the higher dose,
and the renal excretion and clearance rates were similar for both regimens. These
results suggest that an increase in ifosfamide metabolism occurs when the dose is
fractionated. This was confirmed by Piazza et al (1984), who studied ten patients
with lung cancer receiving intravenous ifosfamide 1.8 g m"2 daily for five
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consecutive days, and found nearly a 50% reduction in drug elimination half-life on
day 5 compared to day 1.
In a later study, Lind et al (1989a) gave intravenous ifosfamide 1.5 g m"2 daily for
five days, and noted that the total clearance was increased from a median of 69 ml
min"1 on day 1 to 123 ml min"1 on day 5, although ifosfamide distribution remained
constant. Corresponding figures for non-renal clearance were 60 ml min"1 and 104 ml
min"1 for days 1 and 5 respectively. The half-life of ifosfamide decreased from 6.16
hours on day 1 to 3.76 hours on day 5, with respective figures for the AUC of 575
pg.hr ml"1 and 284 pg.hr ml"1. This provides further evidence that the
pharmacokinetic changes are due to increased metabolism with time, perhaps as a
result of increased liver enzyme activity. Similar results were published by Lewis et
al (1990), who demonstrated a significant increase of 76% in ifosfamide clearance
over a daily administration period of five days. The apparent volume of distribution
was unaffected.
As expected, increased metabolite production occurs with fractionation of ifosfamide
dose. The autoinduction of ifosfamide metabolism can be detected by the second day
of treatment, and subsequently increases (Boddy et al 1993). Lind et al (1990b)
studied the excretion of alkylating metabolites in urine following fractionated
ifosfamide 1.5 g m" daily for five days, administered either orally or intravenously.
The median total alkylating metabolite excretion, expressed as a percentage of the
ifosfamide dose, increased in the intravenous group from 3.45% to 8.13% by day 5,
and in the oral group from 15.18% to 29.15% by day 3. Over the five day period
there was no increase in urinary ifosfamide excretion. In the study of Lewis and
colleagues, there was a significant increase of more than three-fold in the plasma
alkylating AUC on day 5 compared to day 1, whilst Boddy and co-workers detected
up to a three-fold increase in ifosfamide clearance during three days of continuous
infusion, with an increased rate of dechloroethylation (Boddy et al 1993; Lewis et al
1990).
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Hartley et al (1994) studied the urinary excretion of ifosfamide and its metabolites
during three day infusions. The proportion of ifosfamide (expressed as a proportion
of total urinary drug products) in the urine decreased, but those of 2-DCEI, 3-DCEI
and CIPA increased, whilst that of IPM was unchanged. The proportion of each
metabolite remained constant with increasing ifosfamide doses, and there was no
evidence of saturation of metabolic pathways. Small but significant increases in the
fraction of drug converted to 2-DCEI and IPM were observed with successive cycles.
Ifosfamide, 3-DCEI and CIPA appeared in the urine progressively earlier in
successive cycles of treatment. Analysis of metabolite ratios suggested that patients
who metabolised more ifosfamide to 2-DCEI also tended to convert more to 3-DCEI,
and less to CIPA.
Kurowski and Wagner (1993) reported that the Cmax and AUC values of 4-
hydroxyifosfamide and the dechloroethylated metabolites increased approximately
two-fold during a five day treatment schedule. The two metabolic routes were
induced to the same extent, and the relative contribution of accumulation to the total
increase in metabolite AUC on day 5 was negligible. The average Cmin levels of 4-
hydroxyifosfamide, chloroacetaldehyde, 3-DCEI and 2-DCEI accounted for only
2.5%, 4.0%, 5.6% and 4.3% respectively, of the subsequent maximum values.
b Stereoisomerism
Ifosfamide exhibits optical isomerism due to the presence of an asymmetrically
substituted phosphorus atom. It is used as the racemic mixture, but since
oxazaphosphorines require enzymatic activation, the possibility of stereoselective
metabolism exists. In mice, both enantiomers of ifosfamide are eliminated at almost
equal rates, whilst KIPA is formed stereoselectively from s(-)-ifosfamide. However this
does not result in differences in biological activity (Blaschke et al 1986).
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c Age and obesity
Age has a minimal effect on ifosfamide pharmacokinetics. There is a positive
correlation between the elimination of ifosfamide and age, with an increased P half-
life in elderly patients, explained by a higher apparent volume of distribution (Lind et
al 1990a). Total plasma clearance, renal clearance and non-renal clearance are not
affected, but changes in the autoinduction of ifosfamide metabolism can occur. The p
half-life of ifosfamide is shorter in children than in adults, with a higher renal
excretion of ifosfamide and dechloroethyl metabolites (Boddy et al 1993; Boos et al
1992; Goren 1991). Lind et al (1989b) found that the elimination half-life of
ifosfamide is prolonged in obese patients, probably as a result of an increase in the
apparent volume of distribution, rather than decreased clearance. Therefore toxicity
may be more severe in obese patients, although the clinical importance of this is
uncertain, given the large interindividual variation in ifosfamide metabolism.
d Individual and genetic variation
There is a large variation in ifosfamide metabolism, and reports describing these
appeared as early as 1976 (Kurowski and Wagner 1993; Lind et al 1989a; Lind et al
1990b; Norpoth 1976a). Norpoth (1976a) identified the stable alkylating metabolites
in the urine of 25 patients after ifosfamide administration, and suggested a variation
in metabolism between individuals of up to 70%; poor metabolisers of ifosfamide
were identified, in addition to those preferring dechloroethylation or 4-hydroxylation.
The variation in CIPA production has been discussed above. However it is not clear
whether all the variations observed can be explained by the genetic determinants of
the cytochrome P-450 isoenzymes. Philip et al (1988) measured the plasma
pharmacokinetic profiles of ifosfamide and NBP alkylating activity in 33 patients
who had been phenotyped for debrisoquine oxidation. Three were poor metabolisers,
but no correlation was identified between the debrisoquine metabolic ratio and the




Variations in dose and dosage interval affect ifosfamide metabolism. A dose
dependent saturation of enzymatic activation has not been firmly identified, although
some data from a dose intensification study indicate that ifosfamide metabolism may
be saturated at doses above 14 g m"2 (Wagner 1994). However, at single doses of up
to 5 g m~ the half-life is not prolonged, and the decline in plasma ifosfamide
concentrations remains a first order process (Cerny et al 1986).
2.5 Excretion
Ifosfamide and its metabolites are excreted by the kidney, although quantities found
in urine are subject to large interindividual variation. Allen et al (1976) found that
53.1% of the administered dose of ifosfamide is excreted unchanged in the urine, but
lower concentrations have been reported in more recent studies; 2.58% (Lind et al
1990b), 16.6% (Martino et al 1992), 18% (Goren 1991), and 18% (Gilard et al 1993).
In children, a urinary excretion of 14% to 34% has been described (Boos et al 1992).
These variations may reflect differences in analytical techniques. Lind and co¬
workers found that the most common alkylating metabolite in urine was
dechloroethylifosfamide, at concentrations similar to those reported by Norpoth; the
excretion of CIPA was very variable, and the levels of IPM were low (Lind et al
1990b; Norpoth 1976a).
2.5.1 Elimination half-life
The main route of ifosfamide elimination is metabolism, with excretion playing a
minor role. There is a large interindividual variability in half-lives reported in the
literature, and the dependence of the activation of ifosfamide on the cytochrome P-
450 system may be part of the explanation. In most studies of ifosfamide
administered as a bolus injection, or as a short intravenous infusion, at doses of 1 g
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m" to 3 g m" , the terminal elimination plasma half-life is between 30 minutes and
nine hours (Cerny et al 1986; Lewis et al 1990; McNeil and Morgan 1981; Nelson et
al 1976; Piazza et al 1984). However, Allen et al (1976) recorded a half-life of 15
hours; differences in analytical techniques may be responsible, as ifosfamide and
hydrophobic metabolites, such as 2-DCEI and 3-DCEI, are determined together
unless adequate separation steps are taken (Wagner et al 1981). As described
previously, a significant reduction in the terminal elimination half-life of ifosfamide
during fractionated dosage regimens has been identified.
2.5.2 Clearance
Allen et al (1976) described a renal clearance of ifosfamide of 21.3 ml min"1.
Following 1.6 g m"2 to 2.4 g m"2 intravenous ifosfamide daily for three days, Nelson
et al (1976) determined a total body clearance of 14.9 ml min"1 to 24.2 ml min"1, and
a urinary excretion of unchanged ifosfamide of 12.4% to 17.9% of the total dose, but
the assay may have been non-specific. These values of total body clearance are lower
than those subsequently reported.
Following ifosfamide administration, 500 mg orally or an intravenous infusion of up
to 2 g, McNeil and Morgan (1981) calculated a total body clearance of 108 to 148 ml
min"1. The urinary excretion of unchanged ifosfamide was 9.4% to 10.8% of the total
dose. Lind et al (1989a) gave 1.5 g m"2 day"1 oral ifosfamide consecutively for five
days to ten patients; a total body clearance of 51 ml min"1 was obtained on day 1,
increasing to 86 ml min"1 by day 5. The group of Cerny compared 1 g and 2 g doses
of oral and intravenous ifosfamide, reporting total body clearances of 45 to 72 ml
min"1, and 61 ml min"1 after 5 g oral ifosfamide (Cerny et al 1986). Similarly, Lewis
et al (1990) described a total clearance of ifosfamide of 66 ml min"1 on day 1. A renal
ifosfamide clearance of 0.663 L hr"1 m"2 in children indicates that this is not an
important route of elimination in this age group (Boddy et al 1993).
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2.6 Conclusion
Ifosfamide possesses complex pharmacokinetics and metabolism is central to its
cytotoxic activity. The competing processes of dechloroethylation and 4-
hydroxylation are probably important determinants of activity and toxicity in any
given individual. Despite advances in pharmacokinetic understanding, the ultimate
fate of up to 70% of an intravenous ifosfamide dose is not known. The formation of
metabolites not detected by the currently available assays is a possibility. Other
alternative explanations are the conjugation of parent drug or reactive metabolites to
mesna, or endogenous compounds such as glutathione, perhaps followed by biliary
excretion and faecal elimination. It is known that cyclophosphamide is eliminated in
the bile, but only 0.92% to 2.5% of intravenously administered 14C-labelled
cyclophosphamide is found in the faeces (Bagley et al 1973; Dooley et al 1982).
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Chapter 3
The Central Nervous System Toxicity of Ifosfamide
3.1 Introduction
Urotoxicity was the dose limiting side effect of ifosfamide until the introduction of
mesna in 1983, when it was replaced by myelosuppression and neurotoxicity.
Encephalopathy of varying degrees occurs in approximately 10% of patients after
intravenous ifosfamide, and is almost always reversible, but has occasionally proved
fatal. The condition is reported less frequently in children. This chapter reviews the
clinical features of ifosfamide induced encephalopathy, associated risk factors, and
possible aetiological agents and mechanisms of development.
3.2 Clinical features
3.2.1 Incidence
Initial reports of encephalopathy following ifosfamide and mesna suggested an
incidence of approximately 5%, but these effects were poorly characterised (Bruhl et
al 1976; Scheulen et al 1983; Schnitker et al 1976). In 1982, Morgan and co-workers
noted CNS toxicity in 13 of 254 (5.1%) NSCLC patients treated with either
ifosfamide 4 g m"2 day 1, or 1.2 g m"2 days 1 to 5, without mesna (Morgan et al
1982). In a later study, an overall incidence of 11% was found in adults with a
variety of tumour types, using a dose of 5 g m"2 over 24 hours (Watkin et al 1989).
Severe encephalopathy was described in five of 31 women (16%) with cervical or
endometrial carcinoma given ifosfamide 5 g m"2 and mesna 8.2 g m"2, and seven of
41 patients (17.1%) with advanced carcinoma of the cervix developed
encephalopathy following single agent ifosfamide 1.5 g m"2 daily for five days
(Coleman et al 1986; Meanwell et al 1985).
24
Both higher and lower incidences have also been reported. In one study of a 24 hour
intravenous infusion of 5 g m~ ifosfamide, with a total dose of intravenous mesna of
5 g m"2 per cycle, serious CNS toxicity occurred in less than 1% of 103 patients with
small cell lung cancer (SCLC) (Cantwell and Harris 1985). Perren et al (1987)
observed adverse CNS reactions in three of five patients with advanced lung cancer
2 • 2treated with a six hour infusion of ifosfamide 5 g m" with mesna 5 g nf . In another
series of patients, CNS toxicity was seen in 5/18 (28%) given ifosfamide, either as a
single agent or as part of a combination chemotherapy regimen (Merimsky et al
1991). An incidence of 22% (11/50) was reported in a paediatric population
receiving single agent ifosfamide (Pratt et al 1986).
3.2.2 Symptoms
Encephalopathy is usually manifested by somnolence, although other features such
as forgetfulness, nightmares, seizures, tonic clonic spasms, and coma may occur.
Disorientation, motor unrest, emotional lability, depression, echopraxia, and
logorrhoea have also been described (Briihl et al 1976; Miller and Eaton 1992;
Rodriguez et al 1976). Both auditory and visual hallucinations have been
documented (Heim et al 1981; Watkin et al 1989). The visual hallucinations usually
differ from those experienced in psychiatric conditions in that they are often vivid,
complex and frightening. DiMaggio et al (1994) described six patients with
ifosfamide induced visual and/or auditory hallucinations in the presence of a clear
sensorium; all were alert and fully orientated. Interestingly, patients experienced
hallucinations only during periods of eye closure.
With severe and progressive encephalopathy, logorrhoea, palilalia, perseveration of
writing and speech, and marked disorientation appear after 20 to 50 hours, following
which patients may enter a trance, and coma soon follows. Brainstem reflexes are
intially preserved, but circulatory collapse secondary to depression of vital centres is
eventually fatal.
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Seizures, cerebellar signs and cranial nerve dysfunction are more common in
children than in adults. Most of the eleven encephalopathic paediatric patients
described by Pratt et al (1986) developed drowsiness and somnolence. Mental
changes were seen, ranging from irritability and confusion to disorientation and
psychosis, and many exhibited personality and behavioural disturbances. Symptoms
resolved within three days of stopping ifosfamide. Mild to moderate weakness often
developed, and there was one case each of aphasia, ataxia and seizures, with two
developing reversible cranial nerve abnormalities. Salloum et al (1987) reported a
fatality following ifosfamide induced encephalopathy in a four year old girl. This
occurred on the eighth course of treatment, possibly as a result of progressive
subclinical renal toxicity during the first seven courses, with impaired clearance of
neurotoxic metabolites.
The WHO and CTC gradings for neurotoxicity are shown in tables 3.1 and 3.2.
Grade
0 1 2 3 4
Alert Transient Somnolence Somnolence Coma
lethargy < 50% of > 50% of
waking hours waking hours
Table 3.1. WHO grade state of consciousness.
Biochemical disturbances and localising neurological signs are not characteristic,
although a low serum bicarbonate, sodium, potassium, and pH have been reported.
Signs of water intoxication due to inappropriate arginine vasopressin secretion have
also been described (Cantwell et al 1990). Computerised tomographic brain scans
have not shown abnormalities, other than pre-existing asymptomatic metastases,
which are themselves risk factors. Morphometric studies have revealed no correlation
between the severity of the encephalopathy and the width of the ventricles or the sulci
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Toxicity Grade
0 1 2 3 4
Neurosensory none or no mild paraesthesia, mild or moderate severe objective
change loss of deep objective sensory sensory loss, or
tendon reflexes loss; moderate paraesthesia that
paraesthesia interfere with
function
Neuromotor none or no subjective mild objective objective paralysis
change weakness; no weakness without weakness with
objective findings significant impairment of
impairment of function
function
Neurocortical none mild somnolence moderate severe coma,





Neurocerebellar none slight intention tremor, locomotor ataxia cerebellar
incoordination, dysmetria, slurred necrosis
dysdiadocokinesis speech, nystagmus
















mild moderate severe ileus >96 hrs


















Table 3.2. Common Toxicity Criteria (CTC) (neurological).
27
(Merimsky et al 1991), and lumbar punctures and magnetic resonance brain scans
have been reported as normal (Danesh et al 1989; Miller and Eaton 1992; Zulian et al
1995). Perren et al (1987) described a patient with a single CNS metastasis,
previously treated successfully with radiotherapy, who behaved in an atypical
fashion with the development of a mild left hemiplegia and drowsiness 40 hours after
ifosfamide treatment; a computerised tomography scan showed a diffuse decrease in
density throughout the white matter, with some areas of irregular uptake after
contrast.
3.2.3 Timing
The time of onset of encephalopathy is variable; it may occur within two hours of the
start of the infusion, or not appear until 28 days, but is most often seen after 20 to 50
hours. The duration of the acute phase can vary between one and twelve days.
Encephalopathy most often develops on the first cycle. Watkin et al (1989) described
18 cases of serious encephalopathy during the first, second, third and sixth cycle in
eleven, two, four and one patients respectively. One developed encephalopathy
during a 24 hour ifosfamide infusion. The mean time to onset was 46 hours from the
start of the infusion (range 12 - 146 hours), and the median duration three days
(range 1-12 days). Five patients took one week or more to recover, and there was
incomplete recovery in two patients who died on days 22 and 29, with persistent
clinical evidence of encephalopathy. Heim et al (1981) performed a psychiatric
assessment, including tests for long and short term memory, before and after
treatment with ifosfamide in ten nephrectomised patients with advanced renal
carcinoma. Seven patients developed psychological disturbances commencing two
hours after the infusion. Emotional instability and impairment of short term memory
persisted for up to ten weeks in five and four patients respectively. The previous
nephrectomies may have contributed to this high incidence.
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3.2.4 Management
Following the development of encephalopathy, ifosfamide should be stopped and
any electrolyte abnormalities corrected. Sedative drugs can compound the problem
and should be avoided, although the use of high potency neuroleptics such as
haloperidol, titrated to sedation if necessary, has been recommended in very
disturbed patients (DiMaggio et al 1994; Manegold et al 1992). The presence of
intracranial metastases should be considered. Patients may not experience CNS
toxicity if re-challenged, despite the persistence of risk factors. If further
administration is attempted, a prolonged continuous intravenous infusion of
ifosfamide with simultaneous equidose mesna, the correction of hypoalbuminaemia,
and bicarbonate supplements, may prevent CNS toxicity. Piracetam and phenytoin
have been assessed as a prophylaxis (Cerny and Kiipfer 1992). More recently,
methylene blue has become established in the treatment and prophylaxis of
ifosfamide induced encephalopathy, at a dose of 50 mg three times daily (Ktipfer et
al 1994). Haemodialysis improved ifosfamide induced irritability, tremor and ataxia
in a 20 month old child (Carlson et al 1998).
3.3 The electroencephalogram in ifosfamide encephalopathy
Abnormalities in the electroencephalogram (EEG), consistent with a generalised
disturbance, precede clinical symptoms by 12 to 24 hours (Meanwell et al 1985).
Clinical symptoms and EEG abnormalities are highly correlated, but early EEG
disturbances develop in 56% of patients receiving a 24 hour infusion of ifosfamide
without clinical toxicity. During the first 18 hours of treatment, asymptomatic
reduced dominant EEG frequency may occur. This is followed by a further lowering
of EEG background frequency, with high amplitude paroxysmal delta activity. After
20 to 50 hours, low amplitude 1 Hz delta activity, some theta activity and triphasic
waves with an anterior emphasis become evident. A slow reversal of the EEG
abnormalities from about 40 hours leads to clinical recovery after a further 36 hours.
Subsequent progression of clinical and EEG abnormalities is associated with a worse
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prognosis. After 50 hours there may be a further lowering of EEG amplitude and
frequency (1.5 Hz - 2 Hz), disappearance of most high frequency components, and
the absence of triphasic components. A grading system for ifosfamide induced EEG
abnormalities has been described (Table 3.3) (Meanwell et al 1986a).
Grade EEG recording Clinical observation
Normal
A drop in alpha frequency compared with
pretreatment EEG, with or without small
amounts of paroxysmal theta activity
Alert
Transient lethargy
Predominant theta activity, with or without
intermittent delta activity
Somnolence < 50% of the time
and/or mild/moderate disorientation
Predominant delta activity with or without
sharp (complex) wave forms
Somnolence > 50% of the time
and/or severe disorientation,
echolalia, perseveration of writing,
palilalia, logorrhoea, hallucinations
or delusions
Continuous delta activity, complex wave
forms and triphasic waves
Coma
Table 3.3. The Meanwell grading of EEG abnormalities.
Other authors have reported generalised or focal abnormalities, or abnormal waves
(Coleman et al 1986; Heim et al 1981; Zulian et al 1995). Pratt et al (1986)
performed EEGs in 23 paediatric patients who received 51 courses of ifosfamide.
Intravenous ifosfamide, 1.6 g m"2 over 15 minutes, was given daily for five days.
Abnormalities were seen during five courses in four patients with neurotoxicity.
Interestingly, during 42 courses in 19 asymptomatic patients, EEGs became
abnormal in 14 courses. In all patients, slowing of the baseline rhythm was followed
by increased delta activity. One patient, who showed spike activity on the last day of
course 1, had a seizure on day 2 of course 2. The EEG was normal before the seizure,
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but delta activity subsequently appeared. Danesh et al (1989) described high
amplitude, frontally dominant, triphasic waves with a reduction of alpha frequency to
6 Hz, whilst Gieron and colleagues found EEG changes to parallel the clinical course
in two children (Gieron et al 1988). There is no data suggesting that pre-treatment
EEGs predict the development of clinical encephalopathy.
3.4 Risk factors
Numerous risk factors for the development of encephalopathy have been described.
The most important are impaired renal function, low serum albumin, and the
presence of pelvic disease or brain metastases. A reduced serum albumin may be an
indicator of hepatic impairment, and therefore altered ifosfamide metabolism.
Furthermore, any protective protein binding of toxic metabolites will be diminished.
Other factors include a pre-treatment bicarbonate of less than 15 mM L"1, a poor
performance status, an advanced age, prior brain irradiation, or a history of previous
CNS disorders or alcoholism (Manegold et al 1992). A rapid rate of ifosfamide
infusion and previous cisplatin therapy have also been implicated (Goren et al 1987;
Perren et al 1987).
3.4.1 The Meanwell nomogram
Using discriminant analysis, Meanwell et al (1986a) identified low serum albumin,
high serum creatinine and the presence of pelvic disease as variables predisposing to
encephalopathy. The study was based on 77 patients with advanced carcinoma of the
• i 2 2
cervix, treated with a bolus dose of 1.5 g m" mesna, followed by 5 g m" ifosfamide
and 5 g m"2 mesna over 24 hours, then further mesna 3.0 g m"2 to 3.2 g m"2 over 12
hours. Seven patients (9%) developed WHO grade 3 or 4 CNS toxicity. A nomogram
was constructed (figure 3.1). The probability of not developing grade 3 or 4
encephalopathy falls on the intersection of a straight line joining the serum albumin
and serum creatinine concentrations on the appropriate pelvic disease scale.
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The same group performed a prospective study of the nomogram in 45 patients, 22 of
whom had cervical carcinoma (Meanwell et al 1986b). Thirty-eight patients had a
greater than 0.20 computed probability of remaining free from grade 3 or 4 CNS
toxicity, and none developed clinical signs or symptoms of such toxicity (predictive
value of a negative test result 100%). Four of seven patients with a probability of less
than 0.20 developed grade 3 toxicity (predictive value of a positive test result 57%;
95% CI 20% - 84%). It was recommended that ifosfamide is not administered to
patients with less than a 0.20 probability of remaining free from grade 3 or 4 CNS
toxicity.
However the universal applicability of the nomogram has been questioned. Two
patients with encephalopathy described by Perren et al (1987) had calculated
probabilities of freedom from encephalopathy of 0.30 and 0.39. They postulated that
their six hour ifosfamide infusion, rather than the 24 hour ifosfamide infusion used
by the group of Meanwell, may have resulted in higher serum and CSF levels of the
unchanged drug and metabolites, with encephalopathy developing despite lower
degrees of renal and hepatic impairment. It was suggested that if the nomogram is
used with schedules other than the 24 hour infusion from which it was derived, then
the lowest computed probability score should be determined for each schedule.
Similarly, Watkin et al (1989) assessed 18 cases of ifosfamide induced
encephalopathy following ifosfamide 5 g m"2 over 24 hours, either as a single agent
or in combination. The Meanwell nomogram was used retrospectively to determine
the sensitivity of the test. Only three patients had a probability of less than 0.20 of
remaining free of grade 3 or 4 encephalopathy. The sensitivity was 18% (95% CI 0%
- 36%). In another report, three of 27 patients with SCLC given ifosfamide
developed severe neurotoxicity despite Meanwell probabilities of remaining free
from encephalopathy of 0.9 or more (McCallum 1987). The efficacy and accuracy of
the nomogram has also been criticised on the basis of the variation in serum albumin
with the method of laboratory measurement and posture (Hill and Harrop 1986).
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3.4.2 Dose and schedule of ifosfamide
The development of neurotoxicity is dependent on the total ifosfamide dose, dose
limiting toxicity occurring at approximately 18 g m~2, and the schedule of
administration, with less toxicity when ifosfamide is infused continuously over
several days, rather than in daily fractions (Cerny et al 1990a; Elias et al 1990).
Serious encephalopathy has been seen following rapid infusion over six hours
(Perren et al 1987). A five day schedule may be associated with less severe
neurological toxicity than a one day schedule (Coleman et al 1986). Curtin and co¬
workers treated 18 patients with a 24 hour infusion of ifosfamide 2.5 g m"2 to 5 g m"2;
six developed WHO grade 3 neurotoxicity, which was not seen in five patients
receiving a five day infusion at a daily dose of 1.2 g m"2 to 1.5 g m"2 (Curtin et al
1991). A dose response relationship has also been identified following oral
ifosfamide, when an increase in the daily dose results in more severe neurotoxicity.
The total cycle dose is less important than the total daily dose (Manegold et al 1992).
3.4.3 Oral administration
Neurotoxicity occurs more frequently when ifosfamide is given by the oral route,
with an incidence of 50%. Wagner and Drings (1986) found four of six patients
experienced neurotoxicity after 2 g m~2 of oral ifosfamide. Cerny et al (1989b) used 2
g ifosfamide daily, days 1 to 3, with oral etoposide, in SCLC, and one third of
patients developed mild CNS toxicity. In a study of oral and intravenous ifosfamide
in NSCLC, ifosfamide 1.5 g m" daily was administered for five days by both routes
to groups of ten patients (Lind et al 1989a). Two patients in the oral arm became
comatose for 24 to 48 hours, but recovered completely, with no neurological
sequelae, whilst three suffered WHO grade 3 neurotoxicity. Mild degrees of grade 2
encephalopathy were seen in the intravenous arm. Manegold et al (1992) studied four
different schedules of oral ifosfamide (1 g daily for five days; 750 mg, 1 g or 1.25 g
daily for 14 days; [schedules 1 to 4 respectively]), using the Meanwell grading (table
3.3). Grade 1 or 2 CNS toxicity was noted in 2/15 (13%) of patients on schedule 1,
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8/19 (42%) on schedule 2, 8/23 (35%) on schedule 3, and 4/7 (57%) on schedule 4.
Grade 3 toxicity was not seen.
3.4.4 The influence ofdisease
It is not clear whether ifosfamide encephalopathy is a disease specific phenomenon,
although Meanwell and colleagues felt that it is more likely to occur in patients with
bulky, responsive, cervical and endometrial cancers (Meanwell et al 1985). It seems
improbable that encephalopathy is associated with response to chemotherapy, and
cases have been described in patients with ifosfamide resistant tumours. The
products of tumour lysis entering the CNS has been postulated as one mechanism,
but Merimsky et al (1991) found no relationship between tumour response, including
that of Non-Hodgkins lymphoma, and the development of encephalopathy,
suggesting that tumour lysis is not a factor.
3.4.5 Plasma potassium concentrations
In one series of encephalopathic patients, plasma potassium concentrations were
available in seventeen patients, and fell from a mean of 4.12 mM before
chemotherapy to 2.94 mM at the onset of encephalopathy, and to a minimum of 2.88
mM (Watkin et al 1989). In 14 patients the plasma potassium nadir was at the time of
onset of the encephalopathy, and in three the potassium fell subsequently. In two,
hypokalaemia was attributable to prolonged vomiting. Hypokalaemia is an unlikely
pathogenic factor in the encephalopathy, since there was no relationship between
their durations, and it may be a manifestation of tubular damage. It was also
postulated that hypokalaemia is caused by the encephalopathy, and an example of
stress hypokalaemia, which is thought to be an adrenergic effect.
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3.5 Aetiology of ifosfamide induced encephalopathy
The reversibility of ifosfamide induced encephalopathy, the EEG findings of a
generalised cortical disturbance, and an increased incidence with higher doses,
implicate a metabolic encephalopathy. However the chemical entity responsible has
not yet been firmly identified. It is likely to be a metabolite of ifosfamide, and the
evidence for this possibility is reviewed in this section.
3.5.1 Ifosfamide
Radiolabeled ifosfamide can be detected within the CSF two hours after an
ifosfamide infusion. Concentrations after two to three hours are between 23% and
49% of the plasma level (Creaven et al 1974), but only very low CSF concentrations
of ifosfamide metabolites are found, as measured by NPB alkylating activity. Ninane
et al (1989) measured CSF alkylating activity in four children after one hour
ifosfamide infusions, and this was always lower than the plasma concentration. The
mean CSF to plasma concentration ratio during the first 12 hours was 0.53. These
observations led to the hypothesis that encephalopathy may be a consequence of a
direct toxic effect of ifosfamide on the CNS. However, the studies were unable to
assess the contribution of ifosfamide metabolites, as the NBP reaction is an
insensitive test for these compounds. Ifosfamide concentrations in paediatric CSF
have been reported to be almost as high as in plasma, with CSF to plasma ratios of
0.59 to 2 (Kaijser et al 1997; Yule et al 1997).
In patients with ifosfamide induced encephalopathy, the clearance, half-life, and
volume of distribution of ifosfamide are not significantly different to those obtained
in patients without this complication, suggesting that a metabolite is responsible.
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3.5.2 Mesna
Mesna can produce somnolence and fatigue, but little is known of its penetration into
the CSF. The compound binds several metals to albumin, including copper, iron and
lead. It has been postulated that neurotoxicity results from large unusual fluxes of
intra and extra cellular iron or copper ions, disturbing adrenergic and serotonergic
central neurotransmitter systems (Meanwell et al 1985). However it is very unlikely
that mesna is responsible for CNS toxicity, as ifosfamide encephalopathy was seen
prior to its introduction. Mesna may even protect against CNS toxicity, as it
neutralises 4-hydroxyifosfamide, chloroacetaldehyde, acrolein and IPM. The lethal
effects of small amounts of chloroacetaldehyde (5 ppm) in a fish model of
neurotoxicity can be prevented by adding mesna to the water (Cerny and Kiipfer
1992).
3.5.3 Chloroacetaldehyde and dechloroethylation
Chloroacetaldehyde may be a factor in the development of neurotoxicity. It is
neurotoxic in rats (Lawrence et al 1972), and structurally related to chloral hydrate
(trichloroacetaldehyde), which in overdose produces symptoms and signs similar to
ifosfamide induced encephalopathy. Neurotoxicity has not been seen following
cyclophosphamide administration, even after the high doses associated with
peripheral stem cell collection and transplantation; early reports suggested that lower
quantities of chloroacetaldehyde are probably generated following
cyclophosphamide metabolism (Bagley et al 1973; Colvin 1982; Norpoth 1976a).
Goren et al (1986) pointed out that as 50% of ifosfamide can be dechloroethylated,
potentially leading to ten-fold greater quantities of chloroacetaldehyde, and since the
dose of ifosfamide is usually ten times that of cyclophosphamide, the combined
difference in side chain dechloroethylation and dosage suggests that ifosfamide may
yield one hundred times more chloroacetaldehyde than cyclophosphamide.
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A high reactivity and short half-life of three to five minutes make chloroacetaldehyde
notoriously difficult to quantify in biofluids. Goren et al (1986) found mean blood
chloroacetaldehyde levels of 88 pM at six hours and 109 pM at 24 hours in two
patients with neurotoxicity, compared with respective concentrations of 45 pM and
22 pM in four patients without such toxicity. They postulated that the persistently
high levels and temporal relationship to the development of neurotoxicity implicated
chloroacetaldehyde as the cause. Cerny et al (1990a) were unable to confirm the
chloroacetaldehyde threshold of 80 pM to 100 pM, above which neurotoxicity is
likely to develop, as suggested by the group of Goren; it was not seen at levels of up
to 210 pM.
Kurowski et al (1991) performed a cross over study of intravenous and oral
ifosfamide, and found higher plasma concentrations of chloroacetaldehyde with the
oral route. However in a later intravenous study, concentrations on the last day of a
five day ifosfamide schedule of 1.5 g m"2 day"1 were just as high as those following
the same dose given on one occasion orally in the initial study, and no neurotoxicity
was seen.
Dechloroethylifosfamide has been used as an indicator of chloroacetaldehyde
formation. In one study a planned five day course of oral ifosfamide often had to
terminated following neurotoxicity, usually on day 3 (Lind et al 1990b). Oral
administration resulted in a higher recovery of dechloroethylifosfamide, IPM and
CIPA from urine, but there was no relationship between any individual metabolite
and the development of neurotoxicity. A possible explanation is a poor correlation
between urinary and plasma concentrations. In a study of ten day continuous
infusions of ifosfamide in 23 patients, one developed neurotoxicity after six days,
associated with high 2-DCEI and 3-DCEI plasma levels (greater than 40 pg ml"1
compared with less than 14 pg ml"1 for those without encephalopathy) (Kaijser et al
1996). The penetration of 2-DCEI and 3-DCEI into CSF is low in children, levels
either being undetectable or reaching CSF to plasma ratios of less than 0.5 (Kaijser et
al 1997; Yule et al 1997). The stereochemistry of dechloroethylation may also be
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important, and a relationship between CNS toxicity and increased urinary excretion
of (R)-3-DCEI has been postulated (Wainer et al 1994).
Although the bioavailability of oral ifosfamide is almost 100% (Cerny et al 1986;
Wagner and Drings 1986), a small but significant first pass effect would be
compatible with a very toxic metabolite, such as chloroacetaldehyde, preferentially
being produced following oral dosing. The oral route generates higher biliary
chloroacetaldehyde levels in rats compared to the intravenous route (Cerny and
Ktipfer 1992). Following oral cyclophosphamide higher levels of serum alkylating
activity have been found compared to intravenous administration, despite an oral
bioavailability of almost 100%, suggesting the production of a different profile of
metabolites (Juma et al 1979). It is still not certain whether the differences seen after
oral administration are the result of a hepatic effect or even earlier presystemic
metabolism.
Glutathione, a tripeptide thiol, may influence clinical response to ifosfamide by
deactivating alkylating species through conjugation of nucleophilic groups with its
sulphydryl groups. Glutathione has been incorporated into a possible mechanism for
the neurotoxicity after oral ifosfamide (Lind et al 1989c). It has been postulated that
higher hepatic levels of ifosfamide metabolites after oral administration results in a
more pronounced fall in hepatic glutathione than after intravenous administration,
when ifosfamide is distributed throughout the total body water. The liver may then
be unable to detoxify chloroacetaldehyde after oral administration, with elevated
blood levels of this compound. Furthermore, ifosfamide induced encephalopathy is
associated with lower plasma and whole blood levels of glutathione (Mulders et al
1995).
An interesting development in unravelling possible metabolic causes of the
neurotoxic syndrome is the use of methylene blue. This compound has been
employed for many years in the treatment of cyanide poisoning by virtue of its
capacity to act as an electron acceptor. Urinary sarcosine and glutaric acid levels are
elevated in patients with ifosfamide induced encephalopathy, implying an
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impairment of electron transport within the CNS mitochondria, and the neurotoxicity
has been reversed successfully with methylene blue (Kiipfer et al 1994). This
important pharmacodynamic interaction with methylene blue indicates the site of
action of the causative agent, but does not provide absolute identification. It further
supports the possibility that chlorinated metabolites are responsible for the
encephalopathy, as chloroacetaldehyde is known to poison mitochondria. However,
using *H NMR analysis of urine from five encephalopathic patients, Foxall and co¬
workers were unable to detect glutaric acid, and in two patients who received
methylene blue neurological symptoms were not improved (Foxall et al 1997).
3.5.4 Aziridino ifosfamide
Aziridino ifosfamide, a possible metabolite of ifosfamide, has been proposed as a
causative agent (Cerny and Kiipfer 1992). The only other alkylating agent capable of
generating neurotoxicity similar to that seen after ifosfamide is thio-TEPA, also an
aziridine, at doses exceeding 900 mg m"2 (Wolff et al 1990).
3.5.5 4-hydroxyifosfamide
Serum 4-hydroxyifosfamide levels after oral ifosfamide are twice those following
intravenous administration (Kurowski et al 1991). In three Rhesus monkeys given 1
g m" of ifosfamide, a 4-hydroxyifosfamide CSF to blood ratio of 0.13 was found,
higher than the ratio for NPB alkylating activity (Arndt et al 1988). One animal
became neurotoxic, but the levels of 4-hydroxyifosfamide in the CSF were no higher
than in the unaffected monkeys. 4-hydroxyifosfamide and IPM enter the CSF easily
in children, with CSF to plasma ratios of 0.83 to 0.92, and 3.2, respectively (Kaijser
et al 1997; Yule et al 1997).
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3.6 Conclusion
Neurotoxicity following ifosfamide administration remains a significant problem,
particularly with the oral route. An increased awareness of predisposing factors has
permitted the safer selection of patients, and the recent introduction of methylene
blue has allowed prophylactic measures to be taken. The phenomenon remains to be
adequately explained, and although chloroacetaldehyde may be contributory, other as





Quantitatively, the three most important transport fractions of blood are plasma water,
plasma proteins and cells, mainly erythrocytes. In the laboratory, this three
compartmental system, equilibrating in the circulation in the dark and at 37°C, is
reduced for practical purposes to the two compartmental system of plasma, and
analysed at room temperature as if it had only one compartment. The information
present in the three separate fractions of whole blood is therefore combined into one
value. In the case of a compound which is bound to plasma proteins, this composite
value is misleading as a change in the free fraction present in plasma water can be
hidden by the large quantity present on proteins. Binding to erythrocytes also occurs,
but even less consideration has been given to the role of these cells in the transport of
compounds other than oxygen.
There are three reasons for this neglect of the erythrocyte and subsequent lack of
knowledge. Firstly, conceptual difficulties exist, as illustrated by the following
statement: "The erythrocyte has a cell wall, so it really has its own compartment.
Distribution in body fluids does not take effect versus the fraction free in whole
blood, but versus the free concentration in plasma water. From the pharmacokinetic
point of view, I would say that the red blood cells have the lowest priority" as
discussed by a pioneer on erythrocyte studies, M. Ehrnebo (Ehrnebo 1986). As a
result, the transport role of erythrocytes is almost invariably investigated using
washed erythrocytes, as if these cells were indeed separate compartments, and
regardless of the fact that washed erythrocytes do not exist in the circulation (e.g.
Jourdil et al 1993; Zingales 1973). Secondly, the transport function of red cells is
influenced by physiological factors as the role of erythrocytes will often become more
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apparent when protein binding is saturated, and thirdly, bioanalytical limitations
restrict the investigation of the transport role of erythrocytes.
Traditionally, plasma proteins have been viewed as the carriers of drugs, in
equilibrium with plasma water, whilst the erythrocytes have been regarded as a
transport system for blood gases, which bind to proteins within the red cell. However,
the erythrocyte can possess a more extensive transport function. Compounds with a
strong affinity for intracellular proteins may be sequestrated within the erythrocyte.
Such binding does not necessarily imply that compounds are unavailable to the
tissues, but with the exception of oxygen the transport mechanisms have been poorly
defined. For most compounds showing an association with erythrocytes, it is not
known whether they primarily bind to the outside of the erythrocyte, penetrate the cell
membrane, or if both mechanisms are operative. Despite these uncertainties,
erythrocytes may be of great importance in transferring such compounds to the
tissues.
4.2 Indications for the analysis of the red cell compartment
In many clinical situations the analysis of plasma alone is adequate. As the
relationship between erythrocyte cargo and plasma water concentration is often
stable, if desired the quantification of the amount associated with the erythrocyte is a
satisfactory alternative to the measurement of concentrations in plasma water. One
can also envisage some circumstances in which a more elaborate analysis of the
transport system in whole blood is indicated.
A Studies where the erythrocyte itself is the subject of investigation. Red cells
have been used as drug carriers, particularly of cytotoxic agents (Kravtzoff et al 1990;
Tonetti et al 1991), and for certain compounds they can act as a bioreactor (Cossum
1988; Nagasawa et al 1992; Schmiegelow and Bruunshuus 1990). In the treatment of
malaria, the penetration of antimalarial drugs into the erythrocyte is obviously a
critical step (Dua et al 1993; Tajerzadeh and Cutler 1993), and in nutritional studies
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erythrocyte vitamin content is frequently measured (Anderson et al 1989; Fanelli-
Kuczmarski et al 1990). Events in the erythrocyte can often reflect those in other
tissues. For example, the red cell folate level is a widely used indicator of the folate
status of an individual. More recently, erythrocyte glutathione levels have been
proposed as a predictor of tissue intracellular glutathione concentration (Hercbergs et
al 1992), and as a biological marker for the severity of cystic fibrosis (Mangione et al
1994), whilst in children receiving maintenance 6-mercaptopurine for acute
lymphoblastic leukaemia, the level of erythrocyte 6-thioguanine nucleotides (ETGN)
has been found to be important. One study found a correlation between mean ETGN
and the degree of myelosuppression (Schmiegelow and Bruunshuus 1990), and in
another report a multivariate analysis showed that ETGN concentration was an
independent prognostic variable (Lilleyman and Lennard 1994).
B Studies involving the distribution and mutual displacement of body
constituents, foodstuffs and xenobiotics through various blood compartments
(Colburn and Gibaldi 1978; Melander et al 1979). The mutual interaction of valproate
and phenytoin is one such example (Meijer 1991). Sometimes the concentration in the
erythrocyte compartment is greater than that in the plasma, as in the case of
desethylamiodarone, a metabolite of amiodarone (Maling et al 1989). A physiological
model of hydrocortisone transport has been described, in which the erythrocyte is
central to the delivery of this compound to tissues, on account of the faster rate of
dissociation of erythrocyte bound hydrocortisone compared to that bound to Cortisol
binding globulin (Hiramatsu and Nisula 1988). One would also expect that in certain
abnormal conditions (e.g. hyperbilirubinaemia, uraemia), when large quantities of
pathophysiological products bind to plasma proteins, the secondary transport system
will be loaded more heavily (Mabuchi and Nakahashi 1988; Shirkey et al 1985).
Therefore, in the case of certain compounds and in some pathophysiological
conditions, it is worthwhile investigating the relationship between the concentration
on plasma proteins, the steady state load on erythrocytes and the physiological
consequences; some desired or undesired effects may be more closely related to
erythrocyte load than to the concentration on (nearly saturated) plasma proteins. For
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example, in neonates with erythroblastosis foetalis, an unconjugated plasma bilirubin
concentration of 300 pM or more leads to the uptake of bilirubin into the CNS, which
may result in kernicterus. This pivotal plasma concentration may also be
accompanied by a manifest loading of erythrocytes.
4.3 The analysis of the erythrocyte compartment
4.3.1 Methods used in the literature
After collecting a blood sample it is easy to obtain plasma by centrifugation, but the
separation of plasma water from plasma is more laborious and not routinely
performed in clinical laboratories. The degree of plasma protein binding of a
substance is calculated by subtracting the amount present in the plasma water, called
the free fraction, from that present in total plasma.
The red cell fraction presents the most obstacles when analysing the three main blood
fractions, as the residual cell sediment formed following the centrifugation of blood is
difficult to analyse quantitatively using normal volumetric procedures. One approach
to this problem is to measure the volume of the cell sediment in a calibrated
centrifuge tube. However it is then necessary to wash the sediment with saline or
buffer several times before analysis, in order to remove the plasma trapped between
the cells; this has the disadvantage of disturbing the normal equilibrium between red
cells and plasma water (Ehrnebo et al 1974; Garcia-Alvarez et al 1993; Jourdil et al
1993; Reinhart 1993; Reinhart and Rohner 1990; Wanner et al 1990; Zingales 1973).
The effects of such a washing procedure on the results subsequently obtained are
rarely mentioned (Bower 1982; Reinhart 1993; Rustad 1964), and the washing itself
is never analysed. A second approach, in which the erythrocytes remain in their
natural environment, but where the analysis is indirect, is also common in the
literature. The amount associated with red cells is calculated by subtracting the
amount present in plasma, corrected for the haematocrit, from that present in whole
blood (not a medium in which concentrations are routinely measured) (Bower 1982;
45
Ehrnebo et al 1974; Kravtzoff et al 1990; Maulard et al 1990; Tamura et al 1987). As
the quantity associated with red cells is often small compared to the plasma
concentration, two large numbers are used to determine a small one. This is an
inaccurate method, and occasionally even negative values are obtained when the
erythrocyte associated amount is calculated. These problems are frequently not
discussed in the literature, and how the recorded erythrocyte concentrations are
obtained is often not clear (Anderson et al 1989; Fanelli-Kuczmarski et al 1990;
Javaid et al 1985).
4.3.2 Direct analysis ofthe erythrocyte compartment
The use of appropriate methods is of vital importance for demonstrating the transport
role of erythrocytes. The essence is to measure the compounds present in or on
unwashed erythrocytes directly. Three studies in which such an approach was used
are reviewed (Driessen et al 1989a; 1989b; 1989c; 1990). They concern the
compounds valproate, phenytoin, and hydrocortisone. Both in vitro and in vivo work
was described.
The method used to process the erythrocytes in these studies involved harvesting
blood into haematocrit capillaries and separating erythrocyte sediments by
centrifugation at 10,000 g. The capillaries were then cut with a glass knife, and both
the length of the cut fragment and its weight determined. Knowing the weight per unit
length of capillary tubing, the mass of the cells was obtained. The cell mass was
extracted and its drug content analysed. From these measurements a known
concentration in w/v of cell mass was derived. A correction for the difference in
density between red cells and water was not made. During sample pretreatment, care
was taken to maintain the same equilibria as present in whole blood or an erythrocyte
suspension in plasma water. Therefore after sampling, the haematocrit capillaries
were centrifuged immediately and the sediment separated from plasma or plasma
water. The concentration of drug in the red cell sediment was then adjusted for the
residual plasma trapped between the cells. This was determined using l4C-inulin as an
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extracellular marker and appeared to be 2.0%. During sample pretreatment this
trapped plasma may be important to maintain the equilibrium that exists in the
circulation. The quantity of drug bound to plasma proteins was calculated by
subtracting the quantity in plasma water from that in plasma. In vitro, it was
confirmed that the total drug recovery from all the fractions was equal to the amount
added to blood, plasma or the mixture of red cells and plasma water.
Compound loss from plasma proteins and erythrocytes in spiked whole blood in vitro,
following dilution with blank autologous plasma water was investigated. This
reproduced the conditions in capillaries with a discontinuous endothelium, simulating
the contact of blood with blank intercellular tissue water following the initial
exposure of an individual to a compound. Valproate, phenytoin and hydrocortisone
were released relatively easily from the erythrocyte in comparison to plasma proteins,
and this finding is supported by other data in the literature for hydrocortisone
(Hiramatsu and Nisula 1988). The plasma proteins were saturable with all three
compounds, but erythrocytes could not be saturated, not even in high and toxic
concentrations. For phenytoin and hydrocortisone the concentrations on the
erythrocytes and in plasma water increased proportionally. As varying concentrations
of phenytoin and hydrocortisone do not alter the red cell to plasma water ratio, the
erythrocyte concentration reflected the concentration in plasma water.
In vivo work showed that the rate of change of valproate concentration is greater on
erythrocytes than on plasma proteins, and the same phenomenon occurs when
phenytoin is infused linearly over 30 minutes (Driessen et al 1989a, 1989b). A more
rapid decline of the red cell fraction is observed following a bolus injection of
hydrocortisone (Driessen et al 1990). The elimination half-life from each
compartment of whole blood is different; loss from erythrocytes is faster than loss
from plasma proteins, and it appears that for these three compounds, those molecules
associated with erythrocytes, rather than those bound to plasma proteins, are more
likely to exchange with plasma water.
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Differences in the erythrocyte and plasma half-lives of other compounds are reported
in the literature. For example, in a pharmacokinetic study of a new sulphonamide,
highly bound to erythrocytes, the drug was found to have a longer red cell half-life
compared to its plasma half-life (Ito et al 1982), whereas the half-life of diazepam on
erythrocytes is shorter than its plasma half-life (Hariton et al 1985).
In summary, it seems that for certain compounds, erythrocytes form a secondary
transport system in whole blood which, with plasma water, becomes more significant
as the non-protein bound drug concentration increases. Data from dilution
experiments indicate that erythrocyte bound valproate, phenytoin or hydrocortisone
are more readily available to blank plasma water than the protein bound fraction. In
vivo observations, using the same compounds, support the hypothesis that
erythrocytes act as a secondary transport system, more reluctant to load and faster to
discharge than plasma proteins. Although the amount bound to the erythrocytes is less
than that bound to plasma proteins, the faster elimination from erythrocytes, coupled
with the high number of these cells in the circulation (45% v/v) implies that erythrocytes
are important carriers of such compounds. In the case of phenytoin, calculations showed
that between one and five hours after administration, approximately 50% of the drug
leaving the blood originated from erythrocytes (Driessen et al 1989b).
4.4 Conclusion
Traditionally, the erythrocyte compartment has been neglected in pharmacokinetic
studies, and bioanalytical obstacles are a major reason. However, when a direct
determination of valproate, phenytoin and hydrocortisone is performed on unwashed
erythrocytes, it can be seen that the red cells are a transport system with a high
capacity and low affinity compared to plasma proteins. Thus erythrocytes are loaded
last and unloaded first. Contrary to previous concepts, it appears that the erythrocyte
compartment is a readily exchanging blood fraction, with a transfer function at least
as important as the plasma water and protein fractions.
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This capability of erythrocytes to carry substances other than blood gases has not
been fully appreciated or explored. The plasma concentration of a substance is usually
regarded as the optimum reflection of that in tissue cells, but it is likely that the
concentration on erythrocytes is at least equally representative.
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PART II MATERIALS AND METHODS
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Chapter 5
The Analysis of Ifosfamide and its Metabolites in Biofluids
5.1 Introduction
Ifosfamide is stable in vitro and relatively easy to quantify in biofluids.
Radiolabelling with 3H and 14C, gas chromatography (GC) using nitrogen flame
ionisation detection or electron capture detection, and fluorometric techniques have
been employed (Holdiness and Morgan 1983; Kaijser et al 1991b; Kurowski and
Wagner 1993; Wagner and Drings 1986; Wagner et al 1981). High-performance
liquid chromatography (HPLC) and 3IP nuclear magnetic resonance spectrometry
have also been developed (Burton and James 1988; Gilard et al 1993; Margison et al
1986; Martino et al 1992).
The first analytical methods for ifosfamide and its metabolites measured only
ifosfamide and "total alkylating activity", based on the NBP reaction (Friedman and
Boger 1961). In this reaction IPM, CIPA and DCEI have alkylating activity, as does
ifosfamide at high concentrations. However it is not certain whether this translates
into alkylating activity in vivo. Initial techniques used GC to measure ifosfamide,
and total alkylating activity was measured by spectroscopic analysis of the blue
colour produced after reaction with NBP. Improved methods used HPLC, but were
still unable to separate and measure individual metabolites. The NBP reaction is non¬
specific, and only an approximation of total alkylating activity is obtained. Despite
similar ifosfamide doses and amounts of alkylating activity, the metabolic profiles of
ifosfamide metabolites can be quite different, and the total alkylating activity of all
ifosfamide metabolites is higher than activated ifosfamide from which IPM is
derived. Some pharmacokinetic studies have utilised the liberation of acrolein from
the activated metabolites. 7-hydroxyquinolone, formed by reaction with 3-
aminophenol, can be detected fluorometrically (Voelcker et al 1979).
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With the pairing of analytical techniques such as thin layer chromatography (TLC)
with densitometry, and GC with mass spectrometry (GC-MS) (Lambrechts et al
1991), the study of separate metabolites has become possible. A TLC/densitometry
method has been described, enabling the separation and analysis of ifosfamide,
CIPA, KIPA, IPM, and the dechloroethyl metabolites, in plasma and urine (Boddy
and Idle 1992b). Following the separation of metabolites on TLC plates, the plates
are treated with NBP and the site of the metabolites identified by the blue colour.
Metabolite concentration is then determined by densitometry.
5.2 Gas chromatography — mass spectrometry
The mass spectrometer can be used to establish the molecular weight and structure of
organic compounds. The sample is volatised within the spectrometer; the gas-phase
ions so formed are separated according to their mass/charge (m/z) ratios, and are then
usually detected electrically. The ion-currents corresponding to the different species
are amplified and stored on a computer. The peak intensities are plotted as ordinates,
in arbitrary units, or normalised with respect to the most important peak (or some
other selected peak), which is assigned a value of 100.
5.2.1 lonisation andfragmentation
The method of ionisation used is dependent on the physical state of the sample, and
the volatility and thermal stability of the material. Gas-phase molecules are best
analysed with electron impact ionisation (EI+). EI+ of an organic molecule M results
in the formation of a molecular ion M+* by removal of an electron:-
M + e" -> M+* + 2e"
During the ionisation, a certain amount of internal energy is transmitted to the
molecule. This quantity of energy is variable, and its magnitude determines whether
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one or more fragmentation reactions occur. The most likely reactions are those which
have low activation energy, leading to relatively stable ionic or neutral species:-







The successive fragmentation reactions generally lead to ions and radicals consisting
of a single atom, or group of atoms. During fragmentation, the charge is located on
the fragment with the lowest ionisation potential. Therefore in the fragmentation of
BC * into B+ and O, or into B« and C+, if the ionisation potential of B is lower than
that of C, then the major fragmentation path will be into B+ and O; similarly, for
fragmentation of an ion BC+, under the same conditions, the most likely
fragmentation would be into B+ and C, not into B and C+.
Stable fragments can also be produced by a change in the relative positions of the
atoms in a molecule, followed by decomposition of the ion, so called rearrangement
reactions.
5.2.2 Ifosfamide and GC-MS
In terms of technique, GC-MS has the advantage of removing troublesome
background noise, allowing the accurate determination of multiple metabolites. Prior
to introduction into the MS, the metabolites are separated by GC. Ifosfamide
undergoes cyclization in alkaline media resulting in the formation of an aziridine.
This reaction lowers the efficiency of extraction of ifosfamide from an alkaline
solution, but is totally reversed at acidic pH. Ifosfamide itself is sufficiently
thermally stable to enable gas chromatographic determination without derivatisation
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(Lambrechts et al 1991). In contrast, the isomer cyclophosphamide is perfectly stable
under alkaline conditions (no aziridine structure is possible), but needs derivatisation
for GC analysis, otherwise partial thermal cyclization in the injector produces two
separate product peaks. GC generally requires derivatization of metabolites with
trifluoroacetic or heptafluorobutyric anhydride. Several metabolites of ifosfamide
form different derivatives with trifluoroacetic anhydride (TFAA). The trifluoroacetyl
derivatives of oxazaphosphorine metabolites can be measured with picogram
sensitivity by single ion monitoring (SIM) GC-MS. This chapter describes the
development of a GC-MS method for analysing ifosfamide and its metabolites.
5.3 Methods
Ifosfamide, the two possible dechloroethyl metabolites, KIPA, CIPA, IPM, CEA and
OXA were determined by electron capture ionization and electron impact mass
spectrometric detection of the trifluoroacetyl derivatives. Procedures analogous to
those used in the analysis of cyclophosphamide and its metabolites were employed
(Momerency et al 1994).
5.3.1 Chemicals and extraction procedure
Reference compounds of most of the metabolites were provided by ASTA-Werke,
Degussa Pharma Gruppe, Bielefeld, Germany. Water and organic solvents used in
the procedure were of HPLC quality. TFAA was obtained from Janssen Chimica,
Geel, Belgium. A 0.05 M citrate - hydrochloric acid mixture was employed as pH 4
buffer. SEP-PAK solid phase extraction cartridges containing 500 mg of trifunctional
Ci8 reversed phase material, supplied by Millipore, were used on a vacuum manifold
station (Momerency et al 1994).
To extract the acidic metabolites, 500 pi of citrate buffer pH 4 was added to 500 pi
of plasma, together with 25 pi internal standard (IS) solution (cyclophosphamide,
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CPA) (table 5.1). An IS was used to compensate for differences in extraction
efficiency and chromatographic variations after derivatisation. This mixture was
passed over Sep Pak Ci8 solid phase extraction cartridges, previously conditioned
with 5 ml methanol. The cartridges were then washed with 5 ml water, and residual
water removed by blowing 10 ml air through the cartridges. The plasma components
were eluted with 5 ml methanol, which was evaporated under nitrogen, and the
residue subjected to the derivatisation procedure.
To measure the basic metabolites, CEA and OXA, N-chloroethyl-1, 3-oxazolidine-2-
one (the corresponding oxazolidinone of cyclophosphamide, CEOX) was used as the
IS. The metabolites were isolated by ethyl acetate extraction after dilution with 0.05
M borate - sodium hydroxide buffer of pH 10.
5.3.2 Derivatisation
Derivatization comprised two steps; the methylation of the acidic groups of CIPA
and IPM followed by trifluoroacetylation of unhindered phosphoramide groups,
using a large excess of the reagents (Momerency et al 1994). Diazomethane in ether
was added to the residue and the solvent evaporated under nitrogen (methylation of
acids). The residue was re-dissolved in 300 pi ethyl acetate and 300 pi trifluoroacetic
anhydride was added. This solution was held at 70°C for 2 hours (acylation of
amides). The solvent and the excess reagent were again evaporated under nitrogen
and the residue re-dissolved in 250 pi ethyl acetate. These samples were used for
quantitative GC analysis. For the basic metabolites, after centrifugation and
evaporation of the upper layer under nitrogen, the solution was derivatised with
trifluoroacetic anhydride only (there are no acidic groups to methylate).
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Determination of IPA, KIPA, Determination of CEA and OXA
IPM, CIPA, and 2- and 3-DCEI
0.5 ml plasma
4 + IS CPA
+ 0.5 ml buffer pH 4
4
1 ml diluted plasma, vortex
4
C|8 column (500 mg)
I








+ 0.3 ml ethyl acetate
+ 0.3 ml TFAA at 70 °C for 2 hours
4
complete evaporation;




4 + IS CEOX
+ 0.5 ml buffer pH 10
4
1 ml diluted plasma, vortex
4
extraction with ethyl acetate





+ 0.3 ml ethyl acetate




dissolve in 250 pi ethyl acetate
4
GC-MS
Table 5.1. Schematic diagram of the enrichment procedure.
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5.3.3 Gas chromatographic - mass spectrometric analysis
Gas chromatographic separations were performed on a Carlo-Erba Mega Series 5160
chromatograph, equipped with a 25 m x 0.25 mm i. d. fused silica capillary column
coated with a 0.2 mm film of Sil-13 (methyl phenyl siloxane; Chrompack,
Middelburg, Holland). Through a short metal capillary transfer line maintained at
250°C, the fused silica GC column was connected to the combined electron impact -
chemical ionisation source of a Fisons Trio-2A quadrupole mass spectrometer
(Fisons Instruments, UK) maintained at 180°C. EI+ was performed with a trap
current of 200 mA, an electron energy of 70 eV, and an ion repeller potential of 1 V.
Chemical ionisation (CI-) was carried out using a source current of 800 mA, an
electron energy of 40 eV, and an ion repeller potential of 0 V. Multiple ion
monitoring (MIM) was performed on extracts of spiked plasma and patient plasma.
Linear temperature programming of the GC column enabled selection of retention
windows in the chromatogram, during which specific m/z values from the mass
spectra of the metabolites were measured.
The temperature programme for measuring IPM, 2-DCEI, 3-DCEI, IPA, KIPA and
CIPA was 150°C to 240°C, and for CEA and OXA 80°C to 150°C, both increasing
by 6°C min"1. With the exception of CEA and OXA, all compounds were measured
by CI- with electron capture. CEA and OXA were analysed using classical EI+. SIM
was used throughout.
5.3.4 Calibration curves
Standard solutions of known concentrations of ifosfamide and its metabolites (5 ng
ml"1 to 100 ng ml"1 and 0.1 pg ml"1 to 20 pg ml"1 of blank plasma) were submitted to
the same extraction and derivatisation procedures as the patient plasma samples.
These solutions were co-injected in the GC during the same sequence of
measurements as the patient plasma samples, thus keeping the effects of variations in
ion source contamination of the MS as low as possible. The ratio of peak area for a
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given metabolite to that for the internal standard was plotted against the
concentration of that metabolite in the original spiked plasma sample to produce a
calibration curve. Linear regression analysis of the data points (ratio of metabolite
peak area to internal standard peak area, y, against metabolite concentration, x, in the
original plasma) produced a best fit; e.g. the regression equation for IPM was y =
(0.01579 ± 0.00037) x + (0.00125 ± 0.00022) (n = 6).
The intra-assay reproducibility, expressed as relative standard deviation, was
approximately 3%, and the inter-assay reproducibility ranged from 5% to 10% for
sets of four independent extractions.
5.4 Results
5.4.1 Derivatisation
The derivatisation procedures employed generate the bis-trifluoroacetyl derivative of
3-DCEI. On standing in the presence of ether or chloroform, an equilibrium mixture
of the two mono derivatives of 3-DCEI is formed. 2-DCEI was measured as the
monotrifluoroacetyl derivative. The bis-trifluoroacetyl derivative of 2-DCEI was not
detected.
CIPA has two identical phosphoramidic functions, which can be further substituted.
Theoretically both can be trifluoroacetylated, but in practice only one is actually
transformed, probably because of the effect of steric hindrance in the mono
derivative. In the corresponding carboxy metabolite of cyclophosphamide, a further
loss of hydrogen chloride is observed yielding a single cyclic derivative as the only
chromatographic peak (Momerency et al 1994). A similar process does not occur
with CIPA. The metabolite 4-ketocyclophosphamide cannot be derivatized by
reaction with TFAA because of a mesomeric effect involving the endocyclic amidic
nitrogen atom. In contrast, trifluoroacetylation of KIPA occurs smoothly on the
exocyclic nitrogen atom. KIPA does not react with diazomethane solution. Unlike
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the cyclophosphamide mustard (CPM), which decomposes completely to nor-
nitrogen mustard (NNM) during attempts to derivatize with TFAA, IPM does not
decompose during the enrichment and derivatization steps, and can easily be
recovered from plasma. Methylation occurs only on the phosphoramidic acid
function and trifluroacetylation only on one of the equivalent phosphoramidic
nitrogen atoms (figure 5.1). The derivative has an acyclic structure, and the
subsequent loss of hydrogen chloride with the formation of a cyclic product, seen
with several cyclophosphamide metabolites (Momerency et al 1994), is not observed



























The mass spectrum of trifluoroacetylated ifosfamide is shown in figure 5.3.
Trifluoroacetyl ifosfamide produces an EI+ mass spectrum similar to that of the
cyclophosphamide derivative, with a base peak at m/z = 307/309 for the fragment (M



















































































derivatives are shown in table 5.2. EI+ and CI- mass spectra of selected metabolite
derivatives are presented in figures 5.4 and 5.5.
5.4.2 Recovery ofifosfamide metabolites from spiked plasma samples
Extraction yields of ifosfamide metabolites using the Ci8 solid phase extraction procedure
at acidic pH were determined. More extensive data is available for cyclophosphamide
metabolites using liquid extraction with ethyl acetate or chloroform, and solid phase
isolation with either silica gel or Ci8 at pH 4, 7 or 10 (Momerency et al 1994). One would
expect the extraction efficiencies of ifosfamide metabolites to be similar to those of
cyclophosphamide metabolites, as shown for the parent compounds at acidic pH with Ci8
solid phase extraction (table 5.3).
The observed extraction efficiencies at pH 4 were generally higher than 90% for both
dechloroethyl metabolites, the keto metabolite, and for the parent compounds ifosfamide
and cyclophosphamide. The recovery of CIPA was somewhat lower at approximately
75%. Both IPM and CPM are stable in a weakly acidic medium. As CPM decomposed
readily during attempts at derivatization, the efficiency with which it was extracted was
measured by thermospray LC-MS (SIM) of the underivatized form of the molecule. The
ion monitored was the (M + NH4 - HC1)+ at m/z 202. The recovery of IPM from Cis
columns is low, only about 50%, and comparable with that of CPM, but is still 10%
higher than the value given in the literature for extraction of CPM using Amberlite XAD-
4 columns (Jardine et al 1978).
The isolation of the alkaline CEA and OXA metabolites was performed by liquid
extraction with ethyl acetate at pH 10; recoveries were 85% and 90% respectively, an
improvement on the solid phase procedure at pH 7. No further decomposition of the
metabolites was observed during storage of spiked plasma samples at -20°C for at least
three weeks.
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Compound MW Fragment Interpretation
EI+
TFA-IPA 356 307/309 (M - CH2C1)+
TFA-CPA (IS) 356 307/309 (M - CH2C1)+
TFA-2-DCEI 294 245 (M - CH2C1)+
bis-TFA-3-DCEI 390 341 (M - CH2C1)+
TFA-CIPA-Me 402 324/326 (M - NHCH2CH2C1)+
TFA-KIPA 370 335/337 (M - Cl)+
TFA-CEA 175 126 (M - CH2C1)+
TFA-OXA 183 114 (M - CF3)+
TFA-IPM-Me 330 281/283 (M - CH2C1)+
CI-
Group I
TFA-CPA 356 320/322 (M - HC1)"
TFA-2-DCEI 294 274/276 (M - HF)"
TFA-OXA 183 183 (M)"
TFA-CIPA-Me 402 185 ?
Group II
TFA-IPA 356 293/295 (M - CH2CH2C1)"
bis-TFA-3-DCEI 390 327 (M - CH2CH2C1)"
TFA-KIPA 370 307/309 (M - CH2CH2C1)"
TFA-CEA 175 112 (M - CH2CH2C1)"
TFA-IPM-Me 330 267/269 (M - CH2CH2C1)"
MW - Molecular Weight













































































































































CPA: 93.2% ±3.6% CPA (IS): 93.2% ± 3.6%
IPA (IS): 99.7% ±3.7% IPA: 99.7% ±3.7%
DCEC: 99.5% ± 2.8% 3-DCEI: 96.8% ±4.1%
2-DCEI: 92.7% ± 6.4%
KETO-CPA: 90.3% ± 2.6% KIPA: 91.5% ±3.8%
CARBOXY-CPA: 82.5% ± 3.9% CIPA: 74.4% ± 1.9%
ALCO-CPAa: 75.9% ± 5.0% -
CPMb: 56.3% ± 4.0% IPM: 49.8% ±4.2%
a Alco-IPA was not available as a reference compound
b Measured by thermospray LC-MS
Table 5.3. Recoveries of ifosfamide and
cyclophosphamide metabolites using Cig solid phase
extraction at pH 4.
In the procedure used to measure the stable cyclophosphamide metabolites in
plasma, it was observed that CI-, using methane as quenching gas, provided much
better sensitivity than EI+ for many trifluoroacetylated metabolite derivatives
(Momerency et al 1994). The same is true for the ifosfamide metabolites.
During CI-, two different types of fragmentation of the ifosfamide and
cyclophosphamide metabolites occurs; this is illustrated by subdivisions I and II in
table 5.2. The derivatives in group II contain a special functional group which
fragments by the loss of a CH2CH2CI substituent, e.g. the IPM derivative with a
characteristic peak at m/z 267/269. A tentative mechanism is shown in figure 5.6. A
tentative assignment for the base peak fragment ion from the CIPA derivative at m/z
= 185 cannot yet be proposed. However, the fragment is of diagnostic value for the








Figure 5.6. Fragmentation of the derivative of IPM in electron capture chemical
ionization MS.
Table 5.4 lists the retention times of the ifosfamide metabolite derivatives in
increasing order. Separate retention windows can be easily established for SIM of
most ifosfamide metabolites. However, since two regions of partial overlap exist, in
which retention times differ by less than one minute, MIM was applied in these
regions, giving complete separation using the appropriate specific ion masses,
although the ultimate detection sensitivity was reduced by a factor of two to three.
The MIM time intervals in order of increasing retention times are listed in table 5.5.
Injection of a 1 pi aliquot from 50 pi of final derivatised extract enabled the











Table 5.4. Retention times (tR) of ifosfamide
and its metabolites on Chrompack Sil-13;
(Linear temperature programme from 150°C
to 240°C at 6°C min"1).
Electron capture CI- was the most sensitive technique for the quantitative
measurement of ifosfamide, 3-DCEI, KIPA and CIPA; no substantial difference was
observed between EI+ and CI- sensitivity for 2-DCEI and IPM. All these metabolites
can therefore be measured with equally high sensitivity by electron capture CI- (a
typical MIM chromatogram is shown in figure 5.7 a). CEA and OXA were measured
with greater sensitivity by EI+ (a typical SIM chromatogram is shown in figure 5.7
b); it was not possible to detect the parent ion of TFA-CEA, but intense peaks were
observed using the mass fragment m/z 126.02.
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Metabolite Specific ion m/z Retention
derivative window (min)
CI-
TFA-IPM-Me (M - CH2CH2C1)- 266.99 2.0-10.0
bis-TFA-3-DCEI (M - CH2CH2C1)" 327.00 2.0-10.0
TFA-2-DCEI (M - HF)" 274.00 2.0- 10.0
TFA-IPA (M - CH2CH2C1)- 293.01 10.0- 13.5
TFA-KIPA (M - CH2CH2Ciy 306.99 10.0- 13.5
TFA-CIPA-Me (M - ?)- 185.01 13.5 - 17.0
TFA-CPA (IS) (M - HC1)- 320.03 13.5-17.0
EI+
TFA-CEA (M - CH2C1)+ 126.02 2.0 - 6.0
TFA-OXA (M - CF3)+ 114.02 6.0- 12.0
CEOX (IS) (M - CH2C1)+ 100.04 6.0- 12.0
Table 5.5. Multiple ion monitoring programmes for ifosfamide metabolites; dwell
time 0.08 s; span 0.02 a. m. u.
Measurement of the labile primary metabolite 4-hydroxyifosfamide as a separate
peak is not possible. Since the hydroxy structure is stabilised at a weakly acidic pH
(Ikeuchi and Amano 1985), and at least in the case of cyclophosphamide easily
decomposes to CPM during the Ci8 solid phase extraction procedure (Watson et al
1985), it is probable that the IPM concentration measured actually represents the sum
of the free mustard, 4-hydroxyifosfamide, and aldoifosfamide.
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Figure 5.7. CI- SIM and MIM chromatograms (upper, a), and EI+ SIM
chromatogram (lower, b), of a plasma extract.
70
5.5 Conclusion
This chapter describes a new analytical method for the determination of ifosfamide
and its metabolites in human biofluids, using GC-MS. The method was employed to





Following the administration of a drug, the body can be regarded as a collection of
separate compartments, each containing a fraction of the administered dose. The
transfer of compounds from one compartment to another is associated with a rate
constant (k), the magnitude of which determines how fast the transfer occurs. The
moment a drug reaches the blood stream it is subject to both distribution and
elimination. Rate constants associated with distribution are much larger than those of
drug elimination. Therefore drug distribution throughout the body is usually complete
while most of the dose is still in the body. Some drugs attain distribution equilibrium
quickly, essentially before any of the dose is eliminated, and in such cases the body
appears to have the characteristics of a single compartment. However this is too simple
for most drugs. Concentrations in plasma measured shortly after intravenous
administration reveal a distinct distributive phase, i.e. a measurable fraction of the dose
is eliminated before distribution equilibrium is reached, and a multicompartmental
system effectively exists. Two or three compartments are usually used to describe the
time course of a drug in plasma: the rapidly equilibrating, or central, compartment; and
one or two slowly equilibrating, or peripheral, compartments.
6.2 Physical significance of plasma drug concentration
The degree of distribution and binding is a function of the physical and chemical
properties of a drug. At distribution equilibrium, drug concentrations in different parts
of the body are rarely equal. Some sites such as the CNS, or fat, are poorly accessible to
some drugs. Other tissues may have a great affinity for the drug and bind it avidly.
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However once a drug attains distribution equilibrium, its concentration in the plasma
reflects distribution factors, and the simple relationship between amount of drug in the
body (A) and drug concentration in plasma (C) applies:-
A = Vd C 6.1
where Vd is the apparent volume of distribution.
In most situations Vd is independent of drug concentration. Doubling the amount of
drug in the body, e.g. by doubling the intravenous dose, usually results in a doubling of
drug concentration in plasma. This is called dose proportionality, and is often used as an
indicator of linear pharmacokinetics.
Vd is usually a characteristic of the drug rather than the biological system, although it
may be changed by disease and other factors. Vd rarely corresponds to the volume of
plasma, extracellular fluid or total body water, and is usually not an anatomical volume,
but a reflection of drug distribution and a measure of the degree of drug binding. Acidic
drugs are often preferentially bound to plasma proteins rather than to extravascular
sites. Although these drugs distribute throughout body water, their Vd values are small.
Many basic drugs are more extensively bound to extravascular sites than to plasma
proteins, and the value of Vd for these drugs is large.
6.3 Pharmacokinetic considerations of plasma drug concentration
6.3.1 Intravenous administration
It is not necessary to consider absorption when a drug is given by rapid intravenous
injection. As soon as the drug is administered, it undergoes distribution and is subject to
one or more elimination pathways. The amount of drug in the body and the drug
concentration in plasma decrease continuously after injection. At the same time there is
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continuous formation of metabolites and continuous excretion of drug and metabolites.
Eliminated products accumulate while drug levels in the body decline.
Most drugs distribute rapidly, so that shortly after intravenous injection, distribution
equilibrium is reached. Drug elimination at distribution equilibrium is usually described
by first-order kinetics, i.e. the rate of the process is proportional to the amount or
concentration of substrate or drug in the system. As drug concentration falls the
elimination rate falls in parallel. The proportionality constant relating rate and amount,
or concentration, is called a rate constant.
log C = log C0 - kt/2.303 6.2
where C = concentration; t = time; and k = the first-order elimination rate constant. The
term Co is the intercept on the log concentration axis, on extrapolation of the linear
segment to t = 0.
Equation 6.2 indicates that a plot of log C against t will be linear, once distribution
equilibrium is reached. The linear portion of the semi-logarithmic plot of C against t
has a slope corresponding to -k/2.303, and an intercept on the y-axis (i.e. at t = 0)
corresponding to Co.
Although it is possible to calculate the elimination rate constant from the slope of the
line, it is much easier to determine k by:-
k = 0.693 / ti/2 6.3
where ti/2 is the half-life of the drug and is determined directly from the plot.
In a first-order process the half-life is independent of dose or initial plasma
concentration. The half-life of a drug can often be related to the duration of clinical
effect and the frequency of dosing.
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An important indicator of exposure to a cytotoxic is the total area under the plasma
concentration-time curve. Sometimes studies are not carried out long enough to allow
drug concentrations to fall to negligible levels. The total AUC then cannot be
determined directly, only the partial AUC. A widely used method is to determine the
AUC from t = 0 to the last sampling time (t*), by means of the trapezoidal rule, and to
estimate the missing area by the equation:-
Area from t* to oo = C* / k 6.4
where C* is the drug concentration at t = t*, and k is the apparent first-order elimination
rate constant.
This area must be added to the area calculated from time zero to t* (AUCt) to obtain the
total AUC.
6.3.2 Short term constant rate intravenous infusion
Drug concentration in the plasma increases during an infusion. When the entire dose
has been infused at time T, drug concentration reaches a maximum and declines
thereafter. The declining drug concentration is described by:-
log C = log Cmax- (kf / 2.303) 6.5
where f = t - T.
Equation 6.5 applies when distribution equilibrium is essentially reached by the end of
the infusion. A semi-logarithmic plot of C (post-infusion drug concentration in plasma)
against t' yields a straight line, from which the half-life and elimination rate constant can
be estimated. The maximum drug concentration in plasma is always lower after
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intravenous infusion than after bolus injection of the same dose. The more slowly a
fixed dose of a drug is infused, the lower the value of Cmax.
6.3.3 Extravascular administration
A more complex drug concentration-time profile is observed after oral administration
because absorption is not instantaneous, nor does it occur at a constant rate. The rate of
change of the amount of drug in the body is a function of both the absorption rate and
the elimination rate. When the absorption rate is greater than the elimination rate, the
amount of drug in the body, and the plasma drug concentration, increase with time.
Conversely, when the amount of drug remaining at the absorption site is sufficiently
small so that the elimination rate exceeds the absorption rate, the amount of drug in the
body, and the plasma drug concentration, decrease with time. The maximum
concentration after drug administration occurs at the moment the absorption rate equals
the elimination rate. The faster a drug is absorbed, the higher the maximum
concentration in plasma after a given dose, and the shorter the time after administration
when the peak is observed.
First-order drug input assumes that the rate of drug entry is proportional to the
amount of drug remaining to be absorbed. The proportionality factor is the
absorption rate constant (KA). Absorption from the gastrointestinal tract may be
defined by:-
Rate in = KA x G(t) 6.6
where G(t) is the amount of the dose remaining in the gastrointestinal tract at time t.
Many drugs have a KA of 0.5 hr"1 to 2 hr"1. This corresponds to an absorption half-
life (logn [2] / KA) of 20 minutes to 1.5 hours. If the disposition half-life of the drug
is long relative to absorption, then the time of peak drug concentration will be one to
five hours, i.e. approximately three absorption half-lives. Good initial estimates of
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KA can be made by calculating the absorption half-life as one third of the time of
peak concentration, and deriving KA from 0.7 / (absorption half-life) (logn [2] is
approximately 0.7).
When absorption is complete, the rate of change of the amount of drug in the body
equals the elimination rate. The section of the plasma drug concentration-time curve
commencing at the time absorption has ceased is called the post-absorptive phase.
During this phase the decline in drug concentration follows first-order kinetics. The
absorption rate of a drug from the gastrointestinal tract varies with the rate of gastric
emptying, the time of administration with respect to meals, the physical and chemical
characteristics of the drug, and the dosage form, as well as other factors. Similarly, the
amount of an oral dose of a drug that is absorbed depends on biological, drug, and
dosage form considerations. The bioavailability of a drug is defined as its rate and
extent of absorption.
6.3.4 Repetitive dosing
During repetitive oral administration of the same dose at regular intervals, plasma
concentrations during a dosing interval first increase, and then decrease as a result of
absorption, distribution and elimination. The magnitude of the concentration difference
in a dosing interval depends on the rates of absorption and distribution, and on the half-
life of the drug; this concentration difference increases with increasing absorption rate
and decreasing half-life. A simple way of describing the steady state is to consider the
average drug concentration (Css).
6.4 Noncompartmental analysis
This is based on the theory of statistical moments (Yamaoka et al 1978). The zero
moment of a plasma drug concentration-time curve is the total AUC from time zero to
infinity. The first moment is the total AUC resulting from a plot of the product of drug
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concentration and time against time. The total area under the C.t against t plot is termed
the AUMC, or area under the first moment curve.
The ratio of AUMC to AUC for any drug is a measure of its mean residence time
(MRT).
MRT = AUMC/AUC 6.7
MRT calculated after intravenous administration is the statistical moment analogy to
drug half-life. Like half-life, MRT is a function ofboth distribution and elimination.
Clearance is a function of both the intrinsic ability of certain organs, such as the kidneys
and liver, to excrete or metabolise a drug and the rate of blood flow to these organs. The
total body clearance of a drug from the blood is equal to the ratio of the overall
elimination rate of the drug to the drug concentration in blood, where the overall
elimination rate is the sum of the elimination processes occurring in all organs. The
ratio of the overall elimination rate of a drug to its concentration in the blood is equal to
the ratio of the amount of drug ultimately eliminated to the total area under the drug
concentration-time curve. After intravenous administration the amount eliminated is
equal to the dose, and clearance can therefore be expressed as:-
CL = dose/AUC 6.8
One of the most useful properties of statistical moments is that they permit the
estimation of a volume of distribution that is independent of drug elimination. Using
these methods, the apparent volume of distribution at the steady state (Vss) is given by
the product of the intravenous bolus dose and the ratio of AUMC to AUC squared. It
represents the proportionality constant relating the amount of drug in the body at the
steady state after prolonged constant rate intravenous infusion, or repetitive
administration, to the drug concentration, or average drug concentration, at that time.
Vss is independent of drug elimination, and reflects solely the anatomical space
occupied by a drug and the relative degree of drug binding in the blood and
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extravascular space. Estimation of Vss does not require data obtained at the steady state;
this distribution parameter can be calculated after a single dose of drug.
Vss = iv dose * AUMC / AUC2 6.9
where AUMC is the total area under the first moment curve.
Although equation 6.9 applies only to dosing by intravenous bolus, the relationship can
be modified to accommodate other routes of administration. If a drug is given by a
short-term constant rate intravenous infusion, then
Vss = [infused dose* AUMC/AUC2]
- [infused dose * (T)/2 (AUC)] 6.10
where T is the duration of infusion.
6.5 Multiple compartmental analysis
Following intravenous bolus administration many drugs distribute sufficiently slowly so
that a significant fraction of the dose is eliminated before distribution equilibrium is
achieved. The data cannot be described by a single exponential expression (i.e. a single
compartment). At the outset drug concentrations decline rapidly, and these early phases
are typically associated with distribution. Ultimately, a linear relationship between log
concentration and time is observed. Irrespective of the complexity of the model, drug
concentrations in the plasma decline in a first-order manner once distribution
equilibrium is achieved. This final phase is known as the terminal phase, and it is
often assumed that the drug leaves the site of measurement only by elimination
during this phase. The rate constant describing this first-order portion of the curve is
usually termed p. The log-linear region of the curve will have a slope equal to -p /
2.303. Therefore for drugs that require a multiple compartmental description, a terminal
half-life may be defined as:-
79
ti/2 = 0.693 / (3 6.11
Elimination occurs during every phase, and the half-life of each phase is a function
of distribution, re-distribution and elimination processes. As drug elimination
becomes more efficient, and clearance increases, then elimination half-life decreases
in an inversely proportional manner. However changes in distribution also influence
half-life if clearance remains constant. The Vd of ifosfamide increases in older
patients, leading to an increased half-life (Lind et al 1990a). This results in lower
concentrations at the site of measurement for a longer duration, possibly altering
efficacy and toxicity. If clearance and Vd both change by the same proportion, half-
life does not change, but lower concentrations are observed at the site of
measurement.
The half-life always reflects both distribution and elimination, irrespective of the model
used. In a single compartment model, elimination is represented by clearance and
distribution by Vd. Multiphasic profiles possess kinetically distinct components in the
concentration-time profile. The frequency and duration of pharmacokinetic sampling
determines whether such multiple phases can be identified, and the associated half-lives
measured. The half-life associated with a particular phase describes the observed decay
only if the contributions from the other phases are negligible. Each half-life depends to
some extent on every rate constant. If all phases are important, one subset of
pharmacokinetic parameters is unable to describe the full time course of cytotoxic
administration. Cisplatin pharmacokinetics are usually described by biphasic models,
but recently developed sensitive analyses have led to the identification of a very late
terminal phase with a half-life of 720 days, commencing 900 days after the last
administration (Schierl et al 1995).
Various statistical considerations are useful in minimising the problems associated with
model selection, but they do not overcome them. Studies with a single drug in a group
of patients may result in some patients requiring a two compartment model to describe
the pharmacokinetics of the drug, whereas others require a three compartment model.
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6.6 Pharmacokinetic modelling
Therapeutic drug monitoring in conjunction with pharmacokinetic modelling can
potentially improve the outcome of chemotherapy. Relationships between therapeutic
or toxic effects and pharmacokinetic variables first need to be identified. The use of
classical pharmacokinetic studies with large numbers of patients has significant
logistical difficulties, as the collection of frequent multiple blood samples is required.
This can be overcome by population pharmacokinetic modelling and maximum a
posteriori probability (MAP) Bayesian estimation, which enables pharmacokinetic
parameters to be defined using a small number of blood samples, with flexible
sampling times. Bayesian pharmacokinetic forecasting takes population values and
integrates patient specific data to determine individual doses.
Bayes theorem states that "prior beliefs, in the form of a probability distribution, may
be combined with observed data, in the form of a likelihood function, to yield a
posterior distribution" (Abrahms et al 1994). It leads to the following:-
Posterior probability oc likelihood * prior probability 6.12
Bayesian estimation firstly assesses the pharmacokinetic characteristics of a typical
population by calculating the means and standard deviations of the pharmacokinetic
parameters representing all patients included thereafter in a given study. To estimate
individual pharmacokinetic parameter values, the Bayesian estimator then combines
the prior knowledge of the probability density function of the population parameters
with the fractional individual patient data, and possibly physiological parameters
such as body weight, age or gender.
The predictive performance of the estimator must be evaluated. A second group of
patients with similar characteristics to the individuals included in the reference
population must be studied. The rich data (eg multiple blood concentrations)
observed in each patient in this validation group, and more precisely the individual
pharmacokinetic parameter values or variables derived from these data using another
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fitting method (eg non-linear regression), need to be compared with those predicted
by the MAP Bayesian estimator using only one or two concentrations.
One or two stage methods are used. In a two stage approach, the first stage estimates
the pharmacokinetic parameter values of each patient using the pharmacokinetic
model that best fits the concentration time curves. In the second stage, the mean,
standard deviation and covariance of pharmacokinetic parameters are calculated. An
extension of this approach is the iterative two stage MAP Bayesian method (Jelliffe
et al 1998), where the individual pharmacokinetic parameter values are estimated
using MAP Bayesian estimation, permitting the inclusion of patients for whom there
is only one blood sample. The population model parameters are provided initially by
a reasonable estimation determined in a very small number of patients. This
population model is further combined with individual data to obtain the maximum a
posteriori probability of the main pharmacokinetic parameter values of each patient
using the Bayesian approach. The mean and standard deviation values of the
parameters may be computed iteratively, the newly obtained mean and standard
deviations being used as Bayesian priors for the following step. This iterative process
ends when each of the sample mean values becomes stable.
One stage methods consider the data observed in all patients, to which the
pharmacokinetic model is fitted. This provides information about which patient
characteristics are important in determining the pharmacokinetics of the drug and
how much variability can be accounted for by such characteristics. It is not necessary
to obtain all the samples required to establish individual pharmacokinetic profiles, as
these are not determined, and it is possible to scatter different sampling times
between patients to the extent that each patient only needs to be sampled once. The
most widely used model of the parametric one stage methods is the nonlinear mixed
effect model. Each pharmacokinetic parameter is considered as the sum of the "fixed
effect", provided by the population, and the "random effect", which depends on the
individual. The most popular software utilising this approach is NONMEM
(nonlinear mixed effect modelling). NONMEM estimates population parameters as
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typical parameter values with the estimated interindividual variability usually as the
standard deviation.
To date, therapeutic drug monitoring has only proved useful for a few anticancer
drugs such as high dose methotrexate, 5-fluorouracil and the platinum compounds,
due to the lack of identifiable relationships between response and systemic exposure
(Rousseau et al 2000). Many more relationships have been demonstrated between
exposure and toxicity. Kerbusch et al (2001) recently used the NONMEM
programme to develop and validate a model to estimate ifosfamide, 2-DCEI, 3-
DCEI, and 4-hydroxyifosfamide concentrations in a paediatric population using
limited sampling. Cross-validation indicated no bias, and only minor imprecision
(12.5 ± 5.1%) for 4-hydroxyifosfamide.
An improved knowledge of the relationships between the pharmacokinetic parameter
values or exposure variables of cytotoxics and tumour growth or survival rate is
needed. This could contribute to increased treatment efficacy and patient outcome by




The Separation of Red Cells from Plasma and Measurement
of Red Cell Volume
7.1 Introduction
Two approaches are usually used to determine the amount of a compound associated
with red cells (chapter 4). In the first, the erythrocytes are washed prior to analysis, but
this may strip them of their outer layer, which may be important in the transport and
exchange process. A second technique is to measure the concentration in whole blood
and subtract from this the amount present in plasma, corrected for the haematocrit.
However, when a compound is found in high concentrations in plasma relative to red
cells, this approach can be very inaccurate, and may even result in negative values when
the erythrocyte associated concentration is calculated.
Ideally, a direct determination of red cell associated compounds should be performed
on unwashed erythrocytes, maintained in their natural environment, without
disruption of the normal equilibrium existing between red cells and plasma in whole
blood. Before a direct analysis, the red cells must be compressed, reducing the
amount of plasma between the cells to a fixed volume, as low as possible,
approximately 2% (International Committee for Standardisation in Haematology
1980; Pearson and Guthrie 1982; Rustad 1964). The red cells need to be collected in a
reproducible manner, and the volume of the collected cell mass must be known. The
direct method employed by Driessen et al (1989a; 1989b; 1989c; 1990) is so
inconvenient that it is not acceptable for routine use. Only one other example exists in
the literature where a similar procedure was followed (Mating et al 1989).
If the plasma volume between red cells can be diminished, a more direct analysis of
compounds associated with red cells can be performed. A sediment of red cells
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obtained at 10,000 g will contain no more than 2% (v/v) of trapped plasma. It is
therefore possible to separate off and measure such a cell sediment, containing a
constant volume of trapped plasma, with the concentration of compounds on the red
cells unchanged by the procedure. Thereafter, compounds associated with a known
mass of red cells can be quantified. The MESED (measurement of sediment) instrument
(FABRE, Kelmis, Belgium) allows such a separation, and was used for the
measurement of red cell volume, prior to the analysis of ifosfamide and its metabolites
in the plasma and red cell compartments.
7.2 The use of the MESED
7.2.1 The MESED instrument
A reservoir A is inserted into a container B, as shown in Figure 7.1. The reservoir is
fitted tightly into the container so that the small orifice in the reservoir [1] is sealed by
the o-ring in the container [2] (panel a). Fresh blood is collected and anticoagulated in
lithium heparin vacutainers, the reservoir filled with an aliquot of blood, and the unit
placed in a swing out rotor. By centrifuging at high speed (> 5000 g) red cells are
forced into the narrow part of the reservoir [3], into the closed small channel [4], and
into the bottom of the broad part of the reservoir [5], After the first centrifugation some
supernatant plasma is removed for independent analysis.
Before the second centrifugation, the reservoir A is detached by turning A in B, so that
the o-ring [2] no longer occludes orifice [1] (panel b). During the second centrifugation,
the flow resistant red cell sludge, together with the remaining supernatant plasma, is
forced out of the reservoir A into the bottom of the container B, leaving behind a
defined volume of almost pure red cells in the narrow part ofA [3],
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This mass of cells is then transferred to a centrifuge tube by centrifuging the inverted
reservoir alone. The weight of collected cells depends on the exact dimensions of the
narrow part of the reservoir, on the centrifugal force applied, and on the density of the
cells, the density ofnormal erythrocytes being 1.096.
A correction must be made for the plasma trapped in the sediment. The amount of
trapped plasma was determined initially under standardised conditions using an
extracellullar marker, 5lCr-EDTA. The collection of supematent plasma after the first
centrifuge run, and its subsequent analysis, is required for this correction.
A mistral 3000 centrifuge was used (MSE Scientific Instruments, Crawley, UK), with
plastic centrifuge tubes (Sarstedt Ltd, Leicester, UK) in the third centrifugation step.
Centrifuge runs of 3600 g, 3600 g, and 1000 g, each for 10 minutes, were employed. At
speeds greater than 1000 g in the third centrifugation, the centrifuge tubes fractured.
This in turn limited the maximum speed in the first two centrifugations to 3600 g, as
following higher speeds it was not possible to eject the sediment at 1000 g on the third
centrifugation. The problem of sub-optimum speeds was overcome by weighing the
centrifuge tubes before and after the third centrifugation, and calculating the weight of
the erythrocyte sediment.
7.2.2 Calibration
Whole blood samples (1 ml) were spiked with 20 pi of 51Cr-EDTA, (3 MBq in 10 ml)
(table Al, appendix). The blood samples were mixed well at room temperature, allowed
to equilibrate for 15 minutes, mixed well again, and plasma and erythrocytes separated
using the MESED tube, as described above. 100 pi of plasma was used for the y count,
and the red cells were suspended in 150 pi of 0.9% saline before counting. The
calibration samples were counted in a 1282 compugamma CS Universal gamma
counter (LKB Wallac, Perkin Elmer, Denmark). The median percentage of trapped
plasma in the erythrocyte sediment was 3.72%. This is somewhat higher than that
reported by Siebers and colleagues, and may reflect differences in the behaviour of
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51Cr-EDTA and (Co')-EDTA (Brochner-Mortensen et al 1969; Burck 1970; Siebers et
al 1986).
7.3 Assay of ifosfamide and its metabolites in erythrocytes
The red cell sediments generated by the MESED tube were haemolysed by adding
0.9 ml of HPLC quality water, vortexing, and leaving the mixture at room
temperature for 30 minutes. The lysate was diluted with 1 ml of buffer, and then
treated as plasma samples in the subsequent extraction process (chapter 5). Species
adsorbed or incorporated into the red cell are not distinguished, and the erythrocyte
concentrations are minimal values. Although it is not possible to exclude an
incomplete recovery of active compounds from red blood cells, recovery was not
increased with repeated extraction of the erythrocyte lysate. Erythrocyte
concentrations (E) were determined using the calibration curve obtained for spiked
plasma (500 pl):-
E = Pcai x 500/weight of erythrocytes (mg) 7.1
where Pcai is the reading obtained from the spiked plasma calibration curve.
E was expressed in mg Kg"' of red blood cells, or pg ml'1, assuming an erythrocyte
density of 1.
A correction was made for the amount of trapped plasma (3.72%):-
Ec = E + (Ex 0.0372)-(Px 0.0372) 7.2
Where Ec is the corrected red cell concentration, E is the measured erythrocyte
concentration and P is the plasma concentration.
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7.4 Conclusion
The MESED instrument allows a direct analysis of the erythrocyte compartment,
without disturbing the equilibrium present between erythrocytes and plasma.







Ifosfamide induced neurotoxicity can be assessed using the EEG, psychometric testing,
the national adult reading test (NART), the mini-mental state (MMS) examination, and
clinical evaluation of symptoms.
8.1.1 The electroencephalogram
The EEG is the electrical activity recorded by conventionally placed electrodes over
the scalp. It is an attenuated and smoothed form of the electrocorticogram. In the
wakened but relaxed state, rhythmical sinusoidal potentials wax and wane. A
characteristic of the human EEG is the 8 Hz to 12 Hz alpha rhythm in areas posterior
to the central sulcus, occurring independently in both hemispheres, but with similar
frequency on each side. The waves are not action potentials, but are believed to
represent synchronised dendritic potentials superimposed on slowly varying potential
differences across the cortex (DC shifts). Arousal, and especially fixation of attention
on a visual pattern, or performance of mental activity such as calculation,
desynchronizes the alpha rhythm. The synchronised state of the EEG, in the wakened
but relaxed state, results from the inhibitory effect of thalamocortical fibres on the
higher frequency driving of cortical synapses affected by the mesencephalic reticular
formation. When the latter dominates during alerting, the alpha rhythm is
desynchronized. The transition from wakefulness to drowsiness is marked by
increased amplitude of post-central alpha rhythm, and its frequency may slow by 0.5
Hz to 1.0 Hz.
Several traditional frequency bands have been used as measures of drug effects (table
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8.1). Although there is physiological evidence for the independence of these frequency
bands, their boundaries are not strict, and may differ depending on species, population










Table 8.1. Frequency of EEG band widths.
The introduction of computers has facilitated the quantification and processing of drug
induced EEG changes. Quantitative EEG analysis is used now in many areas of clinical
pharmacological research, and can provide information on the intrinsic effects of
centrally acting drugs. Different classes of such drugs produce characteristic EEG
changes. Quantitative EEG analysis can in principle be used to characterise
pharmacokinetic - pharmacodynamic (PK-PD) relationships. EEG parameters appear
to possess several of the ideal features for pharmacodynamic measurements; continuity,
objectivity, sensitivity and reproducibility.
8.1.2 Psychometric tests
The aim of most behavioural or performance research in relation to sedative
compounds is to determine if their use causes a diminished ability to perform routine,




These tests evaluate motor response by requiring the subject to press a button in
response to a critical stimulus. The number correct, and the latency to respond, are
normally used as a measure of task performance. Both simple and choice reaction
time have been employed. Simple reaction time involves only a motor response, for
example, how rapidly the subject presses a button after stimulus presentation. In
choice reaction time, the subject is presented with a single stimulus that is one of a
number of alternatives. This test assesses sensorimotor performance by adding a
recognition time component (stimulus processing time) to the motor movement
aspect of the simple reaction time test.
b Digit symbol substitution
This has been presented in a number of different forms. The task requires sustained
attention and concentration, and evaluates response speed and recognition of sensory
information.
c Tracking
Tracking is an assessment of visuo-motor co-ordination, and may contain elements
of reaction time, fine and course motor control, and attention. The pursuit rota is
regarded as the most basic measure of visuo-motor performance. Compensatory and
adaptive tracking use the input of the subject while attempting to maintain the
position of an indicator on screen. The root mean square of the distance of the
indicator from the centre of the screen is usually the performance measurement in
these tasks. Pursuit tracking requires the subject to follow a path generated by the
device and superimpose their own path.
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The types of test that may be included in a testing battery are many and varied, but
the most commonly applied tests are compensatory tracking, and simple and choice
reaction time tests.
8.1.3 National adult reading test
The NART is a universally applicable indicator of premorbid intelligence levels.
Reading ability is highly correlated with general IQ level in the normal population,
and the NART was specifically designed to provide a means of estimating the
premorbid intelligence levels of adult patients suspected of suffering from
intellectual deterioration.
8.1.4 Mini-mental state examination
The MMS examination is a quick and valuable test for simple bedside screening and
serial assessment of cognitive function (Dick et al 1984).
8.2 Methods
Eleven patients receiving oral ifosfamide 500 mg twice daily were monitored for
neurotoxicity on their first cycle of treatment. Ifosfamide was administered for a period
of 14 days, and assessments were performed on days 0 (baseline), 2, 8 and 15. Cycles
were repeated every 28 days. Seven patients had cervical carcinoma, and four NSCLC.
8.2.1 Electroencephalogram system
The international 10/20 system of EEG electrode placement was used. Twenty-one
channels were recorded through a bandwidth of 0.5 Hz to 30 Hz. The standard sequence
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was 20 seconds eyes open, 20 seconds eyes closed. Epochs of eight seconds were taken
for analysis commencing five seconds after eye opening or closure. Procedures were
continued until ten artefact-free epochs were obtained under both eyes open and eyes
closed conditions.
The EEGs were evaluated blindly and independently by a neurologist, with only the
patient initials given. The day of investigation and whether the patient was receiving
treatment was not indicated. Two main measures were employed. The first was a
system of evaluating the basic background alpha rhythm at 27 different one second
epochs. The mean alpha rhythm of each recording was then determined. The second
evaluation of the recordings assessed the EEG abnormalities, particularly slow activity,
episodic slow activity and paroxysmal activity. In addition, the changes in the recording
due to over breathing and photic stimulation were evaluated. The results were listed and
the records given an arbitrary ranking from the most normal to the most abnormal,
according to the Meanwell grading (table 3.3). The code was then broken, and the
rankings compared to the actual days of the study, 0 (baseline), 2, 8 and 15.
8.2.2 Psychometric tests
The psychometric system used in the Guy's drug research unit was developed to
provide a comprehensive set of fully automated procedures for evaluating the
psychological and behavioural consequences of compounds with potential CNS
activity. The system comprises a battery of psychometric tests installed on IBM
microcomputers, which are fully automated and require the minimum of supervision.
The tests consist of choice reaction time, a continuous attention task, and the salford
tracker, which are considered to be amongst the most sensitive tests available for
psychopharmacological effects. Psychometric tests were performed in the following
order: choice reaction time, salford tracker and continuous attention task.
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a Choice reaction time
This comprises two parts; recognition and motor reaction times (table 8.2). Five
practice tests are allowed, followed by 20 live tests.
Test Description
CR 1 Mean time to take pen off (reaction time)
CR 2 SD of time to take pen off
CR 3 Mean time to put pen on
CR 4 SD of time to put pen on
Motor response time is CR 3 - CR 1
Table 8.2. Choice reaction,
b Salford tracker
This test is a simulated car driving test in which the subject tracks an arrow using a
computer mouse. The maximum distance from the target and the root mean square of
this distance is recorded (table 8.3). In addition, the subject responds to a stimulus
presented in the periphery of vision while simultaneously attending to the tracking task.
The maximum and average response times to ten of these peripheral stimuli per task are
also used as response measures. The distance is measured in pixels, and when
superimposition is perfect the score is zero. One practice session is permitted before
three live sessions.
c Continuous attention task
In this test, patients monitor a series of digits for targets of three consecutive odd or
three consecutive even digits, and signal their detection by pressing a response button as
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quickly as possible. The outcome measures from this task are the average reaction time
to respond to the targets, the number of missed responses, and the number of false
responses. Two hundred numbers are presented, and each number is displayed for one
second.
Test Description
ST 1 Mean minimum time
ST 2 SD of minimum time
ST 3 Mean maximum time
ST 4 SD of maximum time
ST 5 Mean time (to press button)
ST 6 SD of time (to press button)
ST 7 Mean maximum distance
("veering" distance with driving test)
ST 8 SD of maximum distance
ST 9 Mean average distance (from the
point ofperfect superimposition)
ST 10 SD of average distance
ST 1 to ST 6 is to stimulus whilst tracking
Table 8.3. Salford tracker.
Test Description
CA 1 Mean response time
CA 2 SD response time
CA 3 Number of correct sequences missed
CA 4 Number of false responses
16 correct sequences were present in the test
Table 8.4. Continuous attention task.
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8.2.3 National adult reading test
The NART comprises a list of 50 words printed in order of increasing difficulty
(tables 8.5 a-c). They are irregular with respect to the common rules of pronunciation







DEPOT dep ' 0
AISLE il
BOUQUET book ' a, booka, boka '
PSALM sam
CAPON ka ' pn
DENY di-ni















RADIX ra ' diks
ASSIGNATE as ' -ig-nat
HIATUS hi-a ' tas
SUBTLE sut' 1





SIMILE sim ' 1-li
BANAL ban-al'











PLACEBO pla-se ' bo
ABSTEMIOUS ab-ste ' mi-as
DETENTE da-tat (Fr)








SIDEREAL si-de ' ri-al
DEMENSE di-man di-men '
SYNCOPE sing ' ka-pe
LABILE la ' bil
CAMPANILE kam-pan-e ' la,
kam-pan-e ' le
Table 8.5 c. Word lists; only the left hand column was given to the patient.
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The patient reads aloud down the word lists, and the examiner records the number of
errors made according to the pronunciation guide. The Wechsler adult intelligence
scale (WAIS) full-scale, verbal, and performance IQs were predicted from this
reading error score by inserting it into the appropriate formula (Wechsler 1955):-
WAIS full scale IQ = 127.7 - (0.826 x NART error score)
WAIS verbal IQ = 129.0 - (0.919 x NART error score)
WAIS performance IQ = 123.5 - (0.645 x NART error score)
8.2.4 Mini-mental state examination
The MMS test is shown in table 8.6.
8.2.5 Clinical assessment
Neurotoxicity was also assessed clinically. Patients were graded according to the
common toxicity criteria (table 3.2).
8.2.6 Probability ofencephalopathy
The probability of developing encephalopathy was calculated according to the
method of Meanwell et al (1986a). Weights for serum albumin, serum creatinine and
the presence of pelvic disease, together with constants derived from the analysis,
were used to determine classification scores (S1 and S2) for each patient.
SI = -31.3381 + (1.1650 x [albumin]) + (0.1527 x [creatinine]) + (5.2841 x [pelvic
value])
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1 point for 2 objects
correctly named (2)
1 point if the following
sentence is repeated correctly
NO IFS AND BUTS (1)
3 points if a 3-stage command
is correctly executed (3)
Write "close your eyes" and ask
subject to obey what is written -
1 point if subject closes eyes (1)
Subject writes sentence; 1 point if
sensible, with verb and subject (1)
Construct a pair of pentagons 1
inch long; 1 point if subject
copies correctly (1)
REGISTRATION
Name 3 objects (3)
ATTENTION & CALCULATION
Subtract 7 from 100 and 7
from the result. (Repeat
5 times) (5)
RECALL
Ask for 3 objects
repeated in the
REGISTRATION test (3)
Sub Total: (19) + Sub Total: (9)
TOTAL SCORE (max 28) =
Table 8.6. Mini-mental state assessment.
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S2 = -28.5367 + (0.8398 x [albumin]) + (0.2055 x [creatinine]) + (7.1589 x [pelvic
value])
The pelvic value for patients with and without a pelvic lesion is 2 and 1 respectively.
Albumin is measured in g L"1 and creatinine in pM.
The probability of a patient developing grade 0 to 2, rather than grade 3 or 4,
e i ci co
encephalopathy according to the Meanwell grading is e /(e +e ).
8.3 Results
8.3.1 Electroencephalogram
Seven patients were assessed. In all except one, the EEG was abnormal by day 2, with
decreased alpha frequency and the development of pathological slow wave activity. The
changes in the recordings were quite dramatic, and showed some of the features seen in
toxic encephalopathies, and even changes observed in patients with epileptigenic
disturbances. An example of an EEG on day 2 is given in figure 8.1. The results in
some of the patients showed a perfect ranking order. In others this was not perfect, but
there was always an isolation of the records of the 8th and 15th days from those of the
baseline and the 2nd day (table 8.7).
8.3.2 Psychometric tests
Six patients were subjected to psychometric testing. The psychometric data during the
first course of oral ifosfamide are shown in tables A2 to A4, and graphic representations
illustrated in figures 8.2 to 8.4. The mean reaction time and the mean time to place the
pen in the choice reaction test was impaired in all patients except one, although this
failed to reach statistical significance (table A5).
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Figure 8.1. EEGs on day 0 (baseline) and day 2 in patient SO.
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The mean average distance in the salford tracker was significantly increased on day 15
(p = 0.026). The mean response time in the continuous attention task was significantly
increased on day 2 (p = 0.018).
Patient EEG score Mean alpha frequency (Hz)
Day Day
0 2 8 15 0 2 % change
0 to 2
8 15 % change
Oto 15
CB 0 0 9.48 9.86 104.0
EG 0 2 2 3 10.90 9.92 91.0 8.90 8.52 78.2
CH 0 1 3 3 9.68 8.54 88.2 7.62 8.00 82.6
JW 0 1 2 2 9.78 9.54 97.5 8.92 8.46 86.5
LR 0 2 - 3 10.54 8.48 80.5 - 6.98 66.2
SO 0 1 - - 9.94 7.70 77.5 - - -
NH 0 3 - - 10.42 - - - 7.35 70.5
EEG grading is according to Meanwell et al (1986a)
Rank correlation, day against percentage change in alpha frequency, is 0.753; p < 0.001
Table 8.7. Changes in EEG score and mean alpha frequency during oral ifosfamide.
8.3.3 National adult reading test
The results of the NART are given in tables 8.8 and 8.9. Performance decreased
slightly on day 2 in two patients, but was otherwise unchanged.
8.3.4 Mini-mental state examination
No significant changes in this score were observed during oral ifosfamide
administration (table 8.10).
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Choice reaction - mean time to place pen
40 - -- —
0 5 10 15
Day
Figures 8.2 a and b. Choice reaction time.
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Figure 8.2 c (upper). Choice reaction time.
Figure 8.3 a (lower). Salford tracker.
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Figures 8.3 b and c. Salford tracker.
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Salford tracker - mean maximum distance
0 5 10 15
Day
Salford tracker - mean average distance
200 ;
Day
Figures 8.3 d and f. Salford tracker.
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Figure 8.4. Continuous attention task.
8.3.5 Clinical assessment
The neurotoxic symptoms experienced by the patients are described in table 8.11.
Two patients are not assessable for neurotoxicity, one dying suddenly from a
pulmonary embolus on the fourth day of oral ifosfamide. All assessable patients
developed a feeling of detachment, or an inability to concentrate. In addition, four
patients suffered neurocortical disturbances and one anxiety. Neurological
manifestations were evident by day 3 of treatment in all patients, and resolved on
discontinuation of ifosfamide. The Meanwell grading of the EEGs (table 3.3) was not
consistent with the clinical features; a score of 2 or 3 in five patients was associated
with relatively mild neurotoxicity, whilst hallucinations occurred in one patient with
a score of 1. However, two patients in the former group developed severe
neurotoxicity with subsequent courses.
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Patient Day 0 Day 2 Day 8 Day 15
C W C W C W C W
CB 37 13 45 5
EG 45 5 44 6 45 5 45 5
CH 32 18 42 8 40 10 34 16
JW 20 30 25 25 27 23 25 25
LR 41 9 46 4 - - 42 8
SO 26 24 23 27 . . _ .
C = Number correct; W = Number wrong
Table 8.8. National adult reading test.
Patient Day 0 Day 2 Day 8 Day 15
FS V P FS V P FS V P FS V P
CB 117 117 115 124 124 120
EG 124 124 120 123 123 120 124 124 120 124 124 120
CH 113 112 112 121 122 118 119 120 117 114 114 113
JW 103 101 104 107 106 107 109 108 109 107 106 107
LR 120 121 118 124 125 121 - - - 121 122 118
SO 108 107 108 105 104 106 . . _ _ _ -
F S = Full scale IQ; V = Verbal IQ; P = Performance IQ
Table 8.9. National adult reading test; predicted IQ.
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Patient Day 0 Day 2 Day 8 Day 15
CB 26 28 - -
EG - 26 25 25
CH 28 25 26 26
JW 25 28 28 27
LR 28 28 - 28
SO 21 22 - -








CB No 31 82 Not assessable
EG Yes 44 113 Mildly impaired concentration
CH Yes 45 114 Mild feeling of detachment
JW Yes 49 89 Mildly impaired concentration
LR Yes 42 94 Anxiety Neuromood (1)
SO Yes 33 62 Disorientation + hallucinations Neurocortical (3)
PC No 35 80 Somnolence Neurocortical (2)
RC No 34 123 Hallucinations Neurocortical (3)
JT No 33 88 Mildly impaired concentration
NH No 42 69 Somnolence Neurocortical (1)
LJ Yes 39 107 Not assessable
PD = Pelvic disease
Table 8.11. Clinical features during course 1 of oral ifosfamide.
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8.3.6 Probability ofencephalopathy
The probability of each patient remaining free from grade 3 or 4 encephalopathy is
shown in table 8.12. The two patients with grade 3 CTC encephalopathy scored
relatively low probabilities of 0.47 and 0.71.
Patient Pelvic SI S2 esl eS2 esl+eS2 Probability
value
CB 1 22.6 21.5 6.42 x 109 2.19 x 109 8.61 x 109 0.75
EG 2 47.7 46.0 5.44 x 102° 9.07 x 1019 6.35 x 102° 0.86
CH 2 49.1 47.0 2.03 x 1021 2.58 x 102° 2.29 x 1021 0.89
JW 2 49.9 45.2 4.72 x 1021 4.36 x 1019 4.76 x 1021 0.99
LR 2 42.5 40.4 2.91 x 1018 3.41 x 1017 3.25 x 1018 0.90
SO 2 27.1 26.2 6.14 x 10" 2.48 x 10" 8.61 x 10" 0.71
PC 1 26.9 24.5 5.00 x 10" 4.18 x 1010 5.41 x 10" 0.92
RC 1 32.3 32.5 1.11 x 1014 1.24 x 1014 2.35 x 1014 0.47
JT 1 25.8 24.4 1.65 x 10" 4.03 x 1010 2.05 x 10" 0.80
NH 1 33.4 28.1 3.24 x 1014 1.56 x 1012 3.26 x 1014 1.00
LJ 2 41.0 40.5 6.42 x 1017 3.97 x 10'7 1.04 x 1018 0.62
Table 8.12. The probability of developing grade 0 to 2, rather than grade 3 or 4,
encephalopathy on course 1 of oral ifosfamide.
8.4 Discussion
Oral ifosfamide causes significant neurotoxic effects. All patients developed
symptoms during the 14 days of treatment. A feeling of detachment, or an inability to
concentrate, was universal, and one patient developed anxiety, two somnolence, and
two suffered hallucinations.
Other studies have highlighted this type of toxicity. Four of six patients treated by
Wagner and Drings (1986) experienced neurotoxicity after 2 g m"2 of oral ifosfamide,
whilst an incidence of 33% was reported after daily doses of 2 g (Cerny et al 1989).
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Doses lower than 1 g daily, or a shorter duration of treatment than 14 days, appear
more tolerable. Manegold et al (1992) assessed four different schedules of oral
ifosfamide (1 g daily for 5 days; 750 mg, 1 g or 1.25 g daily for 14 days [schedules 1
to 4 respectively]) in 64 patients with stage IV NSCLC. Neurotoxicity was measured
according to Meanwell et al (1986a). Grade 1 or 2 CNS toxicity was seen in 2/15
(13%) of patients on schedule 1, 8/19 (42%) on schedule 2, 8/23 (35%) on schedule
3, and 4/7 (57%) on schedule 4. No grade 3 toxicity was seen. All episodes resolved
on discontinuation of treatment. Somnolence and nightmares occurred most
frequently, but hallucinations, restlessness and forgetfulness were also recorded.
With mild to moderate encephalopathy ifosfamide was stopped. When rechallenged,
five of 18 patients again developed encephalopathy. The time of onset of the
encephalopathy was variable, but occurred in most patients on the second or third
day. Neurotoxicity was evident in the first cycle in 15 cases. In the remaining seven
cases neurotoxicity was first apparent in the second or subsequent cycles. The
increase in the daily ifosfamide dose to 1.25 g led to increased neurotoxicity
suggesting a relationship between dose and neurotoxicity. The total cycle dose was
less important than the total daily dose.
Oral ifosfamide appears to have quite a prominent effect on cerebral function, at least as
evaluated by the EEG, with decreased alpha frequency and the development of
pathological slow wave activity. Other groups have also described a reduction in alpha
frequency (Danesh et al 1989). Psychometric performance was impaired during the
course of oral ifosfamide. This was particularly so for the mean response time in the
continuous attention test, and the mean average distance in the salford tracker test.
Cognitive function and IQ were not affected, although Heim et al (1981) have described
impairment of short term memory in nephrectomised patients given intravenous
ifosfamide.
Oral ifosfamide 500 mg twice daily for 14 days is too neurotoxic for routine use. The
two patients with grade 3 CTC encephalopathy scored relatively low probabilities of
remaining free from this degree of neurotoxicity using the Meanwell assessment,
114
indicating that this predictive approach may be useful for ifosfamide given orally.
However more data is needed to develop precise discriminatory values.
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Chapter 9
The Pharmacokinetics of Oral Ifosfamide
9.1 Introduction
Ifosfamide is usually administered intravenously. Daily fractionation of the dose
over five days results in an increase in the Cmax and AUC of total alkylating
activity, as measured by the NBP reaction (Lind et al 1989a). IPM, CIPA, DCEI, and
ifosfamide at high concentrations, all have alkylating activity in this reaction (chapter
5). Therefore one would expect that fractionation would lead to an increase in
cytotoxicity. Early work confirmed that this type of administration was effective, and
further studies suggested reduced toxicity with five day regimens (Klein et al 1984;
Morgan et al 1982; Rodriguez et al 1976). Fractionated ifosfamide therapy has
become one of the most commonly used methods of administration. Routine clinical
practice is to administer the drug in three or five day fractionated regimens, or as
continuous infusions (Brade et al 1985). An oral fractionated regimen would be
advantageous, minimising hospital admissions; an oral formulation, with a
bioavailability of 100%, was described in 1986 (Wagner and Drings 1986), but its
use has been restricted by an increased incidence of encephalopathy (Manegold et al
1992) (chapter 3).
Ifosfamide is a pro-drug, requiring activation within the hepatic cytochrome P-450
system to form IPM, the ultimate alkylating agent (chapter 2). Dechloroethylation,
with the formation of chloroacetaldehyde, may be important in the development of
encephalopathy. Other ifosfamide metabolites are theoretically possible, as illustrated
by the metabolism of the structural isomer cyclophosphamide. This follows a similar
metabolic fate, but NNM has also been found after intravenous administration in man.
In one report the source of NNM was not clear as cyclophosphamide, 4-
ketocyclophosphamide, carboxyphosphamide and CPM were all capable of
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decomposing to NNM during the freezing and thawing of plasma (Jardine et al 1978).
When CPM is injected into mice NNM is formed, and this in turn yields 3-(2-
chloroethyl)-l, 3-oxazolidine-2-one (Struck et al 1975). In the case of IPM, an
equivalent transformation leads to CEA and OXA (chapter 2); CEA has alkylating
activity, but only one-fifth the potency ofNNM (Sladek 1977).
This chapter is concerned with the pharmacokinetics of oral ifosfamide, and the
generation of 2-DCEI, 3-DCEI, CIPA, KIPA, IPM, and the basic metabolites CEA
and OXA, both of which have not been described previously in biological fluids.
9.2 Methods
Eleven patients were studied, seven females with advanced or recurrent carcinoma of
the cervix, and four males with advanced NSCLC. The median age was 58 years
(range 33 - 70). None had received prior chemotherapy. Oral ifosfamide, formulated
as gelatin capsules, was administered at a dose of 500 mg twice daily, eight hours
apart, for 14 days; film-coated tablets containing 300 mg of mesna were given twice
daily concurrently for uroprotection.
Blood samples were taken before the first dose on days 1 and 14, and at
approximately 0.5, 1, 2, 4 and 6 hours thereafter. The fasting state was maintained
during the initial four hours. Plasma was separated immediately by centrifugation,
and stored at -20°C until analysis. Ifosfamide and its metabolites were determined by
GC-MS, as described in chapter 5. Pharmacokinetic data was obtained using the
MK-MODEL programme (Holford 1990). The AUC was calculated using the
trapezoidal rule to eight hours (AUCs), the time of the second dose (chapter 6). The
absorption rate constant of ifosfamide (KA) was obtained using equation 6.6.
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9.3 Results
P. 3.1 Ifosfamide pharmacokinetics
The pharmacokinetic data are given in the appendix (tables A6 to A23), and
parameters are shown in table 9.1. The profiles from one patient are illustrated in
figure 9.1. The mean absorption rate constant of ifosfamide on day 1 was 1.23 hr"1
(SD ± 1.01), with one patient absorbing the drug very quickly.
Cmax AUC8 KA Cmin
(pM) (pM.hr) (hr1) (pM)
Ifosfamide
Day 1
Mean 53.1 293 1.23
SD 18.5 67 1.01 -
n 11 11 11 -
Day 14
Mean 50.7 256 8.0
SD 25.8 118 - 6.9




SD 0.41 2.9 - -
n 8 10 - -
Day 14
Mean 1.1 8.4 0.17
SD 0.57 2.9 - 0.19
n 6 6 - 6








SD 0.65 5.5 -
n 10 9 -
Day 14
Mean 4.3 27 1.5
SD 1.9 12 1.1




SD 2.5 14 -
n 9 11 -
Day 14
Mean 7.5 58 3.3
SD 4.0 26 2.6
n 6 7 7











Mean 1.5 9.3 .
SD 0.80 3.5 -
n 11 11 -
Day 14
Mean 2.1 15 0.45
SD 1.1 8.5 0.54




SD 0.44 2.44 -
n 9 10 -
Day 14
Mean 1.04 7.74 0.17
SD 0.53 3.85 0.13
n 7 7 7







Mean 7.6 52 .
SD 4.0 23 -
n 9 9 -
Day 14
Mean 7.3 53 1.3
SD 3.2 26 2.1




SD 0.29 2.6 -
n 9 9 -
Day 14
Mean 0.87 10.7 0.18
SD 0.42 2.9 0.30
n 6 6 6















Figure 9.1 a. Plasma concentration-time profiles of ifosfamide and IPM
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Figure 9.1 b. Plasma concentration-time profiles of 2-DCEI and 3-DCEI
after oral ifosfamide administration; day 1 ♦; day 14 □.
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Figure 9.1 c. Plasma concentration-time profiles of CIPA and KIPA after oral




Figure 9.1 d. Plasma concentration-time profiles of CEA and OXA after oral
ifosfamide administration; day 1 ♦; day 14 □.
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The ratios of day 14 Cmax / day 1 Cmax are given in table A23, and the mean values
illustrated in figure 9.3. The ratio for ifosfamide was less than 1, and the highest
ratios were observed with KIPA and 2-DCEI. Overall, the ratios suggest increased













KIPA 2-DCEI 3-DCEI CIPA OXA CEA IPM IPA
Compound
Figure 9.3. Ratio of day 14 Cmax / day 1 Cmax for ifosfamide and its
metabolites (mean values).
The Cmax values on days 1 and 14 were compared, as were the AUCs values on days
1 and 14, using a paired t-test (table A28). The differences between day 1 and day 14
Cmax values of 2-DCEI and CIPA, and AUCs values of CIPA and CEA, were
statistically significant.
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9.3.2 Ifosfamide pharmacokinetics and neurotoxicity
The Cmax of ifosfamide and its metabolites were correlated with the alpha frequency
in the EEG on days 2 and 15, using Pearsons correlation coefficient (tables A24 and
A25). Percentage changes of less than 100% in EEG alpha frequency reflect
increasing neurotoxicity (negative r values). A negative and positive correlation was
noted between CEA Cmax and IPM Cmax respectively. The role of
dechloroethylation in the development of encephalopathy is also implicated; for the
dechloroethylated metabolites, the mean day 14 / day 1 Cmax ratio was greater than
2 (Figure 9.3), whilst neurotoxicity was progressive in all patients during the 14 days
of treatment.
9.4 Discussion
As a limited amount of data is available from the pharmacokinetic study, only certain
trends can be identified. Similar behaviour is suggested for all metabolites except
IPM. There is a tendency to higher values of Cmax, implying more generation during
the treatment period. During prolonged oral ifosfamide administration, metabolism is
directed more to dechloroethylation, and ifosfamide undergoing activation shows a
greater tendency to form CIPA and KIPA, with less quantities of IPM. However it is
not possible to compare days 1 and 14 formally; there was no washout period before
pharmacokinetic sampling on day 14. Furthermore, time points for sampling did not
extend through the two hours preceding the next dose, hampering AUC calculations.
The pharmacokinetic study was part of two larger multi-centre clinical trials of oral
ifosfamide in NSCLC and cervical cancer, specifying a fourteen day period of oral
ifosfamide; these clinical studies were terminated prematurely on account of the
observed neurotoxicity. The pharmacokinetic study would have been improved if a
three day washout period had been allowed after the first dose, and pharmacokinetic
sampling had been performed on the last dose. More time points are necessary to
calculate AUCoo.
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The scarcity of data concerning relationships between pharmacokinetic parameters
and EEG impairment means that interpretation must be cautious. However some
generalisations can be made. With higher ifosfamide AUCs values on day 1, less
impairment was observed in the EEG, implying that higher rates of ifosfamide
metabolism result in greater neurotoxicity. An elevated Cmax of 2-DCEI was
associated with less impairment, whereas the converse was true for the Cmax of 3-
DCEI. Previous studies of oral ifosfamide have not established a link between
ifosfamide metabolites and neurotoxicity; Lind et al (1990b) reported a higher
urinary recovery of dechloroethylifosfamide, IPM and CIPA after oral ifosfamide,
compared to the intravenous route, but there was no correlation between any
individual metabolite and the development of neurotoxicity.
In summary, the results suggest that increased metabolism of ifosfamide, and/or an
accumulation of its metabolites, is associated with a greater impairment of EEG
appearances. It is not possible to identify one particular metabolite. Statistical
analysis must be guarded; the t-tests and correlations imply that the dechloroethyl
metabolites and CIPA may be important, and that these require further study. The
data is consistent with previous reports implicating dechloroethylation in the
aetiology of neurotoxicity; the increase in Cmax of the dechloroethylated metabolites
on day 14 was secondary only to that of KIPA. Neurotoxicity was progressive
throughout the fourteen day period, as metabolites accumulated. Additional work is
needed, with an improved study design, to allow a more complete assessment of the
pharmacokinetic parameters of KIPA, 2-DCEI, 3-DCEI and CIPA during prolonged
treatment with oral ifosfamide.
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Chapter 10
The Formation of Chloroethylamine and 1, 3-Oxazolidine-2-
one
10.1 Introduction
The metabolism of ifosfamide is described in chapter 2. However, plasma profiling
studies of patients receiving ifosfamide have neglected the metabolism of IPM to CEA
(figure 2.2), as predicted by the formation of NNM from CPM (Struck et al 1975).
Hydrolysis of cyclophosphamide to NNM has also been described in vitro (Arnold and
Klose 1960). This chapter investigates the corresponding behaviour of ifosfamide.
10.2 The hydrolysis of cyclophosphamide
In aqueous solution at 70°C, cyclophosphamide hydrolyses to NNM, N-propanolamine
and phosphoric acid (Arnold and Klose 1960). Following more prolonged exposure of
cyclophosphamide solutions to a temperature of 37°C, 2, 2'-dichlorodiethylamine and
2-hydroxy-tetrahydro-2H-1, 3, 2-oxazaphosphorine-2-oxide have been described
(Arnold and Klose 1961). The latter compound is then converted to the phosphoric acid
ester of 3-hydroxypropyl-amine.
10.3 The detection of chloroethylamine and 1, 3-oxazolidine-2-one
The basic metabolites CEA and OXA were extracted from plasma using ethyl acetate,
after dilution with 0.05 M borate - sodium hydroxide buffer of pH 10 (chapter 5). N-
chloroethyl-1, 3-oxazolidine-2-one was employed as the internal standard.
Trifluoroacetylation was performed with TFAA in ethyl acetate at 70°C for two hours.
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The trifluoroacetyl derivatives were dissolved in ethyl acetate and injected on to the GC
column; EI+ was used for mass spectrometric analysis. In the quantitative in vitro work,
extraction was performed with dichloromethane and trifluoroacetylation performed at
65°C for one hour.
10.4 The formation of chloroethylamine and 1, 3-oxazolidone-2-one
following ifosfamide administration in man
10.4.1 Patients studied
Four patients, who are also described in chapters 9 and 11, were studied. Patients AH
2 . 2and ML received 3 g rri ifosfamide (5.35 g and 4.7 g respectively), and 2 g rri mesna,
as a six hour intravenous infusion in 500 ml 0.9% sodium chloride; intravenous boluses
of 800 mg mesna were given immediately before and eight hours after the infusion.
Patients CB and JW were given ifosfamide 500 mg orally as a gelatin capsule with a
300 mg film coated mesna tablet. None had received prior treatment with
oxazaphosphorines. Blood samples were taken at intervals during and following the
intravenous infusion for about 24 hours after completion, and for approximately six
hours after oral administration. Plasma was separated immediately by centrifiigation
and stored at -20°C until analysis. Ifosfamide, IPM, 2-DCEI, 3-DCEI, CIPA, KIPA,
CEA and OXA were determined using GC-MS as described previously (chapter 5).
10.4.2 Results





Figure 10.1 a. Plasma concentration time curves of ifosfamide and
chloroethylamine following intravenous (upper graph, patient AH), and oral
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Figure 10.1 b. Plasma concentration time curves of 1, 3-oxazolidine-2-one and
ketoifosfamide following intravenous (patient AH, upper graph), and oral (patient
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Figure 10.1 c. Plasma concentration time curves of carboxyifosfamide and
isophosphoramide mustard following intravenous (patient AH, upper graph), and





Figure 10.1 d. Plasma concentration time curves of 2-dechloroethylifosfamide
and 3-dechloroethylifosfamide following intravenous (patient AH, upper graph),
and oral (patient CB, lower graph) administration.
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Peak levels of 2-DCEI, 3-DCEI and CIPA occurred about six hours after the end of the
intravenous infusion, and only a small amount of KIPA was seen. Peak concentrations
of IPM, CEA and OXA coincided with the end of the ifosfamide infusion. With oral
administration, the highest concentrations of ifosfamide, IPM and CIPA were observed
after approximately two hours; concentrations of CEA and OXA peaked before that of
ifosfamide.
Unexplained small quantities of CEA (0.21 pg ml"1 [2.6 pM] to 0.47 pg ml"1 [5.9 pM])
and OXA (0.076 pg ml"1 [0.87 pM] to 0.08 pg ml"1 [0.92 pM]) were present in the
plasma before ifosfamide administration, and similar amounts were seen in plasma
taken from the blood bank; neither compound was detected in 0.9% sodium chloride
solutions stored in the same plastic tubes and conditions as the patient plasma samples.
It is interesting that aliphatic amines such as trimethylamine are naturally present in
human biofluids (Ayesh et al 1993).
Following intravenous dosing, much higher plasma concentrations of CEA were found
compared to IPM, suggesting the presence of an additional route of CEA formation. A
similar difference was observed between patients ML and JW; after intravenous
infusion the peak concentration of CEA was 9.73 pg ml"1 (122 pM) and of ifosfamide
20.37 pg ml"1 (78 pM), compared to respective values of 0.43 pg ml"1 (5.4 pM) and
10.45 pg ml"1 (40 pM) following oral administration. The plasma molar AUCoo values
of ifosfamide and its metabolites for patient AH are given in table 10.1.
10.5 The formation of chloroethylamine and 1, 3-oxazolidine-2-one
following the hydrolysis of ifosfamide in vitro
Following the observation of relatively high levels of CEA compared to IPM after
intravenous ifosfamide, in vitro work was performed to explore this further. Aqueous
solutions of ifosfamide, 1000 pg ml"1 (3.8 mM) and 100 pg ml"1 (0.38 mM) were
buffered at pH 4, 7 and 10, maintained at 40°C for five hours, and an aliquot
extracted with 6 ml of dichloromethane. The solvent was evaporated, and the dry
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IPA 2-DCEI 3-DCEI IPM CIPA KIPA CEA OXA
AUCm 2665 160 529 86 110 15 1570 128
% of 6 20 3 4 1 59 5
IPA
Table 10.1. AUG*, (pM hr) of ifosfamide and its metabolites, also expressed as a
percentage of the ifosfamide AUC«,.
residue treated with diazomethane in ether, the solvent again evaporated, and the
residue dissolved in 500 pi of methanol. The methanol solution was then injected
into the GC-MS. In all six samples three peaks were detected: using EI+ ionisation,
the first was identified as phosphoric acid methyl ester; the second as 3-(2-
chloroethyl)-2-methoxy-tetrahydro-2H-l, 3, 2-oxazaphosphorine-2-oxide; and the
third as ifosfamide. CEA was also detected in all six solutions, as described above.
These findings suggest that hydrolysis of ifosfamide to CEA and 3-(2-chloroethyl)-2-
hydroxy-tetrahydro-2H-1, 3, 2-oxazaphosphorine-2-oxide (II) is taking place. In a
further experiment, an aqueous solution of ifosfamide (2000 pg ml"1; 7.6 mM) was
maintained at 40°C for 12 hours. An aliquot was again extracted with
dichloromethane, dried over sodium sulphate, filtered, and evaporated to a residual
volume of 300 pi. An equal volume of trifluoroacetic anhydride was then added, and
the mixture heated at 65 °C for one hour. After evaporation to dryness, the residue
was dissolved in 100 pi of ethyl acetate and the resulting solution injected into the
GC-MS. Using EI+ ionisation the trifluoroacetyl derivatives of ifosfamide, CEA and
2-chloroethyl-3-hydroxypropyl-amine were observed. The hydrolysis of ifosfamide































Figure 10.2. Hydrolysis of ifosfamide; II = 3-(2-chloroethyl)-2-hydroxy-tetrahydro-2H-
1, 3, 2-oxazaphosphorine-2-oxide; III = Phosphoric acid ester of 2-chloroethyl-3-
hydroxypropyl-amine; V = 2-chloroethyl-3-hydroxypropyl-amine.
In view of these findings, quantitative analyses of CEA and ifosfamide were performed
in the following systems: two aqueous solutions of ifosfamide containing 53 pg ml"1
(203 pM) (A) and 5.2 pg ml"1 (20 pM) (B) maintained at 37°C for six hours; whole
137
blood spiked with 1 pg ml"1 (3.8 pM) of ifosfamide and incubated at 37°C for 2.5
hours; and the infusion given to patient AH, prepared once more under the same
conditions, and allowed to drain from the bag at the same rate and temperature (23 °C)
as during administration. Aliquots of aqueous solution, infusate and plasma were
sampled at regular intervals, and analysed following trifluoroacetylation in
dichloromethane, as described above. In all three systems, appreciable amounts of CEA
were present at zero time, as expressed by CEA/ifosfamide ratios (% w/w; % molar) of
21.3; 69.9 (A), 17.3; 56.8 (B), 16.8; 55.2 (plasma), and 13.6; 44.7 (infusate). Significant
chemical hydrolysis of ifosfamide occurs at higher concentrations in aqueous solution
(figure 10.3), the ratio reaching 45.6% (150% molar) in solution A after six hours
compared with 26.0% (85.4% molar) in solution B. The change over time in the cooler
infusate was minimal, with a six hour w/w ratio of 16.2% (53.2% molar), and one of
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Figure 10.3. In vitro hydrolysis of ifosfamide in aqueous solution.
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10.6 Discussion
Significant quantities of NNM have been reported following the intravenous
administration of cyclophosphamide, and as an explanation the metabolism of
carboxyphosphamide has been postulated (Jardine et al 1978). However, the plasma
profiles obtained after ifosfamide administration do not indicate CIPA as a source of
CEA; peak w/w CEA/ifosfamide ratios of 50.2% (165% molar) and 50.1% (164%
molar) were obtained after intravenous administration, compared to corresponding w/w
values of 4.9% (16.1% molar) and 8.2% (26.9% molar) after oral dosing. The relatively
high levels of CEA generated after intravenous infusion, with a curve following the
ifosfamide plasma profile, infer that significant hydrolysis of ifosfamide itself is
occurring, either before or after direct injection into the circulation. This probably
reflects the nature of the hydrolysis reaction, the rate of which is dependent on the
concentration of ifosfamide and therefore the administered dose.
In terms of plasma AUCoo, an ifosfamide value of 2665 pM hr obtained in this study,
after a six hour infusion of 3 g m"2 ifosfamide, is consistent with published results.
Using ifosfamide infusions of 1.5 g m"2 over 20 to 60 minutes, ifosfamide AUCs of
1520 to 2344 pM hr have been reported (Kurowski et al 1991; Kurowski and Wagner
1993; Lewis et al 1990; Lind et al 1989a), whilst figures of 2240 pM hr and 2309 pM
hr have been observed after 20 minute infusions of 2 g nT2 and 3 g nf2 ifosfamide
respectively (Wagner and Drings 1986; Aeschlimann 1998).
The plasma AUCoo of CEA represents 59% of the ifosfamide dose. The amount
generated by the breakdown of IPM is negligible, suggesting that the majority of
CEA has an alternative origin. Dechloroethylation to 3-DCEI accounts for 20% of
the ifosfamide dose, and it is conceivable that 3-DCEI could be further metabolised
to CEA. Hydrolysis of 3-DCEI in vitro can liberate CEA, but with only 2%
degradation at pH 6.8 after 28 days (Gilard et al 1999). However compounds E, D
and A (Figure 10.4) represented approximately 10% of 2-DCEI excreted over 24
hours in the urine of patients receiving 3 g m"2 of ifosfamide as a three hour infusion



















































thought to be the precursor of compounds E and D, which would be formed by
hydrolysis. Unknown metabolites represented 18% of the excreted dose in this study.
In patients treated with cyclophosphamide 60 mg kg"1 day"1 as a three hour infusion,
compounds C, D and F represented approximately 22% and 57% of 3-DCEI excreted
in urine at pH 5.8 and 5.1 to 5.3 respectively (Joqueviel et al 1998).
Carboxycyclophosphamide was metabolized into two phosphoric acid esters, with
the generation of NNM. Urinary excretion of these esters represented approximately
10% of the carboxycyclophosphamide excreted, but was pH dependent, reflecting the
known instability of this metabolite. Nevertheless, such a metabolic route acting on
CIPA would provide another potential source of CEA. Aeschlimann et al measured
the urinary excretion of CEA using GLC, following three single daily intravenous or
oral doses of ifosfamide (Aeschlimann et al 1998). The urinary recovery of CEA was
expressed as a percentage of the total ifosfamide dose, assuming that one mole of
ifosfamide generates two moles of CEA. The methodology was unable to detect CEA
in plasma. There was no difference in the recovery of CEA in urine following
intravenous or oral administration (4.1% to 12.7% compared to 3.2% to 6.5%
respectively). However the interpatient variability of urinary excretion of CEA was
large. The authors postulated that CEA could be metabolized to chloroacetaldehyde,
as it is a substrate of plasma amine oxidase.
The in vitro work suggests that significant chemical hydrolysis of ifosfamide can occur
in aqueous solution (figure 10.3). However, other studies have reported that ifosfamide
is stable in aqueous solution at ambient temperature for nine days (Radford et al 1991),
and at concentrations of 0.6 mg ml"1 and 20 mg ml"1 in 0.9% sodium chloride for one
week at 30°C (Trissel 1992). Kaiser et al found that in the most stable pH range of 5
to 9, the half-life of ifosfamide was 20 hours at 70°C (Kaiser et al 1991a).
Further work by Gilard et al (1997) has not confirmed the results of the in vitro work
described in this chapter, and has suggested that the source of the high CEA levels is
degradation of ifosfamide during the derivatisation procedure. Using NMR analysis,
they studied the in vitro derivatisation of ifosfamide with TFAA under three reaction
conditions: ethyl acetate in a stoppered tube; dichloromethane in a stoppered tube;
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and dichloromethane in a round bottomed flask fitted with a cooling system. There
was no degradation of a 3.8 mM ifosfamide solution, at pH 4, 7 or 10, maintained at
40°C for five hours. Similarly, at pH 7, degradation of a more concentrated solution
of ifosfamide (38 mM) was not seen after 12 hours at 40°C, or 6 hours at 37°C. At
pH 4, after six hours at 37°C, a 38 mM ifosfamide solution suffered a 1.1 molar %
degradation, which reached 3.9 molar % after 24 hours. The major degradation
product was compound III (figure 10.3).
When derivatisation was performed in ethyl acetate, the trifluoroacetyl derivative of
ifosfamide was the predominant constituent in the 19F NMR spectrum (representing
more than 95 molar % of initial ifosfamide), and the total recovery was quantitative.
TFA-CEA was not observed. TFAA derivatisation in dichloromethane, without
controlling solvent evaporation, led to a maximum total recovery of 35 molar % of
the initial ifosfamide, probably as a result of evaporation of the TFA derivatives.
TFA-IF represented less than 1 molar % of the initial ifosfamide, whereas TFA-CEA
was observed in approximately ten fold higher amounts. When the TFA reaction in
dichloromethane was performed in cool conditions, thereby preventing solvent
evaporation, the overall recovery was nearly quantitative (80 molar %). The authors
concluded that ifosfamide degradation is dependent on the method of derivatisation;
the compound is not easily derivatised by TFAA in dichloromethane, and the
combination of heating, solvent evaporation, and the presence of trifluoroacetic acid
in the medium can degrade ifosfamide with the formation of CEA.
The presence of appreciable quantities of CEA at zero time in the four systems
studied (solutions A and B, plasma and infusate) indicate decomposition during
analysis. However in the more concentrated solution A, the CEA/ifosfamide molar
ratio changed from 69.9% at baseline to 150% after six hours at 37 °C (figure 10.3),
implying additional decomposition, unrelated to analytical technique, during this
time period.
CEA is an important product of ifosfamide degradation and appears to be formed
predominantly by hydrolysis. Ethyl acetate was used as a solvent for derivatising
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ifosfamide and its metabolites in the analysis of plasma from the in vivo study,
whereas in the in vitro work dichloromethane was employed. Subsequent work by
Gilard et al has suggested that the use of dichloromethane leads to degradation of
ifosfamide with erroneously high levels of CEA (Gilard et al 1997). Although the
high CEA levels found in vitro may be spurious, degradation of ifosfamide during
analysis of plasma cannot fully explain the differences in CEA levels following
intravenous and oral administration; the same analytical procedure was used,
employing ethyl acetate as a solvent for the derivatisation with TFAA. Furthermore,
an ifosfamide AUC of 4235 pM hr, assuming all the CEA generated is produced by
ifosfamide breakdown during analysis, is perhaps higher than anticipated for the dose
and infusion time of the ifosfamide administered, and the in vivo CEA curve (figure
10.1a) is not exactly parallel to the ifosfamide curve, suggesting mechanisms of CEA
formation in addition to analytical artifact.
The high levels of CEA in vivo may remain an accurate reflection of changes
occurring after intravenous ifosfamide administration. It is clear, however, that
further work on the generation of CEA in vivo is required.
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Chapter 11
The Uptake of Ifosfamide and its Metabolites by
Erythrocytes
11.1 Introduction
The main site of formation of IPM, and its predominant transport form within the
circulation, is not certain. Two possibilities have been envisaged; firstly, the
transport of 4-hydroxyifosfamide to tumour cells, which then convert this compound
to IPM, or secondly the formation of IPM, primarily within the liver, but also within
other tissues capable of activating ifosfamide, followed by transport within the
circulation and direct penetration of tumour cells. The relative contribution of each of
these mechanisms will influence the success of any attempt to administer IPM itself
as a chemotherapeutic agent, a potentially advantageous manoeuvre, which should
not lead to haemorrhagic cystitis or neurotoxicity.
Consequently, an improved knowledge of the processes of distribution of ifosfamide
and its metabolites is needed. Blood consists of plasma and cells, and the vast
majority of the cells are erythrocytes (approximately 45% of total blood volume). It
is becoming clear that the erythrocyte can be a significant carrier of substances in the
circulation, but there is no data concerning the distribution of ifosfamide and its
metabolites throughout whole blood in humans.
New developments in the bioanalysis of the oxazaphosphorines have provided
methods for the separation and accurate measurement of many metabolites in plasma
(chapter 5), and improved techniques of erythrocyte isolation have facilitated the
study of the red cell compartment (chapter 7). The work described in this chapter
investigates the distribution of ifosfamide and seven of its metabolites in the plasma




Five patients were studied during their first course of chemotherapy, and three
additionally through their second course of treatment. 3 g irf2 ifosfamide was given
as a six hour infusion, with mesna as a uroprotector. Three patients also received
mitomycin C and cisplatin, and one patient was also given adriamycin.
11.2.2 Separation ofred cells
Blood samples were taken at 0, 0.5, 1, 2, 4, 6, 7, 9, 12, 24 and 30 hours after
commencing the ifosfamide infusion. The erythrocyte and plasma fractions were
separated immediately using the MESED instrument (chapter 7), and stored at -20°C.
This technique allows the isolation of a known volume of almost pure red cell
sediment, without disturbing the equilibrium normally present between the
erythrocyte and plasma. The harvested erythrocytes were haemolysed totally with de-
ionised water.
11.2.3 Determination ofifosfamide and its metabolites
The concentrations of ifosfamide, IPM, 2-DCEI, 3-DCEI, CIPA, KIPA, CEA and
OXA in the plasma and erythrocyte fractions were measured using GC-MS (chapter
5).
11.3 Results
The pharmacokinetic data are given in the appendix (tables A26 a-h and A27 a-b).
The mean concentration-time curves of ifosfamide and its metabolites, in plasma and
erythrocytes, are shown in figure 11.1 a-d. All compounds entered the red cell
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compartment. Erythrocyte/plasma ratios at six hours, corresponding to the end of the
ifosfamide infusion, are given in table 11.1, and the mean values were greater than
one for all compounds. Comparing erythrocytes and plasma, using a paired t-test,
there were significantly higher concentrations of IPM (p = 0.007), CIPA (p = 0.004)
and ifosfamide (p = 0.004) in erythrocytes. Such differences were not detected for 2-
DCEI, 3-DCEI, KIPA, CEA or OXA. Considering all concentrations after six hours,
significant differences between erythrocytes and plasma were maintained for IPM (p
= 0.0005) and CIPA (p = 0.0007), but not for ifosfamide itself (p = 0.0773).
In terms of the AUC, as calculated by the trapezoidal rule, the mean ratio of
erythrocyte (AUCe) to plasma (AUCp) was also greater than unity in all cases (table
11.2). The difference between AUCe and AUCp was most evident for CIPA (p =
0.0002), ifosfamide (p = 0.0003) and IPM (p = 0.003), but not significant for the
other metabolites (table 11.3).
The mean plasma ifosfamide half-life was 7.1 hours (SD ± 2.5), mean plasma
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Figure 11.1 a. Mean concentration-time profiles for ifosfamide and
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Figure 11.1 b. Mean concentration-time profiles for 2-
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Figure 11.1 c. Mean concentration-time profiles for carboxyifosfamide and
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Figure 11.1 d. Mean concentration-time profiles for chloroethylamine and
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11.4 Discussion
Previous work on the distribution of the oxazaphosphorines and their metabolites has
focused on the identification of the circulating transport form of the activated
compound, which in effect is responsible for conveying the cytotoxicity of these
agents to the tumour cell. Some authors have favoured 4-hydroxycyclophosphamide,
in the case of cyclophosphamide (Domeyer and Sladek 1980; Wagner et al 1977),
and if correct, this compound should be detectable in the plasma. However, this has
not always been the case, a situation explained by the instability of 4-
hydroxycyclophosphamide and difficulties in its detection. Nevertheless, some
groups have identified persistent, albeit small, amounts of 4-
hydroxycyclophosphamide in the plasma of mice (Domeyer and Sladek 1980) and
humans (Wagner et al 1977), proposing that low levels of 4-
hydroxycyclophosphamide in plasma reflect intracellular trapping of this compound
(Domeyer and Sladek 1980).
Other groups have argued that the mustard is the major transport form. Struck et al
(1983) studied the activity of IPM against murine tumours, found it comparable to
ifosfamide, and postulated that IPM acts by membrane alteration and/or non-DNA
alkylation. The authors demonstrated that extracellularly delivered IPM is an
effective agent, with antitumour activity and selectivity in vivo comparable to
ifosfamide and 4-hydroxyifosfamide.
Sladek has reviewed values of the ratio of CPM AUC to 4-
hydroxycyclophosphamide AUC in the plasma of mice, rats and humans, following a
dose of cyclophosphamide, and also the sensitivities of mice and human cell cultures
to CPM and 4-hydroxycyclophosphamide (Sladek 1988). He was able to calculate
percentages of total cell kill hypothetically due to either circulating 4-
hydroxycyclophosphamide or CPM, and found that the former compound was the
circulating metabolite of major importance in the plasma, although the latter also
made a contribution.
154
However such studies have analysed plasma and have not considered the erythrocyte.
The study in this chapter investigated this compartment with a direct technique,
avoiding the need for red cell washing or calculation of red cell concentrations from
those in plasma and whole blood; the results show that ifosfamide and its metabolites
enter the erythrocyte compartment freely, and that IPM and CIPA are concentrated
most significantly within this fraction. At the time of the peak erythrocyte IPM
concentration in one patient, 82% of the total amount of this compound in whole
blood was associated with these cells, 13% was protein bound and 5% was present in
plasma water; considering the whole blood AUC for IPM, calculated from the
haematocrit, 77% was found to reside within the erythrocyte. In addition to this high
uptake by erythrocytes, the rate of loss from these cells is faster than from plasma
(figure 11.1 a). As the concentration of IPM in the erythrocyte fraction declines,
there is no corresponding increase in CEA levels, indicating that the decline is not
due to degradation. In vitro there is a loose association of IPM with the erythrocyte,
and this metabolite is released easily into blank plasma (personal communication, E
A De Bruijn). Therefore erythrocyte mediated transport of IPM within the circulation
is significant, and transfer to tissues plausible. Following intravenous infusion, most
of the ifosfamide is carried by erythrocytes and delivered to the liver. It is
conceivable that a substantial amount of IPM is transferred from the liver to its site
of action associated with the red blood cell and in effect never enters the plasma, a
situation similar to the transport of oxygen. It would be instructive to know whether
an infusion of IPM itself results in the same distribution pattern in whole blood, as
the liver will no longer be a source of IPM.
In early models of the interaction between blood and tissues, compounds have been
described as entering tissues from the plasma water phase. However other models
propose that inhibition of protein binding occurs on the capillary endothelium
releasing protein bound compounds to the tissues (Pardridge and Landaw 1985); as a
result tissue levels correspond more closely to the protein bound fraction than to the
free fraction. This concept is equally important with regard to erythrocytes, as tissues
on the other side of a capillary membrane may be more exposed to compounds
accumulated on these cells (Cornford and Landon 1985), and the compounds may
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enter tissues just as easily from erythrocytes as from plasma water. Flow through
capillaries is intermittent, and red cells are momentarily held in intimate contact with
the capillary endothelium, allowing direct exchange between erythrocytes and
endothelial cells (Kooyman et al 1995).
The structure and function of the tumour interstitium is significantly different from
that of most normal tissues, and solid tumours can possess a special pattern of
vascularisation (Jain 1987). For a solid neoplasm to survive, it must develop an
adequate blood supply through the process of angiogenesis and then maintain the
neovasculature so formed. In achieving this, endothelial cells in tumour vessels can
proliferate more than twenty times faster than in normal vessels (Denekamp 1982).
The action of cytotoxics on the capillary endothelium may contribute to their anti-
tumour effect, as the disruption of a tumour capillary can lead to substantial tumour
cell necrosis. Ifosfamide is used particularly in the treatment of solid tumours, and
the intimate contact between the capillary endothelium and erythrocytes containing
high concentrations of IPM may be important.
The nature of the binding to erythrocytes is currently unclear. Uptake is not restricted
to ifosfamide metabolites, and is usually not as high. Many substances bind to
erythrocytes (chapter 4); for example, the concentration of bilirubin and Cortisol
increases in the erythrocyte compartment once albumin binding sites have been
saturated, and red cells act as major transporters of acetaldehyde from the liver to
tissues (Baraona et al 1987; Hiramatsu and Nisula 1988; Malik et al 1986).
Therefore it must be appreciated that transport by erythrocytes is the rule rather than
the exception. As many different compounds can be transported by red cells, usually
weakly bound and with a shorter half-life on erythrocytes compared to plasma, a
nonspecific binding process such as adsorption to the cell surface comes to mind.
The red cell surface area in a human adult is much larger than that of the total
capillary endothelium. This ensures that the inner surface of the capillary membrane
is in continuous equilbrium with the essentially fragmented membrane of the red cell
compartment, which scrapes its surface. Flowever an association of compounds with
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proteins in the cell interior, such as that seen during adduct formation between
nitrosamine metabolites and globins within haemoglobin (Murphy and Coletta 1993),
cannot be excluded. As far as the transfer of compounds is concerned, the relevant
factor is whether those associated with a red cell can be released to the capillary
endothelium during passage through the capillary.
In conclusion, ifosfamide and its metabolites, especially IPM and CIPA, are sited
primarily on the erythrocyte, which may have a role in the transfer of these
compounds from the site of their formation to the tissues. Erythrocyte associated






Ifosfamide has been used clinically for more than a quarter of a century, and has
become firmly established in the treatment of malignant disease. It possesses complex
pharmacokinetics, producing metabolites responsible for side effects which are
occasionally dose limiting. Dechloroethylation and the production of
chloroacetaldehyde is thought to cause neurotoxicity.
The use of oral ifosfamide was restricted by the development of neurotoxicity in all
patients treated. Psychometric impairment, manifested by decreased performance in the
continuous attention and salford tracker psychometric tests, and EEG abnormalities,
with decreased alpha frequency, were seen. The pharmacokinetic studies were
performed using a newly developed GC-MS method, and the predicted metabolites
CEA and OXA were isolated for the first time in biological fluids. The results indicate
that dechloroethylation is important in the development of neurotoxicity, as suggested
in the literature, but there was also a tendency to increased CIPA and KIPA formation,
at the expense of IPM.
The significance of the red cell compartment in pharmacokinetic studies has been
highlighted, with the need to perform a direct analysis on unwashed erythrocytes. IPM
and CIPA, the open chain and most polar metabolites, were preferentially located in the
red cell compartment, and erythrocyte associated IPM may be an important circulating
form of active ifosfamide.
Ifosfamide induced encephalopathy is unusual in two respects. Firstly, it is dependent
on structural isomerism, with cyclophosphamide incapable of producing a similar
state, after either oral administration, or during the high doses used in autologous
peripheral stem cell procedures. The lack of neurotoxicity with cyclophosphamide is
thought to result from the relatively low degree of side chain dechloroethylation, but
159
even so high levels of 3-DCEI have been detected recently, suggesting significant
chloroacetaldehyde formation (Momerency et al 1994).
Secondly, the greatly increased incidence after oral doses of ifosfamide, lower than
those usually given intravenously. This implies a first pass effect in the liver, or even
before this, although studies have shown a bioavailability of approximately 100%
(Cerny et al 1986; Kurowski et al 1991; Wagner and Drings 1986). The maximum
possible first pass effect of approximately 5%, calculated by Wagner and Drings
(1986), should not influence the overall metabolism of ifosfamide, but it is
conceivable that during the absorption phase, when high concentrations of ifosfamide
reach the liver via the portal vein, a very toxic metabolite responsible for CNS
toxicity is generated to a greater extent. However as 20% to 25% of cardiac output
flows through the liver, about 1.5 g of a standard intravenous dose (5 g m"2) could be
subject to early hepatic metabolism, yet encephalopathy is observed infrequently.
The influence of the gastrointestinal tract on ifosfamide pharmacokinetics and
pharmacodynamics is significant. Perhaps the enterohepatic circulation of ifosfamide
has an effect, as indicated by rat experiments, where the oral route generates higher
biliary chloroacetaldehyde levels compared to the intravenous route (Cerny and
Kiipfer 1992). There are currently no human data available on this aspect of
ifosfamide distribution, nor on the amount of faecal excretion. It is possible that the
appearance of ifosfamide within the gastrointestinal tract is responsible for the
development of encephalopathy, and that it only occurs in some individuals after
intravenous ifosfamide because of variability in the enterohepatic circulation. The
metabolism of other drugs within the gut wall, or by the intestinal flora, has been
described. One dose of radiation can profoundly change the equilibrium of the
intestinal ecosystem, leading to overgrowth of Clostridia species (Cuzzolin et al
1992). Data on the enterohepatic circulation of ifosfamide and its metabolites, after
intravenous administration, are needed.
Gastric residence time, and gastric and duodenal pH changes, may influence the
absorption of ifosfamide. Kiipfer et al (1990) noted two distinct compounds,
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ifosfamide-I and ifosfamide-II, in aqueous solution. Freshly prepared ifosfamide
solutions contain only ifosfamide-II, which is converted to ifosfamide-I on
alkalinisation. The rearrangement is fully reversible on acidification.
Cyclophosphamide is completely stable under the same conditions.
The mechanism of development of neurotoxicity remains obscure, and the identity of
the causative agent elusive. Higher levels of 2-DCEI, 3-DCEI, and particularly CEA,
were generated after intravenous administration, and yet no neurotoxicity was observed.
The hydrolysis of ifosfamide and its dechloroethyl derivatives, illustrated in figures
10.2 and 10.3, typifies the complexity of ifosfamide breakdown. The phenomenon of
encephalopathy remains to be adequately explained, and although
chloroacetaldehyde may be contributory, other as yet unidentified metabolites, or
processes, could also be important.
The in vivo generation of CEA requires further investigation. It has been suggested
that CEA may be produced by ifosfamide decomposition during the analytical
derivatisation process, which is solvent dependent (Gilard et al 1997). However the
samples obtained following oral and intravenous ifosfamide administration were
subjected to the same analytical procedure, and high levels were detected only with
the latter.
The mean Cmax of ifosfamide after oral administration, 14 ± 5 pg ml"1 or 53 ± 18
pM, is in keeping with the previously published values of 33 pg ml"1, or 128 pM
(Wagner and Drings 1986), and 23 pg ml"1 or 88 pM (Cemy et al 1986), following 1
g of oral ifosfamide. However, the Vss and clearance values of ifosfamide after
intravenous administration (mean values of 127 ± 26 L and 12.96 ±3.81 L hr"1
respectively) are somewhat higher than those described in the literature. A
pharmacokinetic study of a six hour infusion of ifosfamide has not previously been
reported, but Granvil et al (1996) found an AUC of 4433 pM hr"1, a clearance of 2.79
L hr"1 m"2, and a Vss of 27 L m"2 after a three hour 3 g m"2 infusion. Whether the
relatively high Vss and clearance values reported in this thesis result from the
characteristics of the patient population studied, the co-administration of mitomycin
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C, cisplatin or adriamycin, or an underestimate of ifosfamide AUC, requires further
clarification.
Other neurophysiological techniques or scanning procedures may shed light on the
encephalopathy. Visual evoked potentials provide additional information to the EEG.
Positron emission tomography scans can visualise the site of action of drugs. Studies on
intracranial blood flow during and after an ifosfamide infusion would be useful, and a
suitably labelled ifosfamide preparation may provide more detailed data on
pharmacokinetic and pharmacodynamic processes occurring in the CNS.
Methylene blue has been used to reverse and prevent ifosfamide induced
encephalopathy. The possibility of using methylene blue with oral ifosfamide arises, but
has the disadvantage that ifosfamide would then have to be co-administered with two
oral medications, methylene blue and mesna. Further work is required on urinary
sarcosine and glutaric acid excretion after ifosfamide administration, and the
interaction between ifosfamide and methylene blue.
Another way to surmount the problem of ifosfamide induced encephalopathy is to
administer IPM itself. This has not been possible in the past due to the high reactivity of
the compound, but a glucose derivative of IPM, D-19575, has recently entered clinical
trials. The agent enters cancer cells, releasing the mustard intracellularly, and has the
advantage of oral administration (Pohl et al 1995). However one needs to remain
cautious. Chloroacetaldehyde has now been shown to be cytotoxic, with activity at least
as high as that of 4-hydroxyifosfamide, and it may be necessary for the action of
ifosfamide (Bruggemann et al 1997). The pharmacodynamic properties of ifosfamide
metabolites warrant further investigation.
Chloroacetaldehyde is known to deplete intracellular glutathione (Lind et al 1989c),
and since erythrocyte glutathione levels have been proposed as a predictor of
intracellular glutathione concentration (Hercbergs et al 1992), investigating
relationships between red cell glutathione levels and ifosfamide neurotoxicity may
prove fruitful. Whether the concentrations of ifosfamide and its metabolites in
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erythrocytes correlate more closely with ifosfamide toxicity than those in plasma
remains to be established. The assay of ifosfamide and its metabolites in the red cell
fraction does not indicate the site of these compounds in the erythrocyte, the location of
which would be useful in understanding potential delivery mechanisms. Ifosfamide has
been found to cause a stomatocytic shape transformation of erythrocytes, indicating an
interaction with the lipid bilayer of the cell membrane (Reinhart et al 1999). Red cells
have been used to deliver adriamycin (Tonetti et al 1991) and methotexate. Once
loaded with methotexate, the erythrocytes can be photosensitized by exposure to
haematoporphyrin derivative, and the methotrexate released in a light dependent fashion
(Flynn et al 1994). The controllable release of cytotoxics from red cells therefore seems
feasible. The finding of higher levels of IPM in the red cell fraction suggests that these
cells act as a sink, and using them to deliver IPM may be possible.
Ifosfamide remains a perplexing drug. Although advances have been made in
unravelling its complex pharmacokinetics, much is yet to be explained. The need to
develop strategies to target the active mustard to the cancer cell, minimising side effects
and maximising efficacy, is as relevant now as it was in 1958.
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Plasma EDTA Total Rate of Pcr-
sample (pi /ml count count (Pcr) background
(100 pi) blood) (Pc) (sec1) (P) (sec1)
1 20 55533 3355 3325
2 20 54982 3322 3292
3 20 53398 3226 3196
4 20 58245 3519 3489
5 20 57129 3452 3422
6 20 56408 3408 3378
7 20 57250 3459 3429
8 20 57610 3481 3451
9 20 57786 3491 3461
10 20 56774 3430 3400
Table A1 a. Calibration data for the MESED tube.
Red EDTA Wj (g) W2 (g) W2-W1 Total count Rate of count Ecr-
cell (pi /ml (mg) (Ec) (ECK) (sec1) background
sample blood) (E) (sec1)
1 20 5.1657 5.2779 112.2 4032 243 213
2 20 5.1344 5.2344 100.0 2523 152 122
3 20 5.1202 5.2234 103.2 2613 158 128
4 20 5.1625 5.2642 101.7 2764 167 137
5 20 5.1657 5.2688 103.1 2634 159 129
6 20 5.1587 5.2692 110.5 2758 166 136
7 20 5.1645 5.2670 102.5 2681 162 132
8 20 5.1614 5.2642 102.8 2526 152 122
9 20 5.1180 5.2211 103.1 2694 163 133
10 20 5.1515 5.2570 105.5 2611 158 128
Table A1 b. Calibration data for the MESED tube.
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E/P Py (E/P x Py /Ey Trapped P
100) (pi) (%)
0.0641 6.41 0.0571 5.71
0.0371 3.71 0.0371 3.71
0.0401 4.01 0.0388 3.88
0.0393 3.93 0.0386 3.86
0.0377 3.77 0.0366 3.66
0.0403 4.03 0.0364 3.64
0.0385 3.85 0.0376 3.76
0.0354 3.54 0.0344 3.44
0.0384 3.84 0.0373 3.73
0.0376 3.76 0.0357 3.57
Pv is the volume of trapped plasma, and Ev is the volume of
erythrocytes, assuming the density of erythrocytes is 1.0.
The mean percentage trapped plasma is 3.89% (SD ± 0.65)
and the median 3.72% (range 3.44 - 5.71).
Table A1 c. Calibration data for the MESED tube.
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Patient Day CR1 CR 2 CR 3 CR 4
EG 0 0.367 0.143 0.612 0.113
EG 2 0.341 0.052 0.616 0.057
EG 8 0.348 0.038 0.585 0.050
EG 15 0.338 0.047 0.634 0.155
CH 0 0.343 0.070 1.070 1.203
CH 2 0.387 0.097 0.777 0.152
CH 8 0.385 0.082 0.800 0.184
CH 15 0.394 0.093 0.807 0.136
CB 0 0.447 0.116 0.698 0.250
CB 2 0.527 0.220 0.734 0.211
JW 0 0.338 0.092 0.608 0.100
JW 2 0.355 0.158 0.800 0.417
JW 8 0.342 0.056 0.730 0.247
JW 15 0.349 0.071 0.741 0.063
SO 0 0.452 0.390 0.769 0.372
SO 2 0.458 0.232 1.052 0.497
LR 0 0.287 0.043 0.615 0.043
LR 2 0.307 0.044 0.766 0.255
LR 15 0.400 0.123 0.847 0.219
Table A2. Oral ifosfamide; choice reaction (see table 8.2);
reaction time is measured in seconds.
Patient Day ST 1 ST 2 ST 3 ST 4 ST 5 ST 6
EG 0 0.307 0.041 0.457 0.023 0.385 0.018
EG 2 0.288 0.030 0.601 0.154 0.391 0.017
EG 8 0.268 0.018 0.462 0.064 0.350 0.019
EG 15 0.296 0.037 0.490 0.029 0.381 0.029
CH 0 0.407 0.045 0.810 0.216 0.547 0.062
CH 2 0.423 0.048 0.852 0.127 0.578 0.050
CH 8 0.402 0.057 0.910 0.285 0.585 0.084
CH 15 0.459 0.033 0.932 0.296 0.614 0.077
CB 0 0.412 0.027 1.050 0.372 0.569 0.061
CB 2 0.508 0.022 0.899 0.223 0.647 0.069
JW 0 0.389 0.040 0.589 0.027 0.487 0.016
JW 2 0.319 0.050 0.628 0.079 0.470 0.027
JW 8 0.325 0.025 1.351 0.665 0.570 0.127
JW 15 0.388 0.056 1.010 0.619 0.555 0.105
SO 0 0.347 0.018 0.627 0.128 0.437 0.034
SO 2 0.293 0.162 0.780 0.198 0.503 0.074
LR 0 0.274 0.040 0.499 0.053 0.378 0.036
LR 2 0.277 0.035 0.619 0.341 0.386 0.048
LR 15 0.294 0.063 1.264 0.723 0.536 0.172
Table A3 a. Oral ifosfamide; salford tracker (see table 8.3); reaction time is
measured in seconds.
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Patient Day ST 7 ST 8 ST 9 ST 10
EG 0 30.80 8.497 7.312 1.393
EG 2 50.20 14.92 7.662 2.230
EG 8 34.60 12.34 7.187 1.475
EG 15 33.80 8.585 8.040 1.682
CH 0 58.20 19.14 11.87 2.325
CH 2 59.80 15.15 12.88 0.782
CH 8 52.40 14.82 13.18 3.963
CH 15 62.40 16.16 15.51 3.012
CB 0 66.00 32.84 10.98 2.076
CB 2 57.00 19.92 8.714 2.092
JW 0 54.40 43.59 7.880 2.604
JW 2 53.00 35.37 8.189 2.295
JW 8 95.40 67.16 14.17 9.048
JW 15 74.00 45.22 12.53 7.269
so 0 104.4 49.04 12.23 6.392
so 2 129.6 65.57 19.09 11.19
LR 0 51.80 15.17 9.951 1.691
LR 2 59.80 36.03 10.57 2.405
LR 15 106.2 65.88 16.86 2.899
Table A3 b. Oral ifosfamide; salford tracker (see table 8.3);
distance is measured in pixels.
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Patient Day CA1 CA 2 CA 3 CA 4
EG 0 0.506 0.082 1 0
EG 2 0.537 0.101 0 0
EG 8 0.535 0.101 0 0
EG 15 0.530 0.122 0 1
CH 0 0.434 0.317 13 2
CH 2 0.574 0.176 11 4
CH 8 0.736 0.099 10 5
CH 15 0.717 0.197 12 1
CB 0 0.589 0.101 5 1
CB 2 0.603 0.094 1 0
JW 0 0.515 0.075 2 1
JW 2 0.522 0.133 1 0
JW 8 0.517 0.072 1 0
JW 15 0.531 0.078 1 0
so 0 0.542 0.028 14 25
so 2 0.631 0.261 11 30
LR 0 0.654 0.165 7 1
LR 2 0.740 0.136 5 3
LR 15 0.451 0.485 13 5
Table A4. Oral ifosfamide; continuous attention task (see




Day 2 Day 8 Day 15
CR1 P 0.085 0.332 0.157
t 1.606 0.506 1.205
n 6 3 4
CR3 P 0.242 0.330 0.395
t 0.754 0.511 0.290
n 6 3 4
CR 3-CR1 P 0.339 0.325 0.481
t 0.440 0.528 0.053
n 6 3 4
T 1 P 0.427 0.085 0.180
t 0.193 2.106 1.077
n 6 3 4
T 3 P 0.134 0.174 0.068
t 1.247 1.214 2.025
n 6 3 4
T 5 P 0.058 0.246 0.059
t 1.896 0.834 2.177
n 6 3 4
T 7 P 0.113 0.229 0.094
t 1.379 0.919 1.695
n 6 3 4
T 9 P 0.198 0.164 0.026
t 0.927 1.282 3.106
n 6 3 4
CA1 P 0.018 0.183 0.391
t 2.865 1.158 0.302
n 6 3 4
Table A5. Comparisons of neurotoxicity on day 1 with
days 2, 8 and 15 (t-test).
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Patient Time IPA 2-DCEI 3-DCEI CIPA KIPA IPM CEA OXA
(hr)
JW Dl 0.00 0 0 0 0 0 0 0.25 0.032
JW Dl 0.48 3.77 0 0.031 0 0 0.09 0.31 0.032
JW Dl 1.38 9.14 0.53 0.29 0.19 0 0.15 0.34 0.043
JW Dl 2.18 10.45 0.52 0.73 0.23 0 0.33 0.4 0.051
JW Dl 4.10 8.52 0.47 0.81 0.32 0.019 0.28 0.43 0.04
JW Dl 5.77 8.36 0.45 0.82 0.28 0.014 0.07 0.33 0.034
JWD14 0.00 1.05 0.67 1.04 0 0.089 0.093 0.16 0.042
JWD14 0.63 1.36 1.2 1.25 0.15 0.092 0.12 0.23 0.044
JWD14 1.48 4.78 1.4 1.42 0.17 0.113 0.19 0.37 0.043
JWD14 2.63 9.00 0.77 1.73 0.34 0.172 0.4 0.54 0.081
JWD14 4.97 7.88 0.74 1.98 0.51 0.15 0.36 0.48 0.1
JWD14 7.02 4.58 0.42 1.85 0.42 0.142 0.085 0.24 0.094
NH Dl 0.00 0 0 0 0 0.000 0.000 0.197 0.013
NH Dl 0.53 4.47 0.163 0.022 0.358 0.024 0.024 0.339 0.039
NH Dl 1.60 12.64 0.188 0.521 0.495 0.11 0.084 0.625 0.097
NH Dl 2.68 11.11 0.214 0.504 0.609 0.134 0.289 1.138 0.098
NH Dl 5.33 10.24 0.522 0.723 0.51 0.106 0.296 0.989 0.08
NH Dl 6.98 7.08 0.41 0.672 0.305 0.066 0.141 0.632 0.068
NHD14 0.00 2.07 0.282 1.16 0.274 0.045 0.088 0.238 0.082
NHD14 0.42 4.1 0.359 1.22 0.289 0.088 0.121 0.279 0.087
NHD14 1.30 10.2 - 1.93 0.354 0.227 0.135 0.564 0.1
NHD14 2.05 11.36 0.479 2.34 0.762 0.452 0.195 0.794 0.117
NHD14 4.17 8.93 0.667 2.23 0.648 0.352 0.296 0.893 0.097
NHD14 6.18 7.95 0.547 2.15 0.419 0.136 0.229 0.624 0.073
CH Dl 0.00 0 0 0 0 0 0 0.12 0.028
CH Dl 0.45 2.19 0 0.01 0 0 0 0.32 0.049
CH Dl 1.13 8.87 0.19 0.03 0 0 0.16 0.35 0.057
CH Dl 2.10 9.68 0.1 0.18 0.25 0 0.22 0.54 0.073
CH Dl 3.37 7.28 0 0.35 0.28 0 0.11 0.46 0.055
CH Dl 5.18 5.45 0 0.33 0.27 0.034 0.07 0.29 0.036
CHD14 0.00 1.19 0.33 0.88 0.35 0.088 0 0.2 0.033
CHD14 0.42 2.52 0.55 0.85 0.38 0.1 0 0.32 0.04
CHD14 1.22 8.19 0.71 1.24 0.45 0.11 0.24 0.32 0.033
CHD14 2.30 10.91 0.35 1.28 0.47 0.205 0.33 0.55 0.058
CHD14 3.97 7.07 0.29 1.21 0.3 0.28 0.19 0.49 0.157
CHD14 6.40 5.23 0 1.2 0.24 0.157 0.063 0.29 0.075
Table A6 a. Ifosfamide and ifosfamide metabolite concentrations (|_ig ml"1) on
days 1 (Dl) and 14(D14).
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Patient Time IPA 2-DCEI 3-DCEI CIPA KIPA IPM CEA OXA
(hr)
EG Dl 0.00 0 - 0 0 0 - - -
EG Dl 0.48 21.4 - 0.22 0.1 0.12 - - -
EG Dl 1.28 20.5 - 0.41 0.32 0.074 - - -
EG Dl 2.72 13.6 - 0.45 0.24 0.051 - - -
EG Dl 4.20 8.4 - 0.4 0.18 0.04 - - -
EG Dl 6.70 5.3 - 0.38 0.053 0.029 - - -
EGD14 0.00 4.1 - 0 0 0.04 - - -
EGD14 0.53 26.2 - 0.31 0.12 0.19 - - -
EGD14 1.20 20.1 - 0.5 0.48 0.096 - - -
EGD14 1.95 11.7 - 0.63 0.35 0.072 - - -
EGD14 3.95 6.86 - 0.58 0.23 0.048 - - -
EGD14 5.78 4.12 - 0.56 0.07 0.024 - - -
CB Dl 0.00 0 0 0 0 0 0 0.21 0.076
CB Dl 0.42 7.21 0.07 0.23 0.036 0 0.19 0.35 0.08
CB Dl 1.13 11.7 0.38 0.75 0.136 0 0.2 0.53 0.16
CB Dl 2.30 14.4 0.36 0.81 0.46 0 0.39 0.32 0.083
CB Dl 4.88 9 0.21 0.85 0.22 0.02 0.22 0.27 0.074
CB Dl 6.63 7.85 0.1 0.76 0.14 0.04 0.18 0.19 0.07
LR Dl 0.00 0 0 0 0 0 0 0.03 0.021
LR Dl 0.52 0.39 0.034 0.021 0.009 0.021 0.023 0.248 0.097
LR Dl 1.33 4.5 0.068 0.081 0.095 0.021 0.131 0.36 0.098
LR Dl 2.28 7.22 0.357 0.506 0.214 0.177 0.216 1.016 0.096
LR Dl 4.22 8.01 0.433 1.34 0.706 0.347 0.224 0.834 0.108
LR Dl 6.15 6.38 0.4 1.26 0.52 0.276 0.18 0.389 0.076
JT Dl 0.00 0 0 0 0 0 0 0.209 0.067
JT Dl 0.60 8.32 0.072 0.133 0.031 0.015 0.067 0.254 0.118
JT Dl 1.47 8.58 0.269 0.156 0.428 0.073 0.09 0.476 0.118
JT Dl 2.70 8.42 0.442 0.563 0.896 0.135 0.084 0.603 0.102
JT Dl 4.55 7.77 0.316 0.646 0.583 0.207 0.047 0.634 0.077
JT Dl 7.38 4.41 0.101 0.602 0.237 0.149 0.039 0.334 0.072
JTD14 0.00 1.25 0.159 0.242 0.035 0.008 0 0.127 0.049
JTD14 0.55 2.16 0.191 0.47 0.233 0.026 0.01 0.382 0.057
JTD14 1.22 7.17 0.197 0.5 0.428 0.067 0.06 0.75 0.078
JTD14 2.58 5.31 0.322 0.454 0.895 0.07 0.054 1.01 0.137
JTD14 5.52 3.96 0.227 0.439 1.09 0.075 0.055 0.771 0.118
JTD14 7.35 3 0.167 0.393 0.7 0.049 0.045 0.506 0.106
Table A6 b. Ifosfamide and ifosfamide metabolite concentrations (|ig ml"1) on
days 1 (Dl) and 14 (D14).
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Patient Time IPA 2-DCEI 3-DCEI CIPA KIPA IPM CEA OXA
(hr)
SO Dl 0.00 0 0 0 0 0 0 0.078 0.066
SO Dl 0.48 7.22 0.026 0.154 0.041 0.071 0.112 0.226 0.077
SO Dl 1.47 16.39 0.077 0.373 0.125 0.099 0.122 0.689 0.094
SO Dl 3.13 17.14 0.28 0.693 0.453 0.147 0.189 0.974 0.143
SO Dl 5.12 13.29 0.357 0.889 0.339 0.089 0.198 0.896 0.099
SO Dl 6.73 9.82 0.325 0.916 0.168 0.075 0.074 0.759 0.076
PC Dl 0.00 0 0 0 0 0 0 0.135 0.016
PC Dl 0.45 4.51 0.24 0.35 0.064 0.03 0 0.298 0.017
PC Dl 1.15 10.35 0.52 0.36 0.062 0.04 0.18 0.315 0.024
PC Dl 2.32 12.06 0.54 1.79 0.098 0.38 0.25 0.501 0.058
PC Dl 4.15 10.86 0.45 1.91 0.076 0.41 0.26 0.258 0.046
PC Dl 6.32 6.12 0.16 1.73 0.064 0.22 0.18 0.236 0.029
PCD 14 0.00 0 0 0.06 0 0 0.02 0.179 0.022
PCD14 0.57 - - - - - - 0.379 0.021
PCD14 1.42 6.48 0.76 0.69 0.064 0.071 0.17 0.428 0.019
PCD14 2.40 9.54 0.84 1.92 0.136 0.356 0.22 0.493 0.027
PCD14 4.47 5.94 0.42 2.16 0.122 0.452 0.24 0.426 0.039
PCD14 6.70 5.04 0.23 1.75 0.102 0.361 0.2 0.34 0.03
LJ Dl 0.00 0 0 0 0 0 0 - -
LJ Dl 0.08 0 0 0.02 0 0.056 0 - -
LJ Dl 1.08 1.82 0 0.04 0.02 0.073 0.11 - -
LJ Dl 2.08 16.48 0.46 1.09 0.38 0.101 0.28 - -
LJ Dl 4.08 10.94 0.28 1.02 0.25 0.21 0.29 - -
LJ Dl 5.92 7.6 0.24 0.83 0.21 0.103 0.2 - -
RC Dl 0.00 0 0 0 0 0 0 0.062 0.042
RC Dl 0.48 9.42 0 0.019 0 0 0.022 0.503 0.048
RC Dl 1.17 12.48 0 0.062 0.039 0.014 0.049 0.608 0.063
RC Dl 2.13 21.71 0.089 0.121 0.125 0.107 0.159 0.757 0.085
RC Dl 4.80 11.33 0.185 0.5 0.175 0.085 0.161 0.981 0.084
RC Dl 6.80 8.42 0 0.469 0.113 0.058 0.033 0.599 0.077
RCD14 0.00 5.02 0.388 1.15 0.272 0.068 0.021 0.503 0.051
RCD14 0.60 13.94 1.19 1.39 0.634 0.123 0.084 0.882 0.062
RCD14 1.05 18.45 1.01 1.51 0.837 0.193 0.146 0.978 0.093
RCD14 3.30 13.59 0.95 1.91 0.93 0.368 0.118 0.831 0.102
RCD14 4.97 8.52 0.75 1.92 0.623 0.271 0.027 0.664 0.051
Table A6 c. Ifosfamide and ifosfamide metabolite concentrations (|ag ml"1) on
days 1 (Dl) and 14 (D14).
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TableA7.Oralifosfamide;famideph r acokin ticm t rsd y1




















































































TableA8.Oralifosfamide;i f ideph rmacokin ticp r met rsd y14.
Patient Tmax Cmax AUCt AUCg
(hr) (nM) (pM. hr) (pM. hr)
CB 1.13 1.91 8.01 11.17
EG - - - -
CH 1.13 0.96 1.31 -
JW 1.38 2.67 11.99 22.64
LR 4.22 2.18 9.17 17.50
SO 5.12 1.80 7.76 12.96
PC 2.32 2.72 12.34 17.25
RC 4.80 0.93 2.97 2.97
JT 2.70 2.23 9.22 10.84
NH 5.33 2.63 11.03 15.69
LJ 2.08 2.32 7.20 14.59
Table A9. Oral ifosfamide; 2-DCEI pharmacokinetic
parameters day 1.
Patient Tmax Cmax Cmin AUCt AUCg
(hr) (pM) (pM) (pM. hr) (pM. hr)
CB - - - - -
EG - - - - -
CH 1.22 3.61 1.66 10.68 26.39
JW 1.48 7.05 3.37 29.36 33.96
LR - - - - -
SO - - - - -
PC 2.40 4.23 0 16.52 20.96
RC 0.60 5.99 1.95 23.06 45.61
JT 2.58 1.62 0.80 8.76 10.84
NH 4.17 3.36 1.42 16.37 26.19
LJ - - . . .
Table A10. Oral ifosfamide; 2-DCEI pharmacokinetic parameters day
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Patient Tmax Cmax AUCt AUCs
(hr) (pM) (pM. hr) (pM. hr)
CB 4.88 4.28 24.47 33.36
EG 2.72 2.27 12.73 18.47
CH 3.37 1.76 5.38 17.00
JW - - 17.12 31.88
LR 4.22 6.75 23.29 40.13
SO - - 21.20 30.20
PC 4.15 9.62 44.90 64.62
RC 4.80 2.52 9.66 15.51
JT 4.55 3.25 17.58 21.03
NH 5.33 3.64 18.26 24.33
LJ 2.08 5.49 22.16 37.29
Table All Oral ifosfamide; 3-DCEI pharmacokinetic
parameters day 1.
Patient Tmax Cmax Cmin AUCt AUCs
(hr) (pM) (pM) (pM. hr) (pM. hr)
CB - - - - -
EG 1.95 3.17 0.00 15.26 27.15
CH 2.32 6.47 4.43 38.11 51.83
JW 4.97 9.97 5.24 60.08 71.90
LR - - - - -
SO - - - - -
PC 4.47 10.88 0.30 52.26 68.11
RC - - 5.79 42.60 79.32
JT 1.22 2.52 1.22 16.33 19.24
NH 2.05 11.78 5.84 64.12 88.92
LJ - - - - -
Table A12 Oral ifosfamide; 3-DCEI pharmacokinetic parameters day
194
Patient Tmax Cmax AUCt AUC8
(hr) (pM) (pM. hr) (pM. hr)
CB 2.30 1.57 5.36 7.93
EG 1.28 1.09 3.96 5.58
CH 3.37 0.96 3.24 10.54
JW 4.10 1.09 4.37 10.10
LR 4.22 2.41 7.71 14.47
SO 3.13 1.55 5.97 8.48
PC 2.32 0.33 1.57 4.50
RC 4.80 0.60 2.66 4.84
JT 2.70 3.06 11.81 13.28
NH 2.68 2.08 11.19 13.92
LJ 2.08 1.30 4.27 8.99
Table A13. Oral ifosfamide; CIPA pharmacokinetic
parameters day 1.
Patient Tmax Cmax Cmin AUCt AUCg
(hr) (pM) (pM) (pM. hr) (pM. hr)
CB - - - - -
EG 1.20 1.66 0.00 4.64 7.78
CH 2.30 1.60 1.19 7.75 11.62
JW 4.97 1.74 0.00 8.26 11.32
LR - - - - -
SO - - - - -
PC 2.40 0.46 0.00 2.25 4.75
RC 3.30 3.17 0.93 13.20 29.03
JT 5.52 3.72 0.12 19.52 22.28
NH 2.05 2.60 0.93 11.50 17.45
LJ . - - - .
Table A14. Oral ifosfamide; CIPA pharmacokinetic parameters day
14.
195
Patient Tmax Cmax AUCt AUCg
(hr) (|iM) (pM. hr) (pM. hr)
CB - - 0.29 4.69
EG 0.48 0.44 1.27 3.43
CH - - 0.28 -
JW 4.10 0.07 0.18 3.05
LR 4.22 1.26 4.44 9.45
SO 3.13 0.53 2.44 4.85
PC 4.15 1.49 6.03 10.10
RC 2.13 0.39 1.67 3.72
JT 4.55 0.75 3.60 5.01
NH 2.68 0.49 2.44 4.15
LJ 4.08 0.76 2.69 6.12
Table A15. Oral ifosfamide; KIPA pharmacokinetic
parameters day 1.
Patient Tmax Cmax Cmin AUCt AUCg
(hr) (pM) (pM) (pM. hr) (pM. hr)
CB - - - - -
EG 0.54 0.73 0.15 1.45 3.64
CH 3.97 1.03 0.32 4.40 7.72
JW 2.63 0.63 0.32 3.56 5.82
LR - - - - -
SO - - - - -
PC 4.47 1.64 0.00 7.27 11.29
RC 3.30 1.34 0.25 4.69 13.05
JT 5.52 0.27 0.03 1.67 2.82
NH 2.05 1.64 0.16 6.29 9.82
LJ - - - - -
Table A16. Oral ifosfamide; KIPA pharmacokinetic parameters day
14.
196
Patient Tmax Cmax AUCt AUCg
(hr) (pM) (pM. hr) (pM. hr)
CB 2.30 1.76 7.42 11.37
EG - - - -
CH 2.10 1.00 2.71 7.68
JW 2.18 1.49 5.25 10.54
LR 4.22 1.01 4.75 10.00
SO 5.12 0.90 4.48 6.73
PC 4.15 1.18 5.66 10.33
RC - - 3.26 4.77
JT 1.47 0.41 1.95 3.41
NH - - 6.24 8.73
LJ 4.08 1.31 5.75 11.70
Table A17. Oral ifosfamide; IPM pharmacokinetic
parameters day 1.
Patient Tmax Cmax Cmin AUCt AUCg
(hr) (pM) (pM) (pM. hr) (pM. hr)
CB - - - - -
EG - - - - -
CH 2.30 1.52 0.00 5.02 7.72
JW 2.63 1.81 0.42 8.23 10.10
LR - - - - -
SO - - - - -
PC 4.47 1.09 0.09 5.84 9.79
RC 1.05 0.66 0.10 2.17 8.02
JT 5.52 0.25 0.00 1.58 3.09
NH 4.17 1.34 0.40 5.97 11.61
LJ - - - - -
Table A18. Oral ifosfamide; IPM pharmacokinetic parameters day
14.
197
Patient Tmax Cmax AUCt AUCg
(hr) (pM) (pM. hr) (pM. hr)
CB 1.13 4.02 8.68 19.44
EG - - - -
CH 2.10 5.28 17.98 54.29
JW 4.10 2.26 8.80 40.88
LR 2.28 12.40 46.53 71.50
SO 3.13 11.27 57.47 78.39
PC 2.32 4.60 14.21 29.09
RC 4.80 11.56 58.10 76.04
JT 4.55 5.34 25.28 31.66
NH 2.68 11.83 54.70 70.87
LJ . - - .
Table A19. Oral ifosfamide; CEA pharmacokinetic
parameters day 1.
Patient Tmax Cmax Cmin AUCt AUCg
(hr) (pM) (pM) (pM. hr) (pM. hr)
CB - - - - -
EG - - - - -
CH 2.30 5.41 1.01 23.26 35.00
JW 2.63 3.65 0.00 20.75 25.84
LR - - - - -
SO - - - - -
PC 2.40 4.50 0.55 23.26 34.04
RC 1.05 11.52 5.55 47.79 95.77
JT 2.58 10.07 0.00 56.97 64.09
NH 4.17 8.75 0.52 38.48 61.04
LJ - - - - .
Table A20. Oral ifosfamide; CEA pharmacokinetic parameters day
14.
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Patient Traax Cmax AUCt AUCs
(hr) (pM) (pM. hr) (pM. hr)
CB 1.13 0.96 0.92 9.69
EG - - - -
CH 2.10 0.52 1.49 11.68
JW 2.18 0.22 0.57 8.13
LR 4.22 1.00 5.17 14.52
SO 3.13 0.88 2.76 8.44
PC 2.32 0.48 1.61 7.73
RC 2.13 0.49 2.64 10.00
JT 0.60 0.59 1.95 5.61
NH 2.68 0.98 5.28 11.37
LJ - - - -
Table A21. Oral ifosfamide; OXA pharmacokinetic
parameters day 1.
Patient Tmax Cmax Cmin AUCt AUCs
(hr) (|iM) (pM) (pM. hr) (pM. hr)
CB - - - - -
EG - - - - -
CH 3.97 1.48 0.06 4.13 10.54
JW 4.97 0.78 0.11 3.68 9.79
LR - - - - -
SO - - - - -
PC 4.47 0.26 0.07 1.03 6.90
RC 3.30 0.69 0.10 2.18 12.53
JT 2.58 0.80 0.00 5.04 8.99
NH 2.05 1.19 0.79 5.86 15.26
LJ - - - - -




IPA 2-DCEI 3-DCEI CIPA KIPA IPM CEA OXA
CB
EG 1.22 - 1.4 1.52 1.67 - - -
CH 1.13 3.77 3.67 1.68 - 1.52 1.02 2.87
JW 0.86 2.64 - 1.59 9.05 1.21 1.61 3.58
LR - - - - - - - -
SO - - - - - - - -
PC 0.79 1.56 1.13 1.39 1.10 0.92 0.98 0.55
RC 0.85 6.43 - 5.31 3.44 - 1.00 1.40
JT 0.84 0.73 0.77 1.22 0.36 0.61 1.88 1.37
NH 0.90 1.28 3.24 1.25 3.37 - 0.74 1.22
LJ - - - - - - - -
Mean 0.94* 2.73 2.04 1.99 3.17 1.07 1.21 1.83
SD 0.16* 2.11 1.32 1.47 3.13 0.39 0.44 1.14
n 7* 6 5 7 6 4 6 6
: excluding PC, mean = 0.97, SD = 0.17, andn = 6
Table A23. Oral ifosfamide; ratio of day 14 Cmax / day 1 Cmax.
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Compound r p n
IPA
D 1 and D 2 0.0436 0.4673 6
D 14 and D 15 -0.2280 0.3862 4
2-DCEI
D 1 and D 2 0.2236 0.3588 5
D 14 and D 15 0.7298 0.2396 3
3-DCEI
D 1 and D 2 -0.2880 0.3561 4
D 14 and D 15 -0.2350 0.3826 4
CIPA
D 1 and D 2 -0.4020 0.2146 6
D 14 and D 15 -0.8300 0.0850 4
KIPA
D 1 and D 2 -0.7160 0.1421 4
D 14 and D 15 -0.8410 0.0795 4
IPM
D 1 and D 2 0.9547 0.0058 5
D 14 and D 15 0.9077 0.1378 3
CEA
D 1 and D 2 -0.8850 0.0232 5
D 14 and D 15 -0.9940 0.0358 3
OXA
D 1 and D 2 -0.3110 0.3050 5
D 14 and D 15 -0.3310 0.3925 3
Table A24. Day 1 (Dl) Cmax and day 2 (D2) a
frequency (percentage change), and day 14 (D14)
Cmax and day 15 (D15) a frequency (percentage
change), correlations for ifosfamide and its
metabolites; (r = Pearsons correlation coefficient).
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r p n
IPA 0.0094 0.4953 4
2-DCEI 0.7621 0.2242 3
3-DCEI 0.0296 0.4906 3
CIPA 0.8951 0.0524 4
KIPA 0.7520 0.2291 3
CEA 0.8811 0.1568 3
OXA 0.9980 0.0203 3
Table A25. Correlation of day 14 Cmax / day 1 Cmax
ratio with day 15 a frequency, (percentage change),





IPA 2-DCEI 3-DCEI CIPA KIPA IPM CEA OXA
AH 0.00 0 0 0 0 0 0 0.47 0.08
Cycle 1 0.15 8.02 0 0.02 0.2 0.04 0.05 1.67 0.42
Plasma 1.05 11.87 0.1 0.2 0.22 0.07 0.24 2.8 0.52
2.07 19.95 0.22 0.6 0.52 0.07 0.44 3.47 0.57
4.15 24.98 0.62 1.81 0.85 0.11 0.88 6.07 0.81
6.27 29.3 1.03 2.31 1.09 0.14 0.93 14.7 1.2
7.48 28.32 1.25 2.41 1.52 0.16 0.82 8.6 0.52
11.83 25.45 1.6 2.54 1.71 0.18 0.77 3.91 0.3
21.92 15.02 0.76 2.01 0.85 0.12 0.31 2.24 0.15




AH 0.00 0 0 0 0 _ 0 0 0
Cycle 1 0.15 8.031 0.161 0.104 0.286 - 0.168 1.22 0.098
Erythrocyte 1.05 15.354 0.314 0.361 0.413 - 0.476 2.95 0.509
2.07 29.577 0.617 1.125 0.606 - 1.255 3.824 0.934
4.15 42.207 0.877 2.625 2.683 - 2.424 8.932 1.71
6.27 54.814 1.384 3.661 4.435 - 3.964 18.624 2.047
7.48 52.408 1.507 4.104 5.09 - 4.572 11.73 1.292
11.83 38.593 1.943 4.48 5.902 - 4.254 5.786 0.643
21.92 15.254 0.942 3.339 2.565 - 1.596 2.476 0.375
25.45 8.396 0.666 2.508 1.021 - 1.038 1.677 0.11
Table A26 a. Plasma and erythrocyte concentrations of ifosfamide and ifosfamide
metabolites ml plasma lfosfamide T1/2 (hr), CL (L hr"1) and Vss (L).
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Patient Time IPA 2-DCEI 3-DCEI CIPA KIPA IPM CEA OXA
(hr)
AH 0.00 0 0 0 0 0 0 0.01 0
Cycle 2 0.33 4.24 0 0.05 0.02 0 0.06 0.23 0
Plasma 1.27 10.35 0 0.11 0.11 0 0.19 0.84 0
2.53 23.6 0.09 0.62 0.15 0 0.33 1.37 0
4.45 26.2 0.31 1.89 0.41 0.004 0.37 2.18 Oo
6.32 29.3 0.84 3.07 0.94 0.01 0.62 3.23 po
7.48 32.1 1.02 3.14 1.51 0.02 1.07 3.79 o.o-
8.88 29.9 0.84 3.24 1.12 0.04 0.76 2.08 Oo
14.72 14.9 0.65 3.32 0.86 0.06 0.4 0.87 0
20.53 10.05 0.32 1.97 0.19 0.04 0.36 0.54 0




AH 0.00 0 0 0 0 0 0 0.02 0
Cycle 2 0.33 6.682 0 0.04 0.03 0 0.226 0.573 0
Erythrocyte 1.27 15.701 0 0.339 0.193 0 0.46 0.913 0
2.53 48.12 0.09 0.662 0.607 0.008 0.517 0.996 0
4.45 52.071 0.383 1.028 1.158 0.021 0.754 2.907 0
6.32 51.638 0.85 1.771 2.415 0.031 0.838 3.355 0
7.48 43.425 1.332 2.34 3.827 0.03 1.756 3.78 0
8.88 37.9 1.224 5.38 3.873 0.019 1.072 2.745 0
14.72 - - - - - - - -
20.53 25.791 0.445 4.006 2.663 0.009 0.817 1.111 0
24.07 9.242 0.125 3.294 1.481 0.009 0.479 0.568 0
Table A26 b. Plasma and erythrocyte concentrations of ifosfamide and ifosfamide




IPA 2-DCEI 3-DCEI CIPA KIPA IPM CEA OXA
DL 0.00 0 0 0 0 0 0 0.05 0
Cycle 1 0.23 4.17 0 0.02 0 0 0 0.66 0
Plasma 0.88 12.4 0 0.3 0.095 0 0.13 0.94 0.058
2.42 16.9 0.13 0.41 0.56 0.26 0.26 1.95 0.12
4.20 28.6 0.46 1.53 1.26 0.36 0.63 2.93 0.15
6.38 50.2 0.52 2.5 2.38 0.43 0.96 3.82 0.091
7.75 39.2 0.68 2.28 2.79 0.56 0.9 2.23 0.063
17.22 11.2 0.22 1.56 0.92 0.15 0.28 - -




DL 0.00 0 0 0 0 0 0 0.2 0
Cycle 1 0.23 5.767 0 0.192 0.107 0 0.107 0.949 0
Erythrocyte 0.88 17.653 0 0.246 0.25 0 0.516 - -
2.42 30.193 0.151 0.378 1.268 0 0.517 1.2 0
4.20 47.371 0.503 1.412 3.308 0.317 0.737 2.137 0.139
6.38 63.193 0.52 2.564 8.544 1.084 0.992 3.627 0.133
7.75 41.698 0.251 2.441 9.351 1.257 1.608 1.93 0.028
17.22 8.338 0.016 0.981 2.882 0.482 0.398 1.41 0.02
21.48 7.542 0.005 0.953 1.995 0.376 0.254 - -
Table A26 c. Plasma and erythrocyte concentrations of ifosfamide and ifosfamide




IPA 2-DCEI 3-DCEI CIPA KIPA IPM CEA OXA
DL 0.00 0 0 0 0 0 0 0.04 0
Cycle 2 0.25 3.63 0 0 0 0 0 0.33 0
Plasma 1.05 9.63 0 0.34 0.04 0.25 0.04 0.79 0.005
2.90 16.7 0.13 1.58 0.07 0.29 0.13 1.59 0.024
4.70 21.8 0.45 2.49 0.25 0.59 0.23 2.21 0.068
6.35 22.4 0.74 6.49 0.45 0.94 0.27 3.5 0.073
8.27 27.8 1.02 5.61 0.59 1.72 0.41 2.88 0.069
17.50 12 0.59 4.11 0.21 0.86 0.09 1.02 0




DL 0.00 0 0 0 0 0 0 0.426 0
Cycle 2 0.25 - - - - - - 0.877 0
Erythrocyte 1.05 19.353 0 0.158 0.083 0 0.34 1.444 0
2.90 33.53 0.398 1.484 0.477 0 0.602 3.048 0.041
4.70 34.417 0.546 3.026 1.524 0.59 1.034 4.193 0.102
6.35 50.647 0.847 6.876 2.004 0.854 1.053 6.812 0.198
8.27 48.393 0.623 5.556 2.541 1.248 1.289 5.099 0.177
17.50 12.247 0.226 4.946 1.046 0.635 0.304 2.146 0.032
21.58 5.57 0 3.182 0.687 0.344 0.199 1.235 0
Table A26 d. Plasma and erythrocyte concentrations of ifosfamide and ifosfamide
metabolites (|ag ml"1); plasma ifosfamide Ti/2(hr), CL (L hr"1) and Vss (L).
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Patient Time IPA 2-DCEI 3-DCEI CIPA KIPA IPM CEA OXA
(hr)
AW 0.00 0 0 0 0 0 0 0 0
Cycle 1 0.57 3.7 0 0.09 0.18 0 0.08 2.01 0
Plasma 1.28 11.2 0.09 0.28 0.4 0 0.41 7.32 0.04
3.05 21.9 0.12 0.56 0.58 0 1.31 11.2 0.14
4.65 28 0.36 1.77 0.74 0.02 1.55 14 0.26
6.83 29.1 0.67 3.41 0.83 0.047 1.6 15.2 0.3
9.20 20.7 0.65 4.34 1.04 0.111 0.72 11.6 0.19
16.53 0° oo 0.29 2.98 0.49 0.043 0.34 5.1 0.11
20.58 5.41 0.21 2.5 0.32 0.029 0.24 3.21 0.05




AW 0.00 0 0 0 0 0 0
Cycle 1 0.57 5.362 0.083 0.371 0.658 0 0.194
Erythrocyte 1.28 12.862 0.132 0.415 1.377 0 1.085
3.05 27.614 0.203 0.913 1.661 0.021 3.232
4.65 40.884 0.464 1.936 2.319 0.029 4.324
6.83 - - - - - -
9.20 37.532 0.816 4.901 3.534 0.193 1.936
16.53 19.398 0.456 3.635 1.082 0.073 0.787
20.58 10.179 0.366 3.155 0.881 0.051 0.531
24.62 5.809 0.244 2.417 0.664 0.042 0.338
Table A26 e. Plasma and erythrocyte concentrations of ifosfamide and ifosfamide
metabolites (p.g ml"1); plasma ifosfamide Tj/2(hr), CL (L hr"1) and Vss (L).
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Patient Time IPA 2-DCEI 3-DCEI CIPA KIPA IPM CEA OXA
(hr)
AW 0.00 0 0 0 0 0 0 0 0
Cycle 2 0.67 6.61 0.05 0.15 0.14 0.14 0.13 4.53 0
Plasma 1.32 13.1 0.08 0.24 0.36 0.18 0.38 11.1 0.024
2.95 14.7 0.28 1.02 0.72 0.2 0.5 13.8 0.036
4.75 16.3 0.47 1.46 1.04 0.29 0.64 16.2 0.041
6.87 21.3 0.64 2.54 1.78 0.33 0.84 19.9 0.054
8.25 19.2 0.58 2.57 2.1 0.39 0.99 17.5 0.038
11.63 13.5 0.38 2.32 1.82 0.24 0.71 11.9 0.025




AW 0.00 0 0 0 0 0 0 0 0
Cycle 2 0.67 7.13 0.06 0.181 0.389 0.15 0.286 5.237 0.011
Erythrocyte 1.32 14.243 0.111 0.365 0.921 0.211 0.837 12.347 0.03
2.95 17.713 0.519 1.477 1.738 0.242 1.549 15.151 0.04
4.75 20.04 0.699 3.07 2.827 0.321 2.063 18.382 0.046
6.87 24.937 0.744 3.558 4.689 0.361 2.721 22.497 0.058
8.25 23.564 0.902 3.941 5.882 0.411 3.058 19.058 0.041
11.63 17.76 0.588 3.567 4.937 0.282 2.466 16.575 0.026
15.03 14.017 0.324 3.253 3.83 0.161 1.395 10.157 0.012
Table A26 f. Plasma and erythrocyte concentrations of ifosfamide and ifosfamide




IPA 2-DCEI 3-DCEI CIPA KIPA IPM CEA OXA
ML 0.00 0 0 0 0 0 0 0 0
Cycle 1 0.55 2.72 0.17 0.19 0.09 0.02 0.019 0.45 0.019
Plasma 1.52 7.08 0.35 0.38 0.45 0.026 0.13 1.23 0.058
2.63 9.37 0.52 0.56 1.44 0.037 0.39 3.61 0.176
4.53 15.67 0.92 1.46 2.48 0.066 0.42 6.07 0.254
6.75 20.37 1.02 3.02 3.33 0.12 0.63 9.73 0.367
9.08 16.95 0.73 3.6 3.59 0.061 0.81 8.62 0.302
11.10 14.65 0.53 4 2.75 0.068 0.49 7.02 0.274




ML 0.00 0 0 0 0 0 0 0 0
Cycle 1 0.55 4.478 0.224 0.297 0.304 0.031 0.213 3.473 0.106
Erythrocyte 1.52 13.48 0.597 0.616 0.825 0.095 0.591 6.226 0.2
2.63 23.381 0.767 0.914 2.298 0.158 0.905 9.838 0.287
4.53 38.729 0.92 1.824 4.549 0.263 1.653 14.753 0.421
6.75 49.432 1.159 3.041 6.353 0.345 3.117 21.844 0.574
9.08 42.624 0.923 4.19 7.385 0.253 2.439 12.908 0.396
11.10 30.108 0.723 4.536 4.197 0.124 1.026 10.375 0.355
31.03 2.485 0 3.209 0.22 0.021 0.119 3.351 0
Table A26 g. Plasma and erythrocyte concentrations of ifosfamide and ifosfamide




IPA 2-DCEI 3-DCEI CIPA KIPA IPM CEA OXA
vw 0.00 0 0 0 0 0 0 0.12 0
Cycle 1 0.33 0.87 0.12 0.33 0.09 0.06 0.32 1.79 0
Plasma 1.58 8.41 0.71 1.22 0.36 0.09 0.4 3.85 0
2.78 15 1.25 2.86 0.98 0.12 0.72 8.54 0.13
4.68 17.4 2.87 4.6 1.56 0.32 0.82 8.86 0.15
6.67 22.4 2.97 6.23 2.02 0.44 1.09 13.4 0.25
7.97 29.1 3.56 9.91 2.95 0.5 0.98 10.1 0.2
16.87 6.1 1.07 5.36 1.7 0.34 0.43 6.29 0.11
21.62 4.28 0.89 2.15 0.56 0.27 0.31 3.7 0




VW 0.00 0 0 0 0 0 0 0.216 0
Cycle 1 0.33 1.234 0.334 0.962 0.133 0.264 0.524 3.034 0
Erythrocyte 1.58 9.428 1.364 2.142 0.424 0.326 1.118 6.616 0
2.78 16.394 1.711 2.303 1.334 0.377 2.103 7.768 0
4.68 19.544 2.881 6.036 2.289 0.524 2.868 8.067 0.075
6.67 21.971 2.906 8.942 2.417 0.526 3.609 7.997 0.089
7.97 30.279 3.271 8.516 3.593 0.596 3.574 9.285 0.114
16.87 11.246 1.359 5.221 2.826 0.372 1.062 4.232 0.056
21.62 6.467 0.729 3.008 0.978 0.291 0.653 1.878 0
26.02 5.081 0.551 1.729 0.262 0.146 0.404 1.287 0
Table A26 h. Plasma and erythrocyte concentrations of ifosfamide and ifosfamide
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Introduction
In order to determine the amount of a compound
associated with red cells, the usual approach is to
measure its concentration in whole blood and sub¬
tract from this the amount present in plasma, cor¬
rected for the hematocrit. However, when the com¬
pound is found in high concentrations in plasma rel¬
ative to red blood cells, this approach can be very
inaccurate and may even result in negative values
when the erythrocyte associated concentration is
calculated.
Obviously, if the plasma volume between red cells
can be diminished, a more direct analysis of com¬
pounds associated with red cells can be performed. A
sediment of red cells obtained at 10,000 x g will
contain no more than 2% (v/v) of trapped plasma.
Therefore, it should be possible to separate off and
measure such a cell sediment, containing a constant
volume of trapped plasma, with the concentration of
compounds on the red cells unchanged by the proce¬
dure. Thereafter, compounds associated (1-4) with a
known mass of red cells can be quantified. We de¬
scribe here an instrument that we have designed to
separate red cells from plasma and allow for the
measurement of red cell volume.
Materials and methods
Reservoir A is inserted into container B, as shown
in Figure 1. The reservoir is fitted tightly into the
container so that the small orifice of the reservoir
(Figure 1, #1) is sealed by the o-ring in the con¬
tainer (Figure 1, panel A, #2). The reservoir is filled
with an aliquot of blood and the unit placed in a
swing out rotor. By centrifuging at high speed
(>5000 x g) red cells are forced into the narrow part
of the reservoir (Figure 1, #3), into the closed small
channel (Figure 1, #4) and into the bottom of the
Correspondence: Dr. E.A. de Bruijn.
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broad part of the reservoir (Figure 1, #5). The
amount of trapped plasma remaining between the
cells may be essential to maintain the same equilib¬
rium between cell and plasma concentrations as ex¬
ists in whole blood. After the first centrifugation
some supernatant plasma is removed for indepen¬
dent analysis. Before the second centrifugation, res¬
ervoir A is detached by turning A in B, so that the
o-ring (Figure 1, #2) no longer occludes the orifice
(Figure 1, panel B, #1). During the second centrif¬
ugation, the flow resistant red cell sludge, together
with the remaining supernatant plasma, is forced
out of reservoir A into the bottom of container B,
leaving behind a defined volume of almost pure red
cells in the narrow part of A (Figure 1, #3). This
mass of cells is transferred to a centrifuge tube by
centrifuging the inverted reservoir alone.
Proteins often bind red cell associated compounds
more avidly than red cells themselves. In these in¬
stances compounds can be quantitatively extracted
by a blank albumin solution from the cell sediment
(5).
To test the accuracy of the instrument, the closed
reservoir (Figure 1, panel A) was filled with 0.5 mL
of fresh anticoagulated blood collected in lithium-
heparin containing vacutainers and centrifuged in a
swing out rotor at a speed of 5000 x g. The distance
from the bottom of the buckets to the central centri¬
fuge axis was 15 cm. Immediately after the first run
a second one was performed with the instrument as
depicted in Figure 1, panel B.
The mass of cells collected in the narrow part of
the reservoir (Figure 1, #3) was then transferred
into a preweighed tapered empty centrifuge tube by
centrifuging the inverted reservoir alone. By re-
weighing the centrifuge tube afterward, the mass of
the cell sediment was obtained. In this way six in¬
struments chosen at random were tested.
Results and discussion
The collected mass of cells was 109.5 mg (±0.2 mg,
n = 6), indicating that the method is reproducible.
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Figure 1 — The MESED (measuring sediment) instru¬
ment. Panel A, Closed position; panel B, open position.
This weight depends on the exact dimensions of the
narrow part of the reservoir, on the centrifugal force
applied, and on the density of the cells, the density of
normal erythrocytes being 1.0964. It is important
that fresh anticoagulated, blood collected in vacu-
tainers be used. The presence of microdots or cold
precipitates predisposes to blockage of the narrow
orifice (Figure 1, #1; ID 0.45 mm), thereby prevent¬
ing the removal of surplus material from the reser¬
voir during the second centrifugation.
The plasma concentration of a compound will of¬
ten be higher than that associated with cells in the
blood, and consequently a correction must be made
for the plasma trapped in the sediment. Therefore
the amount of trapped plasma should be determined
once under standardized conditions with an extra¬
cellular marker. Using 51Cr-EDTA the volume of
trapped plasma appeared to be 3.4-3.9% (v/v) (n =
5) in a range of 5000 x g/5 min-5000 x g/3 min. The
collection of supernatant plasma after the first cen¬
trifuge run and its subsequent analysis is required
for this correction.
The technique we have described has practical ap¬
plications. In previous studies (5,7,8) it was shown
that for a given compound the elimination half-lives
from the various components of whole blood are
quite different. Elimination from the erythrocyte is
as rapid or faster than that from the plasma water,
in contrast to the lower elimination from plasma
proteins. For example, approximately 2-24 h after
the intravenous administration of phenytoin, the
half-life of the protein bound fraction is 67.9 h, that
of the unbound fraction 38.5 h, and that of the red
cell fraction 21.4 h, these values being significantly
different (8). Although the amount bound to eryth¬
rocytes is less than that bound to plasma proteins,
the faster elimination from erythrocytes, coupled
with the high number of these cells in the circula¬
tion (45% v/v) implies that erythrocytes are impor¬
tant carriers of such compounds. In the case of phe¬
nytoin, calculations showed that between 1 and 5 h
after administration, approximately 50% of the drug
leaving the blood originated from erythrocytes.
The amount of trapped plasma determined with
51Cr-EDTA increased from 3.4-3.9% at 5000 x gto
5-8% at 1000 x g. The data stress the importance of
calibration and proper choice of centrifugation con¬
ditions. The amount of trapped plasma (9-11) ap¬
peared to be somewhat higher than that reported by
Siebers et al. (11). This might be due to differences
between the behavior of 0lCr-EDTA (9,10) and
(Co2 + )-EDTA (11).
In conclusion the instrument presently described
could have applications in the following fields:
1. The study of the relationship between the de¬
gree of red cell binding of a compound and the
observed clinical effects of that compound.
2. The study of the mutual displacement of body
constituents, xenobiotics, and foodstuffs in
fractions of whole blood.
3. The determination of the distribution of a com¬
pound and its metabolites between red cells
and plasma, for example, antimalarial drugs
and vitamins; the study of red cells as bioreac-
tors.
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Short Communication
Formation of Chloroethylamine and 1,3-Oxazolidine-2-one following Ifosfamide
Administration in Humans
Ifosfamide is an oxazaphosphorine alkylating agent used exten¬
sively in the treatment of malignant disease. It is a prodrug requiring
activation in the liver by the cytochrome P450 system. Two routes of
metabolism are possible; first, activation to form 4-hydroxyifosf-
amide, with the subsequent formation of IPM1; and second, dechlo-
roethylation to produce 2-DCEI, 3-DCEI, and chloroacetaldehyde.
Carboxyifosfamide, ketoifosfamide, and 4-thioifosfamide are also
generated (fig. 1). The structural isomer cyclophosphamide follows a
similar metabolic fate, but NNM has also been found after intravenous
administration in humans. In one report, the source of NNM was not
clear, because cyclophosphamide, 4-ketocyclophosphamide, carboxy-
phosphamide, and phosphoramide mustard were all capable of de¬
composing to NNM during the freezing and thawing of plasma (1).
When phosphoramide mustard is injected into mice NNM is formed,
and this in turn yields 3-(2-chloroethyl)-l,3-oxazolidine-2-one (2). In
the case of IPM, an equivalent transformation would lead to chloro¬
ethylamine and l,3-oxazolidine-2-one; chloroethylamine has alkylat¬
ing activity, but only one-fifth the potency of NNM (3). We describe
the detection of chloroethylamine and l,3-oxazolidine-2-one in
plasma following oral and intravenous administrations of ifosfamide
in humans.
Four patients were studied. Patients 1 and 3 received 3 g m~2
Abbreviations used are: IPM, isophosphoramide mustard; 2-DCEI, 2-dechlo-
roethylifosfamide; 3-DCEI, 3-dechloroethylifosfamide; NNM, nornitrogen mus¬
tard.
Send reprint requests to; Dr. M. S. Highley, Department of Medical Oncology,
Guy's Hospital, St. Thomas Street, London SE1 9RT, UK.
ifosfamide (5.35 g and 4.7 g, respectively) and 2 g m-2 mesna
(sodium-2-mercapto-ethane sulfonate) as a 6-hr intravenous infusion
in 500 ml 0.9% sodium chloride; intravenous boluses of 800 mg
mesna were given immediately before and 8 hr after the infusion.
Patients 2 and 4 were given ifosfamide 500 mg orally as a gelatin
capsule with a 300 mg film-coated mesna tablet. None had received
prior treatment with oxazaphosphorines. Blood samples were taken at
intervals during and following the intravenous infusion for —24 hr
after completion and for —6 hr after oral administration. Plasma was
separated immediately by centrifugation and stored at —20°C until
analysis.
Ifosfamide and its metabolites were determined using GC/MS as
previously described (4). Isolation of ifosfamide, IPM, 2-DCEI,
3-DCEI, carboxyifosfamide, and ketoifosfamide was performed by
solid-phase C18 extraction at pH 4. Two derivatization steps were
used: methylation of the acidic groups of carboxyifosfamide and IPM,
followed by trifluoroacetylation of unhindered phosphoramide
groups. Analyses were then conducted using negative chemical ion¬
ization by electron capture. Chloroethylamine and l,3-oxazolidine-2-
one were isolated by liquid extraction with ethyl acetate at pH 10.
One-step derivatization using trifluoroacetic anhydride was used and
GC/MS performed in the electron impact ionization mode. The struc¬
tures of the trifluoroacetyl derivatives of chloroethylamine and 1,3-
oxazolidine-2-one with their mass spectra are given in fig. 2.
The plasma metabolite profiles of patients 1 and 2 are shown in fig.
3. Peak levels of 2-DCEI, 3-DCEI, and carboxyifosfamide occurred
—6 hr after the end of the intravenous infusion, and only a small
amount of ketoifosfamide was seen. Peak concentrations of IPM,
chloroethylamine, and l,3-oxazolidine-2-one coincided with the end
CH2CH2C1
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Fig. 1. Metabolism of ifosfamide.
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Fig. 3. Plasma concentration-time curves following ifosfamide administration.
(A) Intravenous (patient 1); (B) oral (patient 2); IF, ifosfamide; CEA, chloroethylamine; KI, ketoifosfamide; CI, carboxyifosfamide; OXAZ, 1,3-oxazolidine-











Fig. 4. Conversion of IPM to chloroethylamine and l,3-oxazolidine-2-one.
of chloroethylamine were found compared with IPM, suggesting the
presence of an additional route of chloroethylamine formation. A
similar difference was observed between patients 3 and 4; after
intravenous infusion, the peak concentration of chloroethylamine was
9.73 pg/ml and ifosfamide was 20.37 pg/ml, compared with respec¬
tive values of 0.43 and 10.45 pg/ml following oral administration.
Significant quantities of NNM have been reported following the
intravenous administration of cyclophosphamide, and, as an explana¬
tion, the further metabolism of carboxyphosphamide was postulated
(1). However, the plasma profiles obtained after ifosfamide adminis¬
tration do not indicate carboxyifosfamide as a source of chloroethyl¬
amine. The relatively high levels of chloroethylamine generated after
intravenous infusion compared with oral dosing, with a curve follow¬
ing the ifosfamide plasma profile, infer that significant hydrolysis of
ifosfamide itself is occurring, either before or after direct injection
into the circulation. In aqueous solution at 70°C, cyclophosphamide
hydrolyzes to NNM, A-propanolamine, and phosphoric acid (8). Other
hydrolytic products have been described following more prolonged
exposure of cyclophosphamide solutions to a temperature of 37.5°C,
including 2-hydroxy-tetrahydro-2//-l,3,2-oxazaphosphorine-2-oxide
(9). We therefore explored the possibility that ifosfamide could be¬
have in a similar fashion.
Aqueous solutions of ifosfamide (1000 pg/ml and 100 pg/ml,
respectively) were buffered at pH 4, 7 and 10; maintained at 40°C for
5 hr; and an aliquot extracted with 6 ml of dichloromethane. The
solvent was evaporated and the dry residue treated with diazomethane
in ether, the solvent again evaporated, and the residue dissolved in 500
pi of methanol. The methanol solution was then injected into the
GC/MS. In all six samples, three peaks were detected: using electron
impact ionization, the first was identified as phosphoric acid methyl
ester; the second as 3-(2-chloroethyl)-2-methoxy-tetrahydro-277-
l,3,2-oxazaphosphorine-2-oxide (I); and the third as ifosfamide.
Chloroethylamine was also detected in all six solutions, as previously
described. These findings suggest that hydrolysis of ifosfamide to
chloroethylamine and 3-(2-chloroethyl)-2-hydroxy-tetrahydro-2//-
l,3,2-oxazaphosphorine-2-oxide (II) is taking place. In a further ex¬
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peak chloroethylamine/ifosfamide ratios of 50.2% and 50.1% (w/w)
after intravenous administration indicate that chemical hydrolysis is
significant in the plasma at body temperature. Corresponding values
after oral dosing are 4.9% and 8.2% (w/w). The higher levels of
chloroethylamine found in the plasma after intravenous ifosfamide
probably reflect the nature of the hydrolysis reaction, the rate of which
is dependent on the concentration of ifosfamide and therefore the
administered dose. Differences in the age or stability of ifosfamide
powder within gelatin capsules or glass vials may also be contribu¬
tory, but an analysis of the capsules was not performed.
In conclusion, chloroethylamine is an important product of ifosf¬
amide degradation and seems to be formed predominantly by hydro¬
lysis. Significant quantities are detected in vivo following high-dose
ifosfamide administration. Further work is continuing on the presence
of chloroethylamine in ifosfamide powder and the determination of
compounds II and V in plasma.
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This review considers the significance and measurement of endogenous compounds and drugs on erythro¬
cytes. Part I examines literature examples where a direct measurement of hydrocortisone, phenytoin and
valproate was performed on unwashed red cells in vitro and in vivo, showing a consistent contribution
of the erythrocyte fraction to the transport of these compounds. In vitro partition experiments using
systems composed of plasma water, plasma proteins and erythrocytes are discussed. When spiked blood
is diluted with blank autologous plasma water, erythrocytes always discharge the compound over-propor-
tionally compared to plasma proteins. In vivo, during the distribution phase, the elimination half-life from
the erythrocyte is the same as or shorter than that from plasma water, and substantial amounts of drug
leaving the circulation originate from erythrocytes. In Part II, the transfer of compounds is considered
and evidence for the facilitated exchange of red cell associated substances between the erythrocyte and
capillary endothelium presented. Situations where a failure to analyse the erythrocyte compartment leads
to the loss of vital information are identified. Part III explores methods for analysing erythrocyte associated
substances, most commonly indirect calculation, or analysis of washed erythrocytes. A direct determination
is rarely performed, but one such method, allowing concurrent plasma analysis, is discussed. An instrument
collects afixed and known quantity of a maximally compressed cell mass, without disturbing the equilibrium
between cells and plasma. To isolate compounds associated with the mass of erythrocytes, the red cell
sediment can often be extracted quantitatively into a blank protein solution.
KEY WORDS: biological transport; erythrocytes; plasma; protein binding; blood specimen collection;
valproic acid; phenytoin; hydrocortisone.
INTRODUCTION
Quantitatively, the three most important transport fractions
of blood are plasma water, plasma proteins and cells, mainly
erythrocytes. In the laboratory, this three compartmental system,
equilibrating in the circulation in the dark and at 37°C, is
reduced for practical purposes to the two compartmental system
of plasma and analysed at room temperature as if it had only
one compartment. The information present in the three separate
fractions of whole blood is therefore combined into one value.
In the case of a compound which is bound to plasma proteins,
this composite value is misleading as a change in the free
fraction present in plasma water can be hidden by the large
quantity present on proteins. Binding to erythrocytes also
occurs, but even less consideration has been given to the role
of these cells in the transport of compounds other than oxygen.
There are three reasons for this neglect of the erythrocyte
and subsequent lack of knowledge. Firstly, conceptual difficult¬
ies exist, as illustrated by the following statement; "The erythro¬
cyte has a cell wall, so it really has its own compartment.
1 Department of Medical Oncology, Guy's Hospital, London, UK.
2 Laboratory for Cancer Research and Clinical Oncology, University
of Antwerp, Universiteitsplein 1 (T-3), B-2610 Wilrijk, Belgium.
3 To whom correspondence should be addressed.
Distribution in body fluids does not take effect versus the frac¬
tion free in whole blood, but versus the free concentration in
plasma water. From the pharmacokinetic point of view, I would
say that the red blood cells have the lowest priority" as discussed
by a pioneer on erythrocyte studies, M. Ehrnebo (1). As a
result, the transport role of erythrocytes is almost invariably
investigated using washed erythrocytes, as if these cells were
indeed separate compartments, and regardless of the fact that
washed erythrocytes do not exist in the circulation. Secondly,
the transport function of red cells is influenced by physiological
factors as the role of erythrocytes will often become more
apparent when protein binding is saturated, and thirdly, bioana-
lytical limitations restrict the investigation of the transport role
of erythrocytes.
In the first part of the review, three reports from the litera¬
ture on the drugs valproate and phenytoin, and the endogenous
compound hydrocortisone, are described in detail and the data
re-evaluated. All three sudies illustrate that when the above
considerations are addressed, erythrocytes do in fact show a
consistent and important transport function.
In part II, a review of the mechanisms and significance
of substance transport by red cells, and subsequent exchange
at the capillary endothelium, is presented.
Part III discusses approaches to the analysis of red cell
associated substances, including a method for the analysis of
0724-8741/96/0200-0186$09.50/0 © 1996 Plenum Publishing Corporation 186
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drugs or endogenous compounds both directly on red cells and
in the plasma of a single blood sample.
PART I
THE TRANSPORT OF SUBSTANCES WITHIN THE
MAIN BLOOD FRACTIONS AND THE
CONTRIBUTION OF THE ERYTHROCYTE (Three
examples from the literature)
Methods of Erythrocyte Investigation
The use of appropriate methods is of vital importance for
demonstrating the transport role of erythrocytes. The essence
is to measure the compounds present in or on unwashed erythro¬
cytes directly. Three studies in which such an approach was
used (2-5) are reviewed in detail. They concern the compounds
valproate, an antiepileptic drug and small fatty acid; phenytoin,
also an antiepileptic drug; and the steroid hormone hydrocorti¬
sone. Both in vitro and in vivo work was described.
The method used to process the erythrocytes in these stud¬
ies involved harvesting blood into haematocrit capillaries and
separating erythrocyte sediments by centrifugation at 10,000
g. The capillaries were then cut with a glass knife, and both
the length of the cut fragment and its weight determined. Know¬
ing the weight per unit length of capillary tubing, the mass of
the cells was obtained. The cell mass was extracted and its
drug content analysed. From these measurements a known con¬
centration in w./v. of cell mass was derived. A correction for
the difference in density between red cells and water was not
made. During sample pretreatment, care was taken to maintain
the same equilibria as present in whole blood or an erythrocyte
suspension in plasma water. Hence after sampling, the haemato¬
crit capillaries were centrifuged immediately and the sediment
separated from plasma or plasma water. The concentration of
drug in the red cell sediment was then adjusted for the residual
plasma trapped between the cells. This was determined using
14C-inulin as an extracellular marker and appeared to be 2.0%,
in accordance with the literature (6). During sample pretreat¬
ment this trapped plasma may be important to maintain the
equilibrium that exists in the circulation. The quantity of drug
bound to plasma proteins was calculated by subtracting the
quantity in plasma water from that in plasma. In vitro, it was
confirmed that the total drug recovery from all the fractions
was equal to the amount added to blood, plasma or the mixture
of red cells and plasma water.
In vitro Partition of Phenytoin, Valproate and
Hydrocortisone Between Plasma Water, Proteins and
Red Cells
Tables I to III, constructed from the original data of
Driessen et al (2-5), show the distribution of these compounds
between the three main blood fractions at 20°C; concentrations
are expressed in weight per volume of blood, plasma, plasma
protein, plasma water or erythrocytes.
(a) Distribution within the Binary System of Plasma Water
and Plasma Proteins, i.e. Plasma
Table I shows the plasma concentrations of phenytoin,
valproate and hydrocortisone, and the concentrations bound to
protein compared to those in plasma water, expressed as the
plasma protein/plasma water concentration ratio. As expected,
the higher the concentration in spiked plasma, the lower the
plasma protein/plasma water ratio of the compound, indicating
that the plasma proteins are saturable with all three compounds.
(b) Distribution within an Erythrocyte and Plasma Water
Binary System
This is an artificial mixture, in which proteins adhering
to erythrocytes are stripped from these cells by washing with
autologous plasma water, before the compounds are added.
Following distribution of the compound between the two frac¬
tions, the erythrocytes are not subjected to further washing.
The observed red cell/plasma water concentration ratios, over
a similar concentration range to that described in Table I, are
shown in Table II.
In contrast to the data shown in Table I, the red cell/plasma
water ratios are constant, indicating that erythrocytes cannot
be saturated by these compounds, not even in the high and
toxic concentration ranges used. Compounds which are distrib¬
uted only in the water phase, and to the same extent both inside
and outside the erythrocyte, should have a red cell to plasma
water concentration ratio of approximately 0.65; substantially
higher ratios indicate accumulation within or on the surface of
the red cell.
(c) Distribution within a Ternary System of Plasma Water,
Plasma Proteins and Erythrocytes, ie Whole Blood
Table III presents the effect of increasing concentration
on the distribution ratios within whole blood.
As the concentration in spiked blood increases, the concen¬
tration in plasma water increases relatively to that on plasma
protein. Comparing the data in Table III with that in Table I,
it must be appreciated that the plasma fraction is now approxi¬
mately 55% of the total volume, and that the erythrocytes
occupy the remaining 45%. Consequently, in addition to compe¬
tition between the binding sites of the different fractions, the
relative volume of these fractions will also influence the
observed concentration ratio. This hinders a direct comparison
of the observed plasma protein/plasma water ratio in plasma
(Table I), with that in blood (Table III). It is striking that as
the total concentration in the system increases, the erythrocyte/
plasma water ratio remains constant for each drug in the binary
system (Table II), and is also constant for phenytoin and hydro¬
cortisone in the ternary system (Table III). This indicates that
for these two compounds, the concentrations on the eiythrocytes
and in plasma water increase proportionally. As varying con¬
centrations of phenytoin and hydrocortisone do not alter the
red cell/plasma water ratio, the erythrocyte concentration is
proportional to the concentration in plasma water.
In Table III, the erythrocyte/plasma water concentration
ratios for hydrocortisone and phenytoin appear slightly
increased and decreased respectively, in comparison with those
in Table II. One must be cautious interpreting this difference,
as it seems that the same blood sample was not used in the
two experiments, and it is known that other substances, e.g.
non-esterified fatty acids, can change the equilibrium between
compartments (7-11). Moreover, in the ternary system, the
equilibrium between red cells and plasma water was established
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Table II. Erythrocyte and Plasma Water Binary System (Hematocrit 0.39 — 0.50; Temperature 20°C)
System concentration and erythrocyte/plasma water concentration ratio (sd)
Valproate Phenytoin Hydrocortisone
System red cell/plasma System red cell/plasma System red cell/plasma
concentration water ratio concentration water ratio concentration water ratio
(p-g/ml) n = 3 (P-g/ml) n = 3 (p,g/ml) n = 3
2.7 0.68 (0.03) 0.8 4.5 (0.2) 0.18 2.1 (< 0.1)
24.7 0.68 (0.01) 5.8 4.5 (0.1) 0.68 2.0 (0.1)
44 0.60 (0.02) 10.8 4.6 (0.2) 1.18 2.0 (0.1)
66 0.70 (0.01) 20.8 4.5 (0.1) 5.18 2.1 (0.1)
88 0.68 (0.02) 50.8 4.5 (< 0.1) 10.18 2.1 (0.1)




room temperature between 3 and 10 minutes after pooling (3).
There are other observations in the literature supporting the
slower equilibration of phenytoin. Graves et al reported a consis¬
tently lower concentration of phenytoin in capillary serum than
in simultaneously sampled venous serum. This difference did
not exist for phenobarbital, and the source of this discrepancy
was not found (17). In another study, an escalating dosage
regimen of phenytoin resulted in significantly lower plasma
concentrations compared with the same dose given in a reducing
Table III. Plasma Protein, Plasma Water and Erythrocyte Ternary Sys¬
tem (whole blood) (Hematocrit 0.39 — 0.5; Temperature 20°C)
Blood concentration with plasma protein/plasma water and erythrocyte/
plasma water concentration ratios
Plasma Erythrocyte/
Blood protein/plasma plasma
Concentration water ratio water ratio
(M-g/ml) n = 3 n = 3
Valproate
2.7 17.0 (0.6) 0.33 (0.01)
23.1 6.3 (1.1) 0.35 (0.04)
44 7.7 (0.4) 0.24 (0.02)
66 6.0 (0.3) 0.37 (0.02)
88 4.4 (0.3) 0.40 (0.04)
132 2.9 (0.3) 0.51 (0.05)
220 1.5 (0.2) 0.55 (0.03)
978 0.3 (< 0.1) 0.66 (0.04)
Phenytoin
0.8 12.7 (0.5) 3.7 (0.3)
5.8 12.8 (0.2) 4.0 (0.3)
10.8 12.0 (0.4) 3.9 (0.3)
20.8 10.8 (0.1) 3.8 (0.3)
50.8 8.6 (0.3) 3.9 (0.3)
100.8 6.4 (0.1) 4.1 (0.2)
Hydrocortisone
0.18 7.2 (0.3) 2.3 (0.1)
0.68 3.2 (< 0.1) 2.4 (0.1)
1.18 2.7 (0.1) 2.4 (0.1)
5.18 2.1 (< 0.1) 2.4 (0.1)
10.18 2.1 (0.1) 2.4 (0.1)
regimen (18). This hysteresis loop may be explained by a slow
equilibration of phenytoin between tissue cells and plasma. A
prolonged time to equilibrium of 60 minutes, between blood
cells and plasma, has also been described for pirarubicin (19).
However, for the majority of drugs in large vessels at
37°C, and in clinical samples drawn from them, it seems likely
that red cells are in equilibrium with plasma.
In vivo Partition of Phenytoin, Valproate and
Hydrocortisone Between Plasma Water, Proteins and
Red Cells
Figures 1, 2 and Table V, also compiled from Driessen et
al (2,3,5), illustrate the in vivo distribution of phenytoin, val¬
proate and hydrocortisone.
Figure 1 shows the log concentration time curves of val¬
proate in the three blood fractions, after an oral dose of 2.4 g
Table IV. Distribution of Substances Between Blood Compartments




volume of whole blood 2.0 ml
total amount of VPA 151.0p,g
VPA in plasma water 16.8%
VPA on proteins 72.2%
VPA on erythrocytes 7.7%
Phenytoin (DPH)
volume of whole blood 2.0 ml
total amount of DPH 21 p.g
DPH in plasma water 5.4%
DPH on proteins 76.1%
DPH on erythrocytes 17.6%
Hydrocortisone (HCOR)
volume of whole blood 1.5 ml
total amount of HCOR 97.5 ng
HCOR in plasma water 11.1%
HCOR on proteins 68.0%
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necessarily imply that compounds are unavailable to the tissues,
but with the exception of oxygen the transport mechanisms
have been poorly defined. For most compounds showing an
association with erythrocytes, it is not known whether they
primarily bind to the outside of the erythrocyte, penetrate the
cell membrane, or if both mechanisms are operative. Despite
these uncertainties, erythrocytes may be of great importance in
transferring such compounds to the tissues. This section dis¬
cusses the erythrocyte in the context of the classic equilibrium
model of plasma proteins, plasma water and tissues.
The Starling Hypothesis
In 1895, Starling introduced the concept of the colloid
osmotic pressure in his article: "On the absorption of fluids
from the connective tissue spaces" (22). At the same time
Hamburger called the absorption of fluid from the tissue spaces
"molecular imbibition" (22). The absorbed fluids also contained
dissolved electrolytes. The movement of tissue water containing
dissolved compounds into a capillary through its endothelium,
as a result of the colloid osmotic pressure, was also visualised
as occurring in the reverse direction towards tissues by virtue of
the arterial pressure. Nevertheless, it is not certain if compounds
need to be dissolved in plasma water to pass a capillary endothe¬
lium into the tissues. An equilibrium between blood and tissues
based solely on compounds dissolved in the plasma water phase
is a commonly held view in bioscience, (e.g. see the quote of
Ehrnebo in the introduction), and is often used in kinetic models
(9,23). However, compounds bound to transport proteins in
blood may use an additional pathway. Pardridge et al suggest
that there are circumstances where the influx of a compound
from capillaries into tissues is greater than can be accounted
for by the influx from plasma water alone. Their model assumes
that an inhibition of protein binding occurs on the capillary
endothelium, thereby releasing the compound, and as a result
tissue levels correspond more closely to the protein bound
fraction than to the free fraction (24,25).
This concept is just as important when considering erythro¬
cytes, as tissues on the other side of a capillary endothelium,
or the capillary endothelium itself, may be more exposed to
compounds accumulated on these cells (26,27). In the studies
reviewed in part I, it was calculated that approximately 40%
of the valproate leaving the circulation in the distribution phase
originated from erythrocytes; for phenytoin, between one and
five hours after administration, this figure was approximately
50%; and for hydrocortisone the value was 28%, between one
and twenty minutes after injection. This is in spite of the much
lower concentration of drug in the red cell fraction compared
to the plasma protein fraction.
Plasma Water as the Central Compartment
Figure 3 shows a dynamic model of whole blood with
tissues. It is assumed that the tissues are "empty", and that the
redistribution of substances from tissue to blood is negligible.
In this model the plasma water is the central compartment.
In a situation of excessive outflow to the tissues, as illustrated
in the figure, the concentration in the plasma water compartment
depends on the influx from proteins and cells. For a substance
bound to plasma protein, the plasma water half-life will be the
same as that on proteins when the red cells are empty, whereas
it equals that on red cells when loaded erythrocytes discharge
and proteins do not deliver substance in any appreciable
amounts to plasma water. As binding to proteins is often
stronger than to erythrocytes, the half-life measured in plasma
water in the case of "empty" tissues will often lie between the
longer one of plasma proteins and the shorter one of red cells
(see part I, Table V), provided both of these compartments are
delivering the substance to plasma water. It seems that the mass
of a substance transferred from plasma proteins or red cells to
tissues, as depicted in Figure 3, depends firstly, on the relative
binding force exerted by these fractions, and secondly, on their
storage capacity. A maximum capacity for erythrocytes is some¬
times recorded in the literature (28), but often such a maximum
cannot be determined (2-4,29,30). Both saturable (hyperbolic)
and non-saturable (linear) uptake processes have been described
(20,23,31), and the non-linear release from erythrocytes of thia¬
zide diuretics, such as chlorothiazide, on account of binding to
intra-erythrocytic carbonic anhydrase, has been well docu¬
mented (21).
It is likely that the hypothetical transport of substances
directly from the red cells to tissues, (dashed arrow in Figure
3), will be difficult to demonstrate using blood samples from
large blood vessels.
The Role of the Erythrocyte
As well as generating the colloid osmotic pressure, the
higher protein content of plasma, compared to the content of
interstitial water, may form a "chemical barrier", to some extent
isolating tissues from many compounds in the-circulation, and
hence from the exterior and each other. Only when the capacity
of the plasma proteins is exceeded, are cells—initially blood
cells—confronted by higher concentrations. The ability of the
erythrocyte to take up and transport molecules is not compro¬
mised by its cell wall, provided that such molecules, located
inside or outside the wall, can be exchanged with the plasma
water fraction or the endothelium during passage through the
capillary, a process well illustrated by the transport of oxygen.
Hence the concentration on erythrocytes will often not be
significant at low plasma concentrations, and it is only as the
plasma concentration increases that erythrocytes carry a physio¬
logically or clinically relevant load. This occurs when plasma
protein binding is saturated, especially locally following an
intravenous bolus injection, or in blood flowing through the
microvilli and transporting substances from the gut lumen to
the portal vein. The experimental conditions described in part
I, where blood is diluted with autologous plasma water, simulate
a capillary with a discontinuous endothelium, found for example
in the liver. Erythrocytes, loaded with compounds absorbed
from the intestinal microvilli, pass through the portal vein and
enter the liver sinusoids, which are lined with fenestrated endo¬
thelial cells; when they come into direct contact with the inter¬
cellular fluid they release their cargo more readily than the
plasma proteins (32) (see Table IV, Part I).
Physical factors, including temperature, affect equilibra¬
tion within whole blood, but to our knowledge there are only
two studies in the literature where partition was observed meth¬
odologically at 37°C (19,23). In vitro, the blood to plasma
concentration ratio of pirarubicin is 1.8 times higher at 37°C
than at 25°C, after 60 minutes incubation, suggesting increased
uptake by erythrocytes (19). Furthermore, the binding of phe-
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darone, a metabolite of amiodarone (48), or cyclophosphamide
(49). A physiological model of hydrocortisone transport has
been described, in which the erythrocyte is central to the deliv¬
ery of this compound to tissues, on account of the faster rate
of dissociation of erythrocyte bound hydrocortisone compared
to that bound to Cortisol binding globulin (CBG) (14). One
would also expect that in certain abnormal conditions (e.g.
hyperbilirubinaemia, uremia), when large quantities of patho¬
physiological products bind to plasma proteins, the secondary
transport system will be loaded more heavily (10,13).
Therefore, in the case of certain compounds and in some
pathophysiological conditions, it is worthwhile investigating
the relationship between the concentration on plasma proteins,
the steady state load on erythrocytes and the physiological
consequences; some desired or undesired effects may be more
closely related to erythrocyte load than to the concentration on
(nearly saturated) plasma proteins. For example, in neonates
with erythroblastosis foetalis, an unconjugated plasma bilirubin
concentration of 300 p.mol/1 or more leads to the uptake of
bilirubin into the central nervous system, which may result in
kernicterus. This pivotal plasma concentration may also be
accompanied by a manifest loading of erythrocytes.
PART III
THE ANALYSIS OF THE ERYTHROCYTE
COMPARTMENT
Methods Used in the Literature
After collecting a blood sample it is easy to obtain plasma
by centrifugation, but the separation of plasma water from
plasma is more laborious and not routinely performed in clinical
laboratories. The degree of plasma protein binding of a sub¬
stance is calculated by subtracting the amount present in the
plasma water, called the free fraction, from that present in
total plasma.
The red cell fraction presents the most obstacles when
analysing the three main blood fractions, as the residual cell
sediment formed following the centrifugation of blood is diffi¬
cult to analyse quantitatively using normal volumetric proce¬
dures. One approach to this problem is to measure the volume
of the cell sediment in a calibrated centrifuge tube. However
it is then necessary to wash the sediment with saline or buffer
several times before analysis, in order to remove the plasma
trapped between the cells; this has the disadvantage of dis¬
turbing the normal equilibrium between red cells and plasma
water, as presented in Figure 3 Part II. The effects of such a
washing procedure on the results subsequently obtained are
rarely mentioned, and to our knowledge the washing itself is
never analysed. A second approach, in which the erythrocytes
remain in their natural environment, but where the analysis is
indirect, is also common in the literature. The amount associated
with red cells is calculated by subtracting the amount present
in plasma, corrected for the haematocrit, from that present in
whole blood (not a medium in which concentrations are rou¬
tinely measured). As the quantity associated with red cells is
often small compared to the plasma concentration, two large
numbers are used to determine a small one. This is an inaccurate
method, and occasionally even negative values are obtained
when the erythrocyte associated amount is calculated. When
analysing the erythrocyte compartment these problems are fre¬
quently not discussed, and how the recorded erythrocyte con¬
centrations are obtained is not clear. Of 56 reports in the
literature describing the analysis of the erythrocyte compart¬
ment, 30 employed the washing technique, 11 used subtraction,
and in 15 the method was not evident.
In the three studies reviewed in part I, a known weight of
erythrocyte sediment was harvested from haematocrit capillar¬
ies, and a correction made for the trapped plasma (2% v./
v.). Although surmounting the limitations described above, the
method is so inconvenient that it is not acceptable for routine
use. Only one other example was found in the literature where
a similar procedure was followed (Maling et al 1989) (48). As
discussed in part II, there is sometimes a need for a direct
analysis of the erythrocyte compartment and a more appropriate
method, which also allows the simultaneous analysis of plasma,
is now available (50) (see below). This has recently been used
to investigate the transport of cyclophosphamide and 4-hydro-
xycyclophosphamide in blood (49), and further work is being
performed with other oxazaphosphorines, the taxanes, antime¬
tabolites, mitomycins and suramin.
Direct Analysis of the Erythrocyte Compartment
A direct determination of red cell associated compounds
must be performed on unwashed erythrocytes, maintained in
their natural environment, without disruption of the normal
equilibrium existing between red cells and plasma in whole
blood. Washing procedures strip the red cells of their outer
layer, which may be important in the transport and exchange
process. Before a direct analysis, the red cells must be com¬
pressed, reducing the amount of plasma between the cells to a
fixed volume, ideally as low as possible, approximately 2%
(6). The red cells need to be collected in a reproducible manner,
and the volume of the collected cell mass must be known.
An instrument (US patent 1993, no. 5256314) meeting
these criteria is described in the literature (50), (Figure 4).
A reservoir A is inserted into a container B, as shown in






Fig. 4. The erythrocyte compartment.
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Summary
Purpose: Oxazaphosphorines are metabolised by a variety of
pathways, one of which leads to activation and the formation
of alkylating compounds. However, the transport forms con¬
veying activated oxazaphosphorines to the tumour cell have
not been fully characterised. There is increasing recognition of
the importance of the erythrocyte as a carrier of compounds in
the circulation, and we have recently described higher concen¬
trations of 4-hydroxycyclophosphamide within the erythrocyte
compartment compared to plasma. We have now determined
the concentrations of ifosfamide and seven of its metabolites in
the plasma and erythrocytes of patients receiving a six-hour
intravenous infusion of ifosfamide.
Patients and methods: Red cells from five patients, receiving
a total of eight cycles of ifosfamide, were separated from plasma
using the MESED instrument, and analysis of red cells and
plasma performed using Gas Chromatography-Mass Spec¬
trometry (GC/MS).
Results: The concentration of all compounds in the erythro¬
cyte compartment was higher than or equal to those in plasma,
and isophosphoramide mustard and carboxyifosfamide showed
a particular affinity for the erythrocyte. The red cell fraction
can contain as much as 77% of the total blood concentration
of isophosphoramide mustard.
Conclusions: Erythrocyte associated isophosphoramide
mustard is an important transport form of activated ifosfa¬
mide. Red cells may have a role in the delivery of activated
oxazaphosphorines to tissues.
Key words: biological transport, blood specimen collection,
erythrocytes, ifosfamide
Introduction
Cyclophosphamide and its structural isomer ifosfamide
are oxazaphosphorine alkylating agents used widely in
the treatment of many solid tumours. They are prodrugs
requiring activation by 4-hydroxylation within the cyto¬
chrome P450 system, with the ultimate formation of
both active and inactive metabolites. In the case of
ifosfamide, isophosphoramide mustard is the final alky¬
lating species, but other metabolites are thought to be
responsible for significant toxic effects, such as haemor-
rhagic cystitis [1] and neurotoxicity [2],
The main site of formation of isophosphoramide
mustard, and its predominant transport form within the
circulation, is not certain. Two possibilities have been
envisaged; firstly, the transport of 4-hydroxyifosfamide
to tumour cells, which then convert this compound to
isophosphoramide mustard, or secondly the formation
of isophosphoramide mustard, primarily within the liver,
but also within other tissues capable of activating ifosfa¬
mide, followed by transport within the circulation and
direct penetration of tumour cells. The relative contri¬
bution of each of these mechanisms will influence the
success of any attempt to administer isophosphoramide
mustard itself as a chemotherapeutic agent, a potentially
advantageous manoeuvre which should not lead to hae-
morrhagic cystitis or neurotoxicity.
Consequently, an improved knowledge of the proc¬
esses of distribution of the oxazaphosphorines and their
metabolites is needed. Blood consists of plasma and
cells, and the vast majority of the cells are erythrocytes
(approximately 45% of total blood volume). It is becom¬
ing clear that the erythrocyte is a significant carrier of
substances in the circulation [3], but there is little data
concerning the distribution of oxazaphosphorines and
their metabolites throughout whole blood in humans.
New developments in the bioanalysis of the oxaza¬
phosphorines have provided methods for the separation
and accurate measurement of many metabolites in plasma
[4, 5], and improved techniques of erythrocyte isolation
have facilitated the study of the red cell compartment
[6], Recently, higher concentrations of 4-hydroxycyclo-
phosphamide have been found within the erythrocyte
compartment compared with plasma [7], and we have
now investigated the distribution of ifosfamide and
seven of its metabolites in the plasma and red cells of
patients receiving an infusion of ifosfamide.
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Figure 1. Mean concentration-time profiles for isophosphoramide mustard (IPM), carboxyifosfamide, ifosfamide and ketoifosfamide.
less, some groups have identified persistent, albeit small,
amounts of 4-hydroxycyclophosphamide in the plasma
of mice [8] and humans [9], proposing that low levels
of 4-hydroxycyclophosphamide in plasma reflect intra¬
cellular trapping of this compound [8].
Other groups have argued that the mustard is the
major transport form. Struck et al. [10] studied the
activity of isophosphoramide mustard against murine
tumours, found it comparable to ifosfamide, and postu¬
lated that isophosphoramide mustard acts by membrane
alteration and/or non-DNA alkylation. The authors
demonstrated that extracellularly delivered isophosphor¬
amide mustard is an effective agent, with antitumour
activity and selectivity in vivo comparable to ifosfamide
and 4-hydroxyifosfamide.
Sladek has reviewed values of the ratio of phosphor-
amide mustard AUC to 4-hydroxycyclophosphamide
AUC in the plasma of mice, rats and humans, following
a dose of cyclophosphamide, and also the sensitivities of
mice and human cell cultures to phosphoramide mus¬
tard and 4-hydroxycyclophosphamide [11]. He was able
to calculate percentages of total cell kill hypothetically
due to either circulating 4-hydroxycyclophosphamide or
phosphoramide mustard, and found that the former
compound was the circulating metabolite of major
importance in the plasma, although the latter also made
a contribution.
However, such studies have analysed plasma and have
not considered the erythrocyte. We have investigated this
compartment with a direct technique [6], avoiding the
need for red cell washing or calculation of red cell con¬
centrations from those in plasma and whole blood; our
results show that ifosfamide and its metabolites enter
the erythrocyte compartment freely, and that isophos¬
phoramide mustard and carboxyifosfamide are concen¬
trated most significantly within this fraction. At the time
of the peak erythrocyte isophosphoramide mustard con¬
centration in one patient, 82% of the total amount of
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to compounds accumulated .on these cells [13], and
the compounds may enter tissues just as easily from
erythrocytes as from plasma water. Flow through capil¬
laries is intermittent, and red cells are momentarily held
in intimate contact with the capillary endothelium, al¬
lowing direct exchange between erythrocytes and endo¬
thelial cells [14].
The structure and function of the tumour interstitium
is significantly different from that of most normal tis¬
sues, and solid tumours can possess a special pattern of
vascularisation [15]. For a solid neoplasm to survive, it
must develop an adequate blood supply through the
process of angiogenesis and then maintain the neovas-
culature so formed. In achieving this, endothelial cells in
tumour vessels can proliferate more than twenty times
faster than in normal vessels [16]. The action of cyto¬
toxics on the capillary endothelium may contribute to
their anti-tumour effect, as the disruption of a tumour
capillary can lead to substantial tumour cell necrosis.
Ifosfamide is used particularly in the treatment of solid
tumours, and the intimate contact between the capillary
endothelium and erythrocytes containing high concen¬
trations of isophosphoramide mustard may be important.
In a study of ten patients treated with cyclophosphamide,
the median AUCE/AUCP ratios for 4-hydroxycyclo-
phosphamide were 1.8 and 1.6 after oral and intravenous
administration respectively [7], Cyclophosphamide is
also more commonly used in solid tumours than in the
leukaemias.
The nature of the binding to erythrocytes is currently
unclear. Uptake is not restricted to oxazaphosphorine
metabolites, and is usually not as high. Many substances
bind to erythrocytes [3]; e.g. the concentration of bilirubin
[17] and Cortisol [18] increases in the erythrocyte com¬
partment once albumin binding sites have been satu¬
rated. and red cells act as major transporters of acetal-
dehyde from the liver to tissues [19],
Therefore it must be appreciated that transport by
erythrocytes is the rule rather than the exception [3]. As
many different compounds can be transported by red
cells, usually weakly bound and with a shorter half-life
on erythrocytes compared to plasma [3], a nonspecific
binding process such as adsorption to the cell surface
comes to mind. The red cell surface area in a human
adult is of the order of 3000 km2, about one million
times larger than that of the total capillary endothelium.
This ensures that the inner surface of the capillary
membrane is in continuous equilibrium with the essen¬
tially fragmented membrane of the red cell compart¬
ment, which scrapes its surface. However, an association
of compounds with proteins in the cell interior, such as
that seen during adduct formation between nitrosamine
metabolites and globins within haemoglobin [20], can¬
not be excluded. As far as the transfer of compounds is
concerned, the relevant factor is whether those associ¬
ated with a red cell can be released to the capillary
endothelium during passage through the capillary.
In conclusion, ifosfamide and its metabolites, espe¬
cially isophosphoramide mustard and carboxyifosfa-
rnide, are sited primarily on the erythrocyte, which may
have a role in the transfer of these compounds from the
site of their formation to the tissues. Erythrocyte asso¬
ciated isophosphoramide mustard then acts as a vital
transport form of activated ifosfamide.
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Electron capture chemical ionization MS
Summary
A method is described for the determination of the antitumor agent
iphosphamide and seven of its metabolites in the plasma of cancer
patients by multiple ion monitoring (MIM) GC-MS, mainly using the
electron capture chemical ionization mode, of stable methyl and/or
trifluoroacetyl derivatives. The metabolites determined were 2- and
3-dechloroethyliphosphamide, 4-ketoiphosphamide, carboxyiphos-
phamide, iphosphamide mustard, and two previously undetected
metabolites, chloroethylamine and 1,3-oxazolidine-2-one.
The isolation of the acidic and neutral metabolites was performed
by solid phase extraction on to Cis adsorbent at pH 4. The weakly
acidic iphosphamide mustard, isolated under these conditions with
a yield of ca 50 %, was measured as a stable methyltrifluoroacetyl
derivative, in contrast to the corresponding phosphoramide mus¬
tard of the isomer cyclophosphamide which decomposes during
derivatization. Chloroethylamine and 1,3-oxazolidine-2-one were
isolated with high yield by liquid extraction with ethyl acetate at
pH 10.
Selective measurement of several metabolite derivatives with simi¬
lar retention times was performed by multiple ion monitoring MS of
specific ion masses, using a methyl phenyl siloxane capillary col¬
umn previously employed in the study of cyclophosphamide meta¬
bolites. Quantitation of metabolites in patient plasma samples could
be performed in the concentration range 3 ng to 20 pg per ml of
original plasma.
1 Introduction
The oxazaphosphorine iphosphamide (IPA; 3-(2-chloroethyl)-2-(2-
chloroethylamino)tetrahydro-2//-l,3,2-oxazaphosphorine-2-oxide)
is an alkylating antitumor agent; it is structurally different from its
isomer cyclophosphamide (CPA) because of a shift of a 2-chlo-
roethyl group from the nitrogen mustard side chain to the nitrogen
of the heterocyclic ring [1], Both IPA and CPA require metabolic
activation by hepatic microsomes in order to exhibit cytotoxic
activity. The formation of a series of alkylating metabolites and
tumor-inactive oxidation products from IPA follows a metabolic
scheme similar to that of CPA (1). The labile primary metabolite,
4-hydroxyiphosphamide, is the precursor of the major cytotoxic
compound, the lphosphamide mustard, but can also be further
oxidized to the corresponding keto and carboxy derivatives. Two
different dechloroethyl derivatives result from oxidation of the side
chains with loss of chloroacetaldehyde
Severe dose-limiting urotoxicity and occasional cases of renal fail¬
ure initially hindered the development of IPA regimens in cancer
chemotherapy. The introduction of concurrent therapy with mer-
capto ethane sulfonate sodium salt (mesna) [2), to prevent the
development of hemorrhagic cystitis by the formation of mesna-
conjugation adducts with the primary metabolite 4-hydroxyiphos¬
phamide and acrolein [3], led to a renewed interest in IPA.
Selective and sensitive assays for IPA and its metabolites in biologi¬
cal fluids should be developed by analogy with the CPA system.
There are, however, some differences between the behavior of the
compounds. Iphosphamide undergoes cyclization in alkaline media
resulting in the formation of an aziridine [4], This reaction lowers
the efficiency of extraction of IPA from an alkaline solution, but is
totally reversed at acidic pH. EPA itself is sufficiently theimally stable
to enable gas chromatographic determination without derivatiza¬
tion [5,6], In contrast, the isomer cyclophosphamide is perfectly
stable under alkaline conditions (no aziridine structure is possible),
but needs derivatization to enable GC analysis, otherwise partial
thermal cyclization in the injector produces two separate product
peaks |5). Several metabolites of iphosphamide form different de¬
rivatives with trifluoroacetic anhydride (TFAA), as will be discussed
further below. The trifluoroacetyl derivatives of oxazaphosphorine
metabolites can be measured with picogram sensitivity by single
ion monitoring (SIM) GC-MS.
This paper presents a full report of procedures for the determination
of iphosphamide, the two possible dechloroethyl metabolites, 4-ke¬
toiphosphamide. carboxyiphosphamide, iphosphamide mustard,
and the chloroethylamine and oxazolidinone metabolites in blood
plasma, using electron capture chemical ionization and electron
impact mass spectrometnc detection of the trifluoroacetyl denva-
tives. The procedure for the determination of CPA metabolites in
blood plasma by similar methods has been descnbed elsewhere [7].
2 Experimental
2.1 Chemicals and Extraction Procedure
Reference compounds of most of the metabolites measured in this
study were generously provided by ASTA-Werke, Degussa Pharma
Gruppe, Bielefeld, Germany. Water and organic solvents used in the
procedure were of HPLC quality grade. The tnfluoroacetic anhy¬
dride reagent (TFAA) was obtained from Janssen Chimica, Geel,
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Belgium. pH 4 buffer was a 0.05 M citrate - hydrochloric acid
mixture. SEP-PAK solid phase extraction cartridges containing 500
mg of trifunctional Cis reversed phase material, supplied by Mil-
lipore, were used on a vacuum manifold station (7).
Details of the enrichment procedure have been descnbed elsewhere
[7|. Original plasma samples were diluted with pH 4 citrate buffer
and the extraction of the major metabolites performed using Cis
cartndges. After elution with methanol and evaporation under
nitrogen, derivatization was accomplished by reaction with dia-
zomethane in ether and tnfluoroacetic anhydnde in ethyl acetate.
The newly identified chloroethylamine and l,3-oxazolidine-2-one
metabolites were isolated by ethyl acetate extraction after dilution
with 0.05 M borate - sodium hydroxide buffer of pH 10.
2.2 Chromatography and Mass Spectrometry
Gas chromatographic separations were performed on a Carlo Erba
Mega Series 5160 chromatograph equipped with a 25 m x 0.25 mm
i.d. fused silica capillary column coated with a 0.2 |im film of Sil-13
(methyl phenyl siloxane; Chrompack, Middelburg, Holland). Both
split (1:10) and splitless (45 s) injection were performed; the injector
temperature was 250 °C.
The fused silica GC column was introduced, through a short metal
capillary transfer line kept at 250 °C, into the combined electron
impact - chemical ionization source of a Fisons Trio-2A quadru-
pole mass spectrometer (Fisons Instruments UK) maintained at
180 °C. Electron impact (EI) ionization was performed with a trap
current of 200 pA, an electron energy of 70 eV, and an ion repeller
potential of 1 V. Chemical ionization (CI) was performed with a
source current of 800 pA, an electron energy of 40 eV, and an ion
repeller potential of 0 V. Multiple ion monitoring was performed on
extracts of spiked plasma and patient plasma. Linear temperature
programming of the GC column enabled selection of retention
Table 1
Characteristic fragments of the EI+ and CI- mass spectra of IPA metabolite derivatives.
Compound M.W. Fragment Interpretation
EI+
TFA-IPA 356 307/309 (M - CH2C1)+
TFA-CPA (IS) 356 307/309 (M - CH2C1)+
TFA-2-DCEI 294 245 (M - CH2C1)+
bis TFA-3-DCEI 390 341 (M - CH2C1)+
TFA-Carboxy-IPA-Me 402 324/326 (M - NHCH2CH2C1)+
TFA-Keto-IPA 370 335/337 (M - Cl)+
TFA-CEA 175 126 (M - CH2C1)+
TFA-OXAZ 183 114 (M - cf3)+
TFA-IPM-Me
r*t
330 281/283 (M - CH2C1)+
Ul—
Group I
TFA-CPA 356 320/322 (M - HC1)"
TFA-2-DCEI 294 274/276 (M - hft
TFA-OXAZ 183 183 (MT
TFA-Carboxy-IPA-Me 402 185 ?
Group II
TFA-IPA 356 293/295 (M - CH2CH2Cir
bis TFA-3-DCEI 390 327 (M - CH2CH2Cir
TFA-Keto-IPA 370 307/309 (M - CH2CH2Cir
TFA-CEA 175 112 (M - CH2CH2Cir
TFA-IPM-Me 330 267/269 (M - ch2ch2c1)-
windows in the chromatogram during which specific m/z values
from the mass spectra of the metabolites were measured.
2.3 Syntheses of the Two New Metabolites
2.3.1 Chloroethylamine
Sodium hydroxide (0.5 g; 12.5 mmol) was added to a solution of
chloroethyiamine hydrochlonde (1.15 g; 10 mmol) in water (20 ml).
This mixture was stirred for 2 mm and extracted with ethyl acetate
(5 x 10 ml). This extract was dried over anhydrous sodium sulfate
for 24 h. After evaporation of the solvent the chloroethylamine was
isolated as a colorless fluid.
2.3.2 l,3-Oxazohdine-2-one
Chloroethylamine hydrochlonde (1.15 g; 10 mmol) was added to a
solution of sodium bicarbonate (0.84 g; 10 mmol) and sodium
hydroxide (0.4 g; 10 mmol) in 30 ml water. The mixture was kept at
40 °C for 45 min, then extracted with ethyl acetate (5 x 10 ml). The
extract was dried over anhydrous sodium sulfate and the 1,3-oxa-
zolidine-2-one isolated as a pale yellowish fluid after evaporation of
the solvent. GC-MS analysis of a solution of this residue revealed
the presence of < 2 % of the original chloroethylamine in the extract.
3 Results and Discussion
3.1 Mass Spectra of Trifluoroacetylated Metabolites of IPA
The mass spectra of the trifluoroacetylated parent compounds IPA
and CPA have been published elsewhere [7j. Tnfluoroacetyliphos-
phamide produces a positive electron impact mass spectrum simi¬
lar to that of the cyclophosphamide derivative, with a base peak at
m/z = 307/309 for the fragment (M - CH2C1)+, as first reported by
Lartigue-Mattei et al. [8], The characteristics of the EI+ and CI-
mass spectra of the derivatives of the metabolites measured in this
study are presented in Table 1.
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Figure 1
Structures of the stable metabolite derivatives of iphosphamide.
The structures of the metabolite derivatives, their full names, and
the abbreviations used in this paper are given in Figure 1.
Selected EI+ and CI- mass spectra of metabolite derivatives are
shown in Figures 2 and 3.
The metabolite 2-DCEI is produced only by the metabolism of IPA
(not of CPA) 3-DCEI is identical with the dechloroethyl metabolite
of cyclophosphamide and is therefore a metabolite of both ox-
azaphosphorines. After derivatization with TFAA, the 2-DCEI was,
therefore, measured as the monotrifluoroacetyl derivative and the
3-DCEI metabolite as the bistrifluoroacetyl derivative (Figure 4).
The mass spectrum of the latter compound was given in a previous
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Figure 3
Electron capture chemical ionization mass spectra of TFA-2-DCEI, TFA-1,3-













The formation of the dechloroethyl metabolites of IPA and CPA.
Carboxyiphosphamide has two identical phosphoramidic functions
which can be further substituted. Theoretically both can be tri-
Quoroacetylated, but in practice only one is actually transformed,
probably because of the effect of steric hindrance in the mono
derivative. In the corresponding carboxy metabolite of cyclophos¬
phamide, a further loss of hydrogen chlonde is observed yielding a
single cyclic derivative as the only chromatographic peak [7|. A
similar process did not occur with the carboxyiphosphamide. The
structures of the final derivatives of the two corresponding carboxy
metabolites of IPA and CPA are thus different, as is shown in
Figure 5
In the procedure used to measure the stable cyclophosphamide
metabolites in blood plasma (7), it was observed that negative
chemical ionization in the electron capture mode, using methane


























The structures of the carboxy derivatives of IPA and CPA.
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impact or positive chemical ionization for many trifluoroacetylated




























Fragmentation of the derivative of IPM in electron capture chemical ionization
MS.
A tentative assignment for the base peak fragment ion from the
carboxy-IPA derivative at mJz = 185 cannot yet be proposed. The
fragment is, however, of diagnostic value for the carboxy-IPA de¬
rivative; it is, therefore, further used in quantitative work.
3.2 The Derivatization Step
The derivatization procedure applied to IPA metabolites isolated
from plasma is identical to that for CPA metabolites described
elsewhere and involves two steps - methylation of acidic func¬
tions of carboxyiphosphamide and iphosphamide mustard followed
by trifluoroacetylation of unhindered phosphoramide functions [7]
using a large excess of the reagents. The bis-trifluoroacetyl deriva¬
tive of the 3-DCEI metabolite is produced quantitatively when, after
methylation of the plasma extract by diazomethane in ether, the
solvent is evaporated completely and replaced by ethyl acetate for
trifluoroacetylation. On standing in the presence of ether or chloro¬
form, an equilibrium mixture of the two mono derivatives of 3-DCEI
is formed from the bis derivative.
The metabolite 4-ketocyclophosphamide, cannot be derivatized by
reaction with TFAA because of a mesomeric effect involving the
endocyclic amidic nitrogen atom [7], In contrast, trifluoroacetylation
of 4-ketoiphosphamide occurs smoothly on the exocyclic nitrogen
atom. 4-Ketoiphosphamide does not react with diazomethane so¬
lution. Unlike the cyclophosphamide mustard (CPM), which de¬
composes completely to the nor-nitrogen mustard during attempts
to derivatize with TFAA, the iphosphamide mustard (IPM) does not
decompose during the enrichment and derivatization steps and can
easily be recovered from plasma. Methylation occurs only on the
phosphoramidic acid function and trifluoroacetylation only on one
of the equivalent phosphoramidic nitrogen atoms (Figure 7). The
derivative has an acyclic structure and the subsequent loss of
hydrogen chloride with the formation of a cyclic product, seen with


















3.3 Recovery of IPA Metabolites from Spiked Plasma Samples
In electron capture (CI-) mode, two different types of fragmentation
occur for the IPA and the CPA metabolites; this is illustrated by
subdivisions I and II in Table 1. The derivatives in group II contain
a special functional group which fragments by the loss of a
CH2CH2CI substituent, e.g. the iphosphamide mustard derivative
with a charactenstic peak at m/z 267/269. A tentative mechanism
is shown in Figure 6
An extensive study was performed to determine the efficiencies of
extraction of mixtures of CPA and its metabolites from plasma
samples spiked at typical concentrations of 10 gg/ml, using liquid
extraction with ethyl acetate or chloroform and solid phase isolation
with either silica gel or Cis at pH 4, 7, or 10. The results of these
expenments have previously been discussed in detail [7|. In view of
the similar recoveries obtained for IPA metabolites under these
conditions, an extensive study at these pH values in triplicate for all
methods of isolation was not performed. The only comparison was
of the extraction yields obtained for CPA and EPA metabolites using
the Ci8 solid phase extraction procedure at acidic pH. The results
of these experiments are listed in Table 2
Table 2
Recoveries of IPA and CPA metabolites using C18 solid phase
extraction at pH4.
CPA IPA
CPA: 93.2 % ± 3.6 %
IPA (IS): 99.7 % ± 3.7 %
DCEC: 99.5 % ± 2.8 %
Keto-CPA: 90.3 % ± 2.6 %
Carboxy-CPA: 82.5 %±3.9'
Alco-CPAa): 75.9 % ± 5.0 %
CPMb): 56.3 % ± 4.0 %
CPA (IS): 93.2 % ± 3.6 %
IPA: 99.7 % ± 3.7 %
3-DCEI 96.8 % ±4.1 %
2-DCEI 92.7 % ± 6.4 %
Keto-IPA: 91.5% + 3.8%
Carboxy-IPA: 74.4 % ± 1.9 %
IPM: 49.8 % ± 4.2 1
al Alco-IPA was not available as a reference compound.
bl Measured by thermospray LC-MS.
The observed extraction efficiencies at pH 4 are generally higher
than 90 % for both dechloroethyl metabolites, the keto metabolite,
and for the parent compounds IPA and CPA. The recovery of the
carboxy metabolite of IPA is somewhat lower, ca 75 %. Both iphos¬
phamide and cyclophosphamide mustard are stable in a weakly
acidic medium. As the cyclophosphamide mustard decomposed
readily during attempts at derivatization, the efficiency with which
it was extracted was measured by thermospray LC-MS (single ion
monitoring) of the underivatized form of the molecule. The ion
monitored was the (M + NH4 - HC1)+ at m/z 202. The recovery of
the iphosphamide mustard from Cis columns is low, only about 50
%, and comparable with that of CPM, but still 10 % higher than the
value given in the literature for extraction of CPM using Amberlite
XAD-4 columns [9],
The isolation of the alkaline chloroethylamine and 1,3-oxazolidine-
2-one metabolites was performed by liquid extraction with ethyl
acetate at pH 10; recoveries were 85 % and 90 % respectively, an
improvement on the solid phase procedure at pH 7. No further
decomposition of the metabolites was observed during storage of
spiked plasma samples at -20 °C for at least three weeks. The
schematic diagram in Table 3 illustrates the ermchment procedure
applied to patient plasma samples.
3.4 Gas Chromatographic - Mass Spectrometric Analysis of the
Metabolites
From the study of the gas chromatography of the CPA metabolites,
it was found that complete separation of all the metabolites could
be achieved on a 25 m x 0.25 mm i.d. capillary column coated with
a 0.2 |im film of Sil-13 (Chrompack) [7). The same capillary column
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Table 3
Schematic diagram of the enrichment procedure.
Determination of IPA, Keto-IPA, IPM, Determination of CEA and OXAZ
Carboxy-IPA, and 2- and 3-DCEI
0.5 ml plasma
i + internal standard CPA
+ 0.5 ml buffer pH 4
i
1 ml diluted plasma, vortex
i
Cis column (500 mg)
i








+ 0.3 ml ethyl acetate
+ 0.3 ml TFAA at 70 °C for 2h
I
complete evaporation




i + internal standard CEOX
+ 0.5 ml buffer pH 10
1
1 ml diluted plasma, vortex
i
extraction with ethyl acetate





+ 0.3 ml ethyl acetate




dissolve in 250 pi ethyl acetate
GC-MS
Table 4
Retention data for CPA and IPA metabolites on Chrompack Sil-13a>.
CPA tR [min] IPA tR [min]
bis TFA-DCEC 7.41 TFA-IPM-Me 6.71
TFA-IPA (IS) 12.66 bis-TFA-3-DCEI 7.40
bis TFA-Alco-CPA 13.88 TFA-2-DCEI 8.26
TFA-CPA 14.82
TFA-Carboxy-CPA-Me 17.48 TFA-IPA 12.63
Me-Keto-CPA 18.25 TFA-Keto-IPA 12.93
TFA-Carboxy-IPA-Me 14.03
TFA-CPA (IS) 14.83
Linear temperature program from 150 to 240 °C at 6 7min.
was, therefore, used for the separation of the derivatives of the IPA
metabolites. Table 4 lists the retention times of the metabolites of
both oxazaphosphorine derivatives on this column in order of in
creasing retention time.
It is apparent from the table that separate retention windows can
easily be established for single ion monitoring of the individual
metabolites of cyclophosphamide. Since two regions of partial over¬
lap exist for iphosphamide metabolites, in which retention times
differ by less than 1 min, multiple ion monitonng was applied in
these regions, giving, complete separation using the appropriate
specific ion masses, although the ultimate detection sensitivity was
reduced by a factor of 2 to 3. Splitless injection of a 1 pi aliquot from
50 pi of final derivatized extract enabled determination of metabolite
plasma concentrations in the range of 3 ng/ml to 20 pg/ml
Table 5
Multiple ion monitoring programs for IPA metabolites3'.




TFA-IPM-Me (M - CH2CH2CI)" 266.99 2.0-10.0
bis TFA-3-DCEI (M - CH2CH2CI)- 327.00 2.0-10.0
TFA-2-DCEI (M - HF)" 274.00 2.0-10.0
TFA-IPA (M - CH2CH2CI)- 293.01 10.0-13.5
TFA-Keto-IPA (M - CH2CH2CI)- 306.99 10.0-13.5
TFA-Carboxy-IPA-Me (M - ?r 185.01 13.5-17.0
TFA-CPA (IS) (M - Heir 320.03 13.5-17.0
EI+
TFA-CEA (M - CH2C1)+ 126.02 2.0- 6.0
TFA-OXAZ (M - CF3)+ 114.02 6.0-12.0
CEOX (IS) (M - CH2C1)+ 100.04 6.0-12.0
al Dwell time 0.08 s, span 0 02 a.m u.
The multiple ion monitoring time intervals in order of increasing
retention times were as listed in Table 5
Negative chemical ionization by electron capture was the most
sensitive technique for the quantitative measurement of IPA.
3-DCEI, 4-keto-IPA, and carboxy-IPA; no substantial difference was
observed between EI+ and CI- sensitivity for 2-DCEI and IPM.
These metabolites can, therefore, all be measured with equally high
sensitivity by electron capture CI- (a typical MIM chromatogram is
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IBB SIM of nS-L-- 307
Keto-IPA
SIM of n/z= 274
2-DCEI
SIM of n/z- 267
IPM











SIM of n/-z- 126
CEA
SIM of »/z= 114
OXAZ
SIH of n/i- 100
CEOX (Int.st.)
4.a 6.a a.B 10.0 12.0 14.0
Figure 8
CI— MIM chromatogram (a) and E1+ SIM chromatogram (b) for a patient plasma
extract.
shown in Figure 8a). Only the CEA and OXAZ metabolites were
measured with greater sensitivity by electron impact ionization,
using a temperature program from 80 to 150 °C at a rate of 6 °/min
(a typical SIM chromatogram is shown in Figure 8b).
To compensate for differences in extraction efficiency and chroma¬
tographic variations after derivatization, CPA was added to the
original plasma as internal standard (IS) for quantification of most
EPA metabolites. A different internal standard (the corresponding
IV-chloroethyl-l,3-oxazolidine-2-one metabolite of CPA (CEOX),
available as a reference compound) was used for the measurement
of the chloroethylamine and l,3-oxazolidine-2-one metabolites.
Blank plasma samples spiked with a mixture of metabolites were
submitted to the same enrichment procedure as the patient sam¬
ples, and the sample extracts used after derivatization to construct
calibration curves in the concentration ranges 5 to 100 ng and 0.1
to 20 fig metabolite per ml of original plasma. Measurements of
patient and spiked plasma sample extracts were, where possible,
performed on the same day, in order that calibration curves and
patient plasma measurements were determined under similar con¬
ditions of ion source contamination.
Linear regression analysis of the measured data points (ratio of
metabolite peak area to internal standard peak area, Y, against
metabolite concentration, X, in the original plasma) produces a best
fit; as an example, the regression equation for IPM was Y= (0.01579
± 0.00037)X+ (0.00125 ± 0.00022) (n = 6)
The intra-assay reproducibility, expressed as relative standard de¬
viation, was approximately 3 %, and the inter-assay reproducibility
ranged from 5 to 10 % for sets of four independent extractions.
Measurement of the labile pnmary metabolite 4-hydroxyiphos-
phamide as a separate peak was not possible by the procedure
described herein. Since the hydroxy structure is stabilized at a
weakly acidic pH (Ikeuchi et al. (10)) and, at least in the case of the
isomer cyclophosphamide, will easily decompose to the phos-
phoramide mustard during the Cis solid phase extraction procedure
(Watson et al. (11 J), we suggest that the measured iphosphamide
mustard concentration actually represents the sum of the free
mustard and the hydroxyiphosphamide and aldophosphamide in
the patient plasma samples. This hypothesis will be confirmed by
additional expenments, using the recent method of Hongand Chan
[12] to measure the original hydroxy - aldo tautomeric pair as a
silylated cyanohydnn after liquid extraction of the plasma.
The proposed method of analysis has been applied successfully to
the determination of iphosphamide metabolites in the blood plasma
of patients after oral administration of iphosphamide in combination
with mesna (IPA/Mesna chemotherapy).
Figure 9 shows a typical concentration - time profile of IPA-me-
tabolites from a cancer patient who received an oral dose of 500 mg
iphosphamide in combination with mesna.
[PA
1 1.5 2 2.5 3 3.5 4 4.5 5
Elapsed Time after administration (h)
Figure 9
Example of a profile of concentration against time for IPA metabolites in the
blood plasma of a cancer patient.
The interpretation of the pharmacokinetic resuits of our studies wiil
be discussed elsewhere.
4 Conclusion
A new analytical method is presented for the determination of the
antitumor drug iphosphamide and seven metabolites in the blood
plasma of cancer patients. After solid phase extraction on to Cis
columns and reaction of the residue with diazomethane and tri-
fluoroacetic anhydride, the stable derivatives were separated on a
methyl phenyl siloxane GC capillary column and measured selec¬
tively by multiple ion monitoring GC-MS. The acidic and neutral
metabolites were measured by electron capture chemical ioniza¬
tion. The active iphosphamide mustard was determined as a stable
methyltrifluoroacetyl derivative. The labile primary metabolite
4-hydroxyiphosphamide could not be determined by this procedure
and will require trapping in the original plasma.
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